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Abstract 
 
Introduction: Early growth response 1 (EGR1) is a zinc-finger transcription factor 
involved in the regulation of cell growth. It can act as either a tumour suppressor or a 
tumour promoter with a role in the induction of apoptosis in cancer cells by various 
pathways and is likely to play a role in colorectal cancer (CRC). EGR1 also appears 
to play a significant role in inflammatory pathways, therefore a possible role in 
Inflammatory Bowel Disease (IBD) is hypothesised. Patients with IBD have a 
greater risk of developing CRC, which is increased with duration of symptoms and 
severity of inflammation and dysplasia. The aim of this study is to determine whether 
EGR1 is differentially expressed in diseased colon tissue and to investigate novel 
EGR1-protein interactions in CRC cell lines.  
 
Methods: The relative EGR1 expression in CRC cell lines and in normal mucosa and 
tumours of colorectal cancer patients was determined by qRT-PCR. IBD patient 
samples were also examined for differential EGR1 expression levels by qRT-PCR, 
before and after stimulation with inflammatory mediators. Statistical analysis of the 
data was performed using ‘R’ statistical package, with the mixed-model ANOVA. 
Statistical significance was set at < 0.05. The genotype of three EGR1 variants was 
determined in the samples using PCR and sequencing, and the methylation status of 
regions of the EGR1 promoter was determined using bisulfite sequencing. A yeast-
two hybrid screen was conducted with EGR1 as bait, and screened against a SW480 
CRC cell line library. Interesting novel interactions were investigated using 
immunocytochemistry and immunoprecipitation, as was the novel interaction 
between EGR1 and NOD2 and between EGR1 and components of the cytoskeleton.  
 
Results: Investigation into the relative EGR1 mRNA expression in CRC has shown 
that there is differential expression of EGR1 between matched normal mucosa and 
tumour.  EGR1 expression is decreased in IBD patients compared with healthy 
controls. Induction of EGR1 by inflammatory stimuli also appears to be aberrant in 
these patients. The differential expression of EGR1 was not associated with aberrant 
methylation of a large region of the EGR1 promoter in either the CRC or IBD 
 
  v
patients or with the genotype of EGR1 variants. EGR1 localises to both the 
cytoplasm and the nucleus in CRC cell lines and this study demonstrate interactions 
with the IBD susceptibility protein NOD2 and with components of the cyotskeleton.  
A yeast-two hybrid screen conducted with EGR1 as bait using a CRC cell line library 
has identified several other novel protein interactions of EGR1 in CRC cell lines.  
 
Conclusion: EGR1 is differentially expressed in both CRC and IBD, and in the case 
of IBD shows aberrant activity, suggesting that EGR1 may play a role in both 
colorectal diseases. EGR1 interacts with the IBD protein NOD2, and components of 
the cytoskeleton in CRC cells. Several novel protein interactions with EGR1 have 
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Colorectal cancer (CRC) is one of the most common cancers in the UK, and 
worldwide, and therefore presents a considerable health problem with the incidence 
rates of CRC increasing. Similarly incidence rates for inflammatory bowel disease 
(IBD) are also on the rise as much of the world is beginning to adopt an increasingly 
more western lifestyle. Early Growth Response 1 (EGR1) transcription factor has 
been identified as a novel susceptibility gene for both CRC and IBD. The research in 
this thesis will investigate the expression and localisation of the EGR1 transcription 
factor in colorectal disease in order to have a better understanding of the role that 
EGR1 may play in both of these diseases. 
 
EGR1 is differentially expressed in several different cancers, and this study will 
examine the expression of EGR1 in matched normal mucosa and tumour samples of 
CRC patients, and in IBD patients. It also examines the localisation of EGR1 in 
colorectal cancer cell lines and investigates some novel EGR1-protein interactions, in 
particular an interaction between EGR1 and the IBD susceptibility gene product 
NOD2. There are only a few known proteins that interact with EGR1 and this thesis 
will investigate some novel EGR1 interactions, determined by a yeast-two hybrid 
screen. 
 
This chapter will initially introduce colorectal disease, looking at both colorectal 
cancer and inflammatory bowel disease, which includes Crohn’s disease and 
ulcerative colitis. It will proceed to discuss EGR1 and the role that it has to play in 
both cancer and inflammation. The chapter will conclude with an overview of some 










1.1 Colorectal Cancer (CRC) 
 
Colorectal cancer (CRC) is cancer of the colon and rectum. It can also be used to 
describe cancer of the anus and appendix. It generally develops from adenomatous 
polyps that form in the epithelial lining of the colon, which then go on to form a 
carcinoma through a series of genetic mutations.  Approximately 60% of tumours are 
formed on the left side of the colon, mainly the sigmoid colon, rectosigmoid junction 
and the rectum (Kinzler and Vogelstein 1996). 
 
 
CRC is the third most common cancer in the UK in both men and women, with the 
second highest mortality rate after lung cancer (UK National Statistics 2011) and the 
incidence rates of CRC have greatly increased in the last 30-40 years. In 2008 32,600 
men and women were diagnosed with CRC in the UK. The risk of developing CRC 
is 1 in 16 for men, and 1 in 20 for women (Cancer Research UK 2011) with the risk 
increasing with age. Worldwide, 60% of all CRC cases occur in developed countries, 
with America, Australasia and Western Europe having the highest incidence rates. 
The lowest rates of CRC are seen in Africa (excluding South Africa) and South-
Central Asia (Globocan 2008). Eastern European countries and East Asia have seen 
greatly increasing rates of CRC as they adopt an increasingly more western lifestyle 
suggesting that there is an important role for environmental factors in the 
development of CRC. 
 
A family history of the disease is an important risk factor for CRC and 
approximately 30-40% of CRC is thought to have a hereditary component. However 
only ~5% of all CRC cases occur through known genetic mutations, which are 
accounted for by Familial Adenomatous Polyposis (FAP), Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC) and other rare related disorders. It is evident that both 
genetic and environmental factors have important roles to play in the development of 







1.1.1 Environmental risk factors for CRC 
 
There are several lifestyle factors that have been attributed to the development of 
CRC. Evidence suggests that a diet of red meat and unsaturated fats, high alcohol 
consumption, smoking and obesity can all contribute to a risk of developing CRC 
(Huxley, Ansary-Moghaddam et al. 2009). Patients with diabetes and inflammatory 
bowel disease (IBD) have also been shown to have a higher risk of CRC. Conversely 
it has been shown that physical activity, a diet of vegetables and taking non steroid 




Although it has been suggested that dietary fibre may help prevent against CRC, the 
data is inconsistent. In some studies there does appear to be a reduced risk of CRC 
with a consumption of fruit and vegetables (Riboli and Norat 2003; van Duijnhoven, 
Bueno-De-Mesquita et al. 2009) however others have failed to show a convincing 
association and at most is likely to have a small inverse association with CRC (Key 
2011). One study showed no association with cereal fiber and colorectal cancer 
(Terry, Giovannucci et al. 2001) but the overall data for this is again inconsistent 
(Du, Li et al. 2010). A study investigating an association between flavonoids and 
CRC showed that there an inverse risk on consumption of flavonoids and 
associations with other dietary components include vitamin B, vitamin D, folate and 
methionine (Theodoratou, McNeill et al. 2007; de Vogel, Dindore et al. 2008; 
Theodoratou, Farrington et al. 2008; Theodoratou, Farrington et al. 2008). 
 
The consumption of red meat has been shown to have an association with CRC. This 
is not surprising when considering that the countries which have the lowest rates of 
CRC are ones in which a vegetarian and fish diet are prominent, and the omega-3 
fatty acid, commonly found in oily fish, has been found to decrease the risk of CRC 
(Theodoratou, McNeill et al. 2007) . A meta-analysis involving 19 different studies 
and 8,000 cases showed that there is a 20% increase in risk between individuals who 
consume the highest amounts of red meat or processed meat to those that consume 
the lowest (Larsson and Wolk 2006).  
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1.1.1.2 Physical activity and weight 
A review combining 19 different cohort studies showed that exercise is protective 
against colon, but not rectal, cancer in both men and women (Samad, Taylor et al. 
2005). Similarly the study conducted by Huxley et al, 2009, looking at 27 cohorts 
indicated that physical activity reduced the risk of CRC by 20%, and again it is more 
protective for colon than rectal cancer.  (Huxley, Ansary-Moghaddam et al. 2009), 
Conversely, a study using 31 cohorts showed that individuals that have a BMI 
>30kg/m2 have a 20% greater risk of developing CRC than those with a healthy BMI 
of <25kg/m2 (Moghaddam, Woodward et al. 2007). 
 
 
1.1.1.3 Smoking and alcohol 
An analysis using 21 cohort studies showed that there is a significant increase in the 
risk of CRC based on alcohol consumption. Individuals that are considered heavy 
drinkers are at 60% increased risk compared with light or non-drinkers (Huxley, 
Ansary-Moghaddam et al. 2009). Cigarette smoking also significantly increases the 
risk for CRC, with a greater risk evident for rectal than colon cancer, and the 
incidence increases with duration of smoking (Liang, Chen et al. 2009). 
 
 
1.1.1.4 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
It is known that NSAIDS, such as aspirin, can reduce the risk of developing CRC by 
up to 40%. A study showed that a low dose of aspirin over a prolonged period of 
time (5-10 years) significantly reduces the risk of CRC (Din, Theodoratou et al. 
2010). The toxicity of NSAIDs renders them impractical for use as a 
chemopreventative agent for CRC so the mechanism by which they exert their effect 








1.1.2 Hereditary forms of CRC 
 
There are several inherited forms of colorectal cancer, the two most common being 
Familial Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colorectal 
Cancer (HNPCC). Investigations into FAP and HNPCC has allowed for significant 
progress to the understanding of the development of sporadic CRC. The major forms 
of hereditary colorectal cancer with the genetic mutations they are associated with 
are summarised in Table 1. FAP and HNPCC will be discussed in detail below. 
 
 
Syndrome Gene Lifetime risk 
Familial Adenomatous Polyposis (FAP) APC 100% 
Attenuated FAP (AFAP) APC 69% 
Hereditary Nonpolyposis colorectal cancer 
(HNPCC) 
MMR genes   
(esp. MSH2, MLH1)   
80% 
MUTYH-Associated Polyposis (MAP) MUTYH 80% 
Peutz-Jeghers syndrome (PJS) STK11 39% 
Juvenile polyposis syndrome (JPS) SMAD4/BMPR1A 39% 
Cowden syndrome (CS) PTEN rare 
Table 1.1: Hereditary forms of CRC  
(Migliore, Migheli et al. 2011) 
 
 
1.1.2.1 Familial Adenomatous Polyposis (FAP) 
 
FAP is an autosomal dominant syndrome that is caused by a germline mutation in the 
adenomatous polyposis coli (APC) gene (Groden, Thliveris et al. 1991; Nishisho, 
Nakamura et al. 1991). It occurs in 1 in 12,000 patients, and accounts for ~ 0.5-1% of 
all CRC cases. FAP is characterised by the development of hundreds to thousands of 
adenomas, with one or more progressing to carcinoma by 35-40 years of age, 
predominantly on the left side of the colon (70-80%) (Lynch and de la Chapelle 
2003). Homozygous APC mutations in mice are embryonic lethal, and a 
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heterozygous mutation results in the development of intestinal polyps similar to those 
found in FAP and are used as a model for intestinal tumorigenesis (Heyer, Yang et 
al. 1999; Aoki and Taketo 2007).  
 
The APC gene is located on chromosome 5q21 and the majority of APC mutations 
found in FAP result in a stop codon and a truncated protein. APC has a role in cell 
adhesion and migration and is also known to be involved in the regulation of the cell 
cycle. APC is modulated via the Wnt signalling pathway, which is involved in the 
regulation of !-catenin (Galiatsatos and Foulkes 2006). In the absence of stimulation 
!-catenin is held in multi-protein complex with APC, Axin, GSK-3p and CK1. The 
!-catenin molecule can become phosphorylated by protein kinase A (PKA), and 
other kinases, which leads to its ubiqinitation and degradation. Upon stimulation by 
Wnt, the !-catenin is no longer held in complex and does not become 
phosphorylated. It translocates to the nucleus where it activates gene expression. 
Loss of APC causes accumulation of !-catenin in the nucleus resulting in gene 
activation of transcription factors T-cell factor (TCF) and lymphoid enhancer factor 
(LEF) and a constitutively active pathway (Galiatsatos and Foulkes 2006).   
 
APC gene codes for a ~300-kDa protein which is localised in the cytoplasm, at the 
basolateral membrane of CRC epithelial cells (Smith, Johnson et al. 1993). There are 
several distinct domains in the APC protein, including a basic domain which binds 
microtubules, Armadilo repeats, and !-catenin, axin, EB1 and HDLG binding 
domains, illustrated in Figure 1.1. Germline mutations are mostly found at the 5’ half 
of the coding region, particularly in exon 15, around codons 1061 and 1309 (Polakis 
1995). Two-thirds of the mutations found are frameshift mutations with the 
remaining being single base substitutions. It has been shown that the mutated APC 
protein does not bind microtubules (Smith, Levy et al. 1994). It was also shown that 
expression of wild-type APC in CRC cells which endogenously express mutated 














Figure 1.1: Illustration of APC and its protein binding domains. 
(Polakis 1995). The APC protein is ~300kDa, with binding sites for !-catenin and 

























1.1.2.2 Hereditary Non-polyposis Colorectal Cancer (HNPCC) 
 
Hereditary Non-polyposis colorectal cancer (HNPCC) is the most common form of 
hereditary CRC accounting for ~4% of all CRC cases. Patients have an earlier onset 
of CRC than sporadic CRC and the tumours are predominantly localised on the right 
side of the colon (Lynch and de la Chapelle 2003). HNPCC is caused by germline 
mutations in DNA mismatch repair (MMR) genes. The MMR systems involves 
several proteins which are involved in the recognition and repair of nucleotide errors 
that may occur during DNA replication.  
 
There are 5 MMR genes that have been shown to carry mutations in HNPCC; MLH1, 
MSH2, MSH6, PMS1 and PMS2. Mutations in MLH1 (mutL homologue) and MSH2 
(mutS homologue) account for >70% of mutations identified in patients and have 
been detected in ~45-70% of HNPCC patients. Mouse models have been generated 
for the human honologues of MutS and MutL and these MMR knockout mice 
demonstrate DNA repair defects and cancer phenotypes similar to those of patients 
with HNPCC (Taketo and Edelmann 2009). 
 
HNPCC tumours are characterised by changes in the sequence of repetitive DNA 
sequences that are localised at microsatellite regions, termed microsatellite instability 
(MSI), which occurs after the loss of the MMR genes, with ~90% of HNPCC tumour 
displaying MSI (discussed in more detail in section 1.1.4.2.). However ~60% of 
patients who fulfil the clinical hereditary criteria for HNPCC do not have a known 
MMR mutation (Fearon 2011).The clinical hereditary criteria for HNPCC is 
determined by the Amsterdam criteria. The Amsterdam criteria states that at least 
three relatives must have a HNPCC-related cancer. These include CRC, endometrial, 
small bowel, ureter or renal-pelvis. One person should be a first-degree relative of 
the other two, at least two successive generations should be affected and at least one 
person should be diagnosed before the age of 50. FAP should also be excluded 





1.1.3 Adenoma-carcinoma sequence of CRC 
 
An adenoma-carcinoma  sequence was first postulated in 1988 by Vogelstein et al 
(Vogelstein, Fearon et al. 1988), and subsequent studies resulted in the development 
of the adenoma-carcinoma sequence model to explain the progression of CRC from 
adenoma to carcinoma through alterations in oncogenes and tumour suppressor genes 
(Kinzler and Vogelstein 1996). Figure 1.2 illustrates the sequence of the 
development of colorectal cancer incorportating some of the key genetic mutations 
and the stage at which they occur and the two main forms of genetic instability that 
are associated with CRC, chromosomal instability and microsatellite instability.  
Genetic instability associated with CRC will be discussed in the next section. It is 
known that mutation of the APC gene is an early occurring event in the adenoma-
carcinoma sequence, with loss of APC considered a key event in the initiation of 
development of CRC (Kinzler and Vogelstein 1996).  
 
The adenoma-carcinoma model depicts the sequence of some of the major mutations 
and genomic effects that are observed in the progression of CRC. Some mutations 
occur early in the development of CRC, such as APC, and other mutations are only 
seen in the later stages of CRC tumour development. However not all of the 
mutations seen in the CRC are responsible for the initiation, progression and/or 
maintenance of the tumour. Although it has been estimated that there can be ~80 
mutated genes in a CRC tumour, it is thought that less then <15 of that mutations 
seen CRC are considered “drivers” of CRC initiation or progression and then rest of 
the mutations seen are only “passenger” mutation, ie ones that have occurred as a 
result of tumorigenesis, but are not responsible for its initiation, progression or 
maintenance. Some of the mutations are likely to occur somatically, where as others 
occur as the increase in genetic instability in the tumour increases with tumour 
development. For example, it has been shown that 18q21.2 region is consistently 
disrupted in CRC, and it was thought the DCC gene could potentially have a role as a 
driver in CRC. However it is now more likely that it is the SMAD4 gene that has a 
key role in tumorigenesis, not DCC as was originally thought (Sjoblom, Jones et al. 
2006; Starr, Allaei et al. 2009; Ji, Tang et al. 2010). Other important mutations 
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highlighted in the adenoma-carcinoma sequence which are now thought to be 
important driver mutations include KRAS, p53 and PTEN. Several of the key genes 
associated with CRC will be discussed in detail in section 1.1.5, with further 
elobration as to how EGR1 relates to some these key genes in cancer discussed in 
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Figure 1.2: Progression of CRC 
(Grady and Carethers 2008). Illustration of the adenoma-carcinoma progression of 
CRC with the associated form of genetic instability, chromosomal instability and 
microsatellite instability. The key mutations and their timing in the progression of the 
adenoma-carcinoma sequence are highlighted. Genetic instability and mutations in 



















  12 
1.1.4 Genetic instability in CRC 
 
Almost all CRC cases have a form of genetic instability, and it is thought to be an 
essential step in the formation of cancer. There are two main types of genetic 
instability associated with CRC; chromosomal instability and microsatellite 
instability which are mutually exclusive, but result in the loss of the same pathways 
via different means.  Both types of instability occur early in the development of 
colorectal cancer with the instability increasing as the cancer progresses (Shibata, 
Peinado et al. 1994; Stoler, Chen et al. 1999) (Figure 1.2). 
 
 
1.1.4.1 Chromosomal instability (CIN) 
Chromosomal instability (CIN) is the most common form of genetic instability in 
colorectal cancer occuring in ~85% of all CRC cases, and it is this genetic instability 
that is thought to drive the adenoma-carcinoma sequence (Vogelstein, Fearon et al. 
1988; Fearon and Vogelstein 1990). Chromsomal instability is associated with a 
worse prognosis for CRC (Walther, Houlston et al. 2008). CIN occurs through 
abnormal segregation of chromsomes and structural re-arrangements such as 
translocations and deletions which results in the gain or loss of entire chromosomes 
or large regions of chromosomes leading to aneuploidy and a loss of heterozygosity 
(Lengauer, Kinzler et al. 1998). 
 
Loss of heterozygosity (LOH) occurs frequently in CRC which can result in the 
inactivation of tumour suppressor genes and is though to be one of the key steps in 
the carcinogenesis of CRC. LOH is loss of one allele at a specific point and often 
occurs at loci where one of the allels is already abnormal e.g. through mutation. For 
example LOH occurs at chromosome 5q, where it is thought to affect APC, in ~20-
50% of CRC tumours and as APC mutations occur at an early stage of CRC 
development this often results in the loss of both wild-type allele. A large proportion 
of CRC tumours (70%) show LOH at 17p, affecting p53 which is located at 17p13.1. 
LOH also occurs at chromosome 18q in CRC tumours (~70%), with evidence to 
suggest a role for tumour suppressor genes located there such as DCC, SMAD2 and 
SMAD4 (Grady and Markowitz 2002). These genes are also frequently mutated in 
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CRC and the relevance of these genes and their signalling pathways will be discussed 
in section 1.1.5.   
 
 
The cause of CIN is not yet fully understood as many of the genes causing CIN in 
tumours are unknown. However studies in yeast have shown that over a 100 different 
genes can cause CIN in yeast. These include genes involved in cell cycle checkpoint, 
kinetochore structure and function, centrosome and microtubule formation,  
chromosome condensation and sister-chromatid cohesion (Grady and Carethers 
2008). Interestingly it has also been shown that mutations in APC may contribute to 
chromosomal instability, through a disruption in the kinetochore-microtubule 
attachment causing an impairment in chromosome segregation (Fodde, Kuipers et al. 
2001; Kaplan, Burds et al. 2001). 
 
 
1.1.4.2 Microsatellite Instability (MSI) 
 
Microsatellite instability is changes in the sequence of repetitive DNA sequences that 
are localised at microsatellite regions. Inactivation of MMR genes results in an 
inability to repair errors that occur during replication at microsatellite sequences. 
Besides microsatellite regions, DNA replication errors can also occur in genes which 
have short nucleotide repeats such as An or CAn in their coding region such as 
TFG!II, IGF2R and BAX. Tumours can be MSI-high (MSI-H) or MSI-stable (MSS), 
MSI-stable tumours are usually CIN.  
 
MSI-H tumours appear in ~15% of sporadic CRC cases, which can be caused by 
mutations in the same MMR genes as HNPCC. About 10% of mutations are in 
MSH6 which is rarely mutated in HNPCC (Kinzler and Vogelstein 1996). The 
criteria of a MSI-H tumour depends on at least two unstable loci out of a possible 
five loci (BAT25, BAT26, D5S346, D2S123 and D17S250) called the Bethesda 
panel (Boland, Thibodeau et al. 1998). Inactivation of MMR genes can also occur 
through aberrant methylation of the gene promoter region and MSI-H tumours in 
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1.1.4.3 CpG island methylator phenotype (CIMP) pathway 
 
The CIMP pathway is characterised by methylation of CpG islands inducing 
transcriptional silencing of, in general, tumour-suppressor genes, and is thought to be 
an alternative molecular pathway to CRC than the CIN pathway tumours described 
earlier (Toyota, Ahuja et al. 1999). Epigenetic changes in DNA occur at CpG 
dinucleotides, and regions that are enriched for CpG dinucleotides are called CpG 
islands. These islands usually occur in the 5' regions of genes, and are found at ~50-
60% of genes. Global hypomethylation occurs in colorectal neoplasia, at an early 
stage in the cancer development, resulting in aberrant gene activation. Most CpG 
islands are unmethylated, however many of these CpG islands can become aberrantly 
methylated in cancer and this aberant methylation is associated with gene silencing. 
Aberrant methylation of a gene promoter is an early event in the development of 
colorectal cancer (Feinberg and Tycko 2004). Methylation of CpG islands occurs 
more frequently with increasing age and many genes are methylated in normal 
ageing musosa as well as in tumours. This is referred to as A-type methylation. 
However a study by Toyota et al, 1999, showed that there are several genes which 
undergo methylation only in colorectal tumours, known as C-type methylation 
(Toyota, Ahuja et al. 1999).  
 
In CRC there are many genes which have been found to be aberrantly methylated, 
including MLH1. In CIMP tumours, silencing of the MMR genes is caused by 
aberrant methylation of predominantly the MLH1 promoter (Weisenberger, 
Siegmund et al. 2006) and occurs in >80% of MSI-H tumours. It is also possible to 
have a CIMP CRC phenotype independent of MSI-H, ie that are microsatellite stable 
(Jass 2007). The CIMP positive tumours can be split into two subgroups. Group 1 are 
characterised by MSI, have a high rate of BRAF mutations (>50%) and a better 
prognosis, whereas group 2 are MSS and have a high frequency of KRAS mutations 
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(92%). CIMP positive mutations rarely have mutations in APC or TP53 (Kim, Lee et 
al. 2010).  
 
The discovery of the CIMP phenotype has led to the idea that there may be three 
pathways to developing CRC, chromosomal instability (CIN), epigenetic instability  
(CIMP/MSS) and epigenetic instability with mircosatellite instabiltiy (CIMP/MSI) 
(Issa 2008). Given the discovery of the CIMP phenotype and a further understanding 
of the mutations necessary to drive the progression of CRC, Figure 1.3 below, taken 
from a review by Kim, Lee et al, 2010, has adapted the classical adenoma-carcinoma 
sequence model and summarised the three potential pathways to sproadic CRC 
development, with some of the key mutations associated with the different pathways, 






































Figure 1.3: Pathways to CRC development 
(Kim, Lee et al. 2010). Illustration of the three potential pathways to sporadic CRC 
development; CIN, CIMP/MSI and CIMP/MSS. CIN tumours are associated with 
aneuploidy and mutations in APC, p53, KRAS, PIK3CA and SMAD. CIMP tumours 
with MSI are associated with BRAF mutations, a good prognosis and methylation of 
MLH1 promoter. CIMP tumours with MSS are associated with KRAS mutations, 
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1.1.5 Mutations in CRC 
 
There are several key genes that are regularly mutated in CRC which lead to its 
activation and progression including APC, KRAS, p53, BRAF, DCC and PIK3CA. 
Malignant tumours have a higher number of mutated genes compared with 
adenomas, suggesting that mutations accumulate through the adenoma-carcinoma 
development (Lea, Jackson et al. 2009). 
 
1.1.5.1 APC mutations in sporadic CRC 
Mutations in the APC gene resulting in an inactive form of APC, occur in the 
majority (~70-80%) of sporadic CRC cases (Segditsas and Tomlinson 2006). 
Mutation of APC is an early event in CRC development (Powell, Zilz et al. 1992) 
(Figure 1.2). Both alleles of APC are inactivated in both sporadic and FAP cancers. 
Somatic mutations in CRC have been shown to predominantly occur in one region of 
the APC gene termed mutation cluster region (MCR). This cluster region is from 
codon 1286 to 1513, with mutations at codons 1309 and 1450 most common, 
similarly to germ-line mutation, 95% of somatic mutations result in a truncated 
protein product (Miyoshi, Nagase et al. 1992) 
 
Germline mutations in APC are 100% penetrant with mutations in APC considered to 
be the initation mutation event in CRC but other mutations are required for 
development of the early adenocarcinoma to full carcinoma. APC mutations occur in 
the earliest stages of CRC development and it has been postulated that APC is a 
‘gatekeeper’ gene of cell proliferation in the epithelial layer of the colon, and its 
genetic alteration is enough to initiate tumour formation (Kinzler and Vogelstein 
1996). 
 
1.1.5.2 RAS genes 
Mutations in KRAS are another early event in the development of CRC and are found 
in 30-50% of tumours (Baldus, Schaefer et al. 2010). The majority of KRAS 
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mutations are located at codon 12 and 13 and result in a constitutively active protein 
(Davies, Bignell et al. 2002). KRAS mutations are thought to contribute to the 
progression of CRC from early adenoma to an intermediate adenoma but are not 
necessary for the initiation of CRC development like APC (Kinzler and Vogelstein 
1996) (Figure 1.2). KRAS is a member of the RAS family, small G-proteins which 
are regulated by receptor tyrosine kinase growth factors such as EGFR. Upon 
activation Ras proteins activate downstream signalling pathways such as the MAPK 
and PI3K pathways (Malumbres and Barbacid 2003). BRAF is one of the 
downstream targets of the Ras proteins and is mutated in ~10% of CRC tumours, 
predominantly at codon 600 (Davies, Bignell et al. 2002). BRAF mutations are 
associated with CIMP tumours, particularly those that are MSI-H (Domingo, Espin et 
al. 2004; Kambara, Simms et al. 2004) 
 
1.1.5.3 TP53 
The tumour suppressor gene p53, located at 17p13.1, is mutated in ~50% of CRC 
tumours. It is involved in the regulation of DNA damage and normally acts as a 
tumour suppressor gene. Mutations in p53 occur in the later stages of the adenoma-
carcinoma sequence and are predominantly missense mutations. Mutations in p53 
usually occur at CpG dinucleotide repeats, resulting in G:C to A:T transitions, and 
effect its DNA-binding activity (Baker, Preisinger et al. 1990). 
 
1.1.5.4 PIK3CA 
Mutations are found in PIK3CA in ~20-30% of colorectal tumours (Samuels, Wang 
et al. 2004). They are both constitutents of the PI3K signalling pathway. PIK3CA is 
an isoform of the p110 catalytic subunit of PI3K. The PI3K signalling pathway is 
activated via receptor tyrosine kinases (RTKs), which then results in the 
phosphorylation of AKT and activation of downstream targets. Mutations of 
PIK3CA usually occur in either the helical or kinase domain (exons 9 and 20), 
resulting in increased kinase activity and the phosphorylation of AKT in the absence 
of growth factor stimulation of the RTKs (Chalhoub and Baker 2009). 
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1.1.5.5 Phosphatase and tensin homolog (PTEN) 
Mutations of PTEN also occur in CRC (~10%) and are more frequent in MSI-H 
tumours (Guanti, Resta et al. 2000; Dicuonzo, Angeletti et al. 2001). PTEN is an 
antagonist of the PI3K pathway and loss of PTEN function results in PIP3 
accumulation, phosphorylation of AKT and constitutive activation of the 
downstream signalling pathways, which includes activation of NF-%B, and MDM2, 
the p53 inhibitor (Samuels, Wang et al. 2004; Chalhoub and Baker 2009).  
 
1.1.5.6 TGF! signalling pathway 
LOH occurs at chromosome 18q in CRC tumours (~70%) and is one of the most 
commonly observed genetic alterations in CRC, with evidence to suggest a role for 
tumour suppressor genes located there such as DCC, SMAD2 and SMAD4. SMAD2 
and SMAD4 are mutated in ~5-10% of CRC tumours (Grady and Markowitz 2002). 
SMAD2 and SMAD4 are involved in the TGF! signalling pathway. TGF! is a 
cytokine that is involved in growth inhibition, apoptosis and differentiation. It 
activates a heterometric receptor complex consisting of serine-threonine kinases. 
Once the receptor is activated it triggers the phosphorylation of downstream targets 
including SMAD2 and SMAD3. SMAD2 and SMAD3 can form a heterodimeric 
complex, or a heterotrimeric complex with SMAD4 and regulate gene transcription 
involving transcription factors such as tissue factor (TF) (ten Dijke and Hill 2004). 
Dysregulation of TGF! signalling can also occur through mutations of TFG!R2 in 
~30% of CRC. In 85% of MSI-H tumours frameshift mutation occur in TGF!R2, 
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1.1.6 Identification of risk alleles in CRC 
 
Many studies are now focusing on the identification of novel risk alleles for CRC, 
the hypothesis being that there are many low penetrant risk alleles which convey a 
small or moderate risk to CRC. A large number of genome wide association studies 
(GWAS) have been conducted in order to begin to elucidate some of these risk 
factors. Replicated studies by Dunlop et al have determined up to ten low penetrant 
risk alleles that confer a risk to colorectal cancer. Interestingly several of these loci 
contain genes found to be involved in the TGF! signalling pathway which is already 
known to dysregulated in CRC. Figure 1.4 below (Tenesa and Dunlop 2009) 
illustrates a summary of the components of the TFG! pathways and highlights some 
of the somatic mutations that are known to occur in CRC as well as the new risk 
alleles identified. GWAS studies have also identified several susceptibility loci for 
CRC, with an enrichment for genes linked to the MAPK pathway (Lascorz, Forsti et 
al. 2010). A meta-analysis of several different GWAS studies identified four novel 
susceptibility loci for CRC, located at chromosome 1q41, chromosome 3q26, 
chromosome 12q13 and chromsome 20q13 (Houlston, Cheadle et al. 2010), with 
several variants identified in the BMP pathway as conferring a risk to CRC 
(Tomlinson, Carvajal-Carmona et al. 2011). Therefore it may be that there are many 
other low penetrant risk alleles for CRC in known or novel pathways leading to 
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Figure 1.4: TGF!  signalling pathway 
(Tenesa and Dunlop 2009). GWAS studies have identified several novel 
susceptibility loci for CRC, with an enrichment for the TGF! signalling pathway 
evident. This figure illustrates the TGF! pathway with known somatic mutations in 
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1.2 Inflammatory Bowel Disease (IBD) 
 
 
Inflammatory bowel disease consists of two relapsing disorders, Crohn’s disease 
(CD) and ulcerative colitis (UC), that are characterised by a chronic inflammatory 
condition of the intestines. IBD has an early onset age, occurring at ~15-30 years of 
age, with earlier onset occurring in patients with a family history of the disease. 
Ulcerative colitis presents as continuous inflammation from the rectum extending to 
the colon, with the inflammation affecting only the mucosal layer of the intestine. 
However Crohn’s disease can affect any part of the gastrointestinal tract, from the 
mouth to the anus and the disease presents with transmural lesions. The inflamed 
areas of mucosa are alternated with regions of healthy appearance. 
 
There are high incidence rates of IBD in North America and Northern European 
countries, with lower incidences reported in Africa, south-east Asia, Australia and 
South America. This north-south gradient may be due to genetic factors however it is 
more likely to be due to environmental factors. Incidence rates are increasing in 
countries that previously had low rates of IBD and there are increasing incidence 
rates in immigrants from these countries following a move to more developed 
countries (Vermeire and Rutgeerts 2005; Baumgart, Thomas et al. 2009; Ishihara, 
Aziz et al. 2009).  
 
IBD is caused by a combination of both environmental and genetic factors, as well as 
microbial agents and the response of the immune system (Fiocchi 1998). It is known 
that IBD results from an aberrant response of the immune system to commensal flora 
and antigens in the intestine. The epithelial layer is the first defense to bacterial 
infection and acts as a barrier. It has been shown that this barrier can be more 
permeable in IBD patients with defects found in the junctions of the epithelial cells 
as well as defects in mucus production (Roda, Sartini et al. 2010). The innate 
immune response has become of increasing interest in understanding IBD, and 
several genes involved in the innate immune system have been shown to be 
associated with IBD (discussed in section 1.2.2). 
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The immune response of IBD patients is defective in several ways including different 
expression of Toll-like receptors (TLRs) in intestinal epithelial cells than observed in 
healthy individuals and defects in T-cell activation and clearance (Vermeire and 
Rutgeerts 2005; Baumgart and Carding 2007; Ishihara, Aziz et al. 2009). 
 
Although similar, CD and UC have clinical and molecular differences. Mouse 
models of intestinal inflammation have shown that the inflammation usually involves 
either a Th-1 or Th2-type T cell mediated inflammation and it is found that CD is 
characterised by the Th1-type T cell-mediated inflammation, which results in an 
increase of IL-2, IFN-# and TNF (Strober, Fuss et al. 2002). In UC however there is 
an inflammatory response that is associated with a Th2-type T cell inflammation 
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1.2.1 Environmental risk factors for IBD 
 
Similar to CRC, IBD is a disease that is attributed to both environmental and genetic 
risk factors. Environmental factors include smoking, diet, geography, sanitation and 
hygiene (Fiocchi 1998). Interestingly smoking appears to be only a risk for CD 
whereas it appears to be protective against UC (Mahid, Minor et al. 2006). Other 
factors that have been suggested to play a role in the development of IBD include 
usage of oral contraceptives, appendectomy, stress and childhood conditions.  
 
1.2.1.1 Cigarette Smoking 
The evidence for cigarette smoking as a risk factor for IBD is interesting as it has a 
negative effect on CD patients but a positive effect for UC patients (Mahid, Minor et 
al. 2006). It has been shown that cessation of cigarette smoking increases the risk UC 
and patients with UC found that symptoms worsen when they quit smoking, with 
improvement found when they resumed smoking (Cosnes 2004; Loftus 2004). One 
study showed that smoking has a dose-dependent beneficial effect on symptoms of 
UC (van der Heide, Dijkstra et al. 2009). UC patients who smoke are half as likely to 
require hospitalization for the disease and former smokers with UC are 50% more 
likely to require hospitalization (Cosnes 2004; Loftus 2004).  
 
Conversely smoking is a risk factor for CD, with smokers more than twice as likely 
to develop the disease. Former smokers are also at an increased risk compared to 
people who have never smoked. CD patients who smoke have a higher risk of flare-
up, and are associated with more disease complications and a lower quality of life 
(Cosnes 2004; Loftus 2004). 
 
1.2.1.2 Diet 
The effect of diet in the development of IBD has been extensively studied however 
the results are inconsistent. Several food types have been suggested to play a 
negative role in IBD, with an excessive consumption of carbohydrates, high 
consumption of mono-/poly-unsaturated fat, vitamin B and sugar all suggested to 
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increase risk (Geerling, Dagnelie et al. 2000). Some studies have shown that high 
consumption of dietary fibre, fruit, vegetables, and fish have been suggested to be 
protective against the development of IBD, but other studies are inconclusive (Amre, 
D'Souza et al. 2007). 
 
1.2.1.3 Childhood factors 
It has been suggested that children who were breastfed have a lower risk of 
developing IBD. However although breastfeeding has been postulated to have a 
protection against IBD, the results are unclear with conflicting studies (Molodecky 
and Kaplan 2010). It has been shown that CD is more common in patients who had 
hot water available in the childhood home, but not with UC, with the suggestion that 
this may be contributing factor to the increase in CD in developed countries in the 
last 50 years (Gent, Hellier et al. 1994). Other childhood factors that have been 
suggested to be associated with decreased risk of IBD include growing up in 
crowded living conditions, large families, absence of tap water, and absence of hot 
water (Baumgart and Carding 2007; Molodecky and Kaplan, 2010) leading to a 
‘hygiene hypothesis’ where excessive sanitation and hygiene in childhood limits 
exposure to infections necessary to acquire immunity against diseases. However 
patients with CD have been shown to be from smaller households with less siblings 
and lower birth rank has been associated with an increase in the risk of both UC and 
CD, and potentially due to an increase in the exposure of childhood infections 




Appendectomy appears to be a risk factor in the development of CD, but confers a 
protection against the development of UC. It has been shown that there is a negative 
association between having an appendectomy and the development of UC, with 
evidence to suggest that an appendectomy is protective for UC (Rutgeerts, D'Haens 
et al. 1994). However the opposite appears to be evident for the development of CD. 
A study by Anderson et al, 2003, showed that there is an increased risk of developing 
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CD, dependent on sex, age and the diagnosis of CD at the time of operation 
(Andersson, Olaison et al. 2003). An appendectomy is associated with an increased 
risk of developing strictures in CD (Baumgart & Cardin, 2007), however other 
studies are less clear as regards to risk with some studies showing no association 
with risk (reviewed Molodecky & Kaplan, 2010). 
 
1.2.1.5 Other factors 
A meta-analysis involving nine studies suggested that there is a modest association 
between taking oral contraceptives and the development of CD and UC (Godet, May 
et al. 1995). Although the data is not always consistent it has been suggested that 
there is an increased risk of IBD in women who take oral contraceptives (Boyko, 
Theis et al. 1994). Another environmental factor thought to be involved in IBD is 
stress. It is thought that flare-ups in IBD symptoms can be triggered by stress and 
depression, with an increased likelihood of relapse in times of adverse life conditions 
and stress (Mawdsley and Rampton 2005).  
 
 
A study reviewing the literature and a meta-analysis of 23 studies suggested that a 
Helicobacter pylori infection may be protective against the development of IBD 
(Luther, Dave et al. 2010), which ties in with the evidence suggesting that children 
who grow up with more sanitary conditions are more likely to develop IBD 
(discussed section 1.1.1.3). However the occurrence of IBD is more common after a 
gastrointestinal infection and patients with IBD have higher levels of mucosal 
bacteria (Baumgart and Carding, 2007), suggesting a complex relationship between 
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1.2.2 Genetic risk factors for IBD 
 
1.2.2.1 Family history 
A positive family history of the disease is the largest independent risk factor for IBD, 
there is a strong genetic link for IBD and it has been reported that between 5-22% of 
all patients with IBD have family member affected with IBD. Hence a family history 
is a strong risk indicator for IBD and the risk of a first degree relative developing 
IBD is higher with CD than UC, with siblings being the first degree relative with the 
highest risk (Russell and Satsangi 2004). It has been shown that there is a relative 
risk of 13-36% in siblings of CD patients, and a lesser risk in siblings of UC patients 
of 7-17% (Thompson, Driscoll et al. 1996; Halfvarson, Bodin et al. 2003; Vermeire 
and Rutgeerts 2005). It is known that monozygotic twins have a higher rate of 
disease concordance (37% for CD and 10% for UC) than dizygotic twins (7% for CD 
and 3% for UC). This suggests that genetic factors may play a stronger role in CD 
than in UC (Thompson, Driscoll et al. 1996; Halfvarson, Bodin et al. 2003; Vermeire 
and Rutgeerts 2005). 
 
 
1.2.2.2 Susceptibility genes for IBD 
There has been a lot of success in determining susceptibility genes for IBD, using 
both linkage studies and genome-wide association studies (GWAS). It has been 
shown that although CD and UC share some susceptibility genes, many are 
associated with only either form of IBD. In some cases the underlying gene causing 
the association has been identified (Noble, Nimmo et al. 2006). To date GWAS 
studies have identified 71 susceptibility loci for CD and 47 susceptibility loci for UC 
(Anderson, Boucher et al. 2011; Franke, McGovern et al. 2011). 
 
 
NOD2 was the first susceptibility gene identified for CD using linkage studies and 
later confirmed by GWAS. Several other genes involved in innate immunity and 
inflammatory pathways have also been identified such as IL-23R, TLR4, TLR5, IL-
12, STAT3 and NOD1, whereas other genes identified have been discovered in 
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interesting and unexpected pathways such as ATG16L1 involved in the autophagy 
pathway (Barrett, Hansoul et al. 2008). There have been several knock-out mouse 
models developed for IBD genes and although some knock-out strains such as 
STAT3 KO or IL-10 KO knock-out can spontaneously develop intestinal 
inflammation other knock-out mouse models including NOD2 KO and ATL16L1 KO 
do not, suggesting that other factors, either genetic or environmental, are necessary 
for IBD to develop (Mizoguchi and Mizoguchi 2010). 
 
 
1.2.2.3 Il-23 pathway 
One interesting gene candidate that has been identified in IBD is IL-23R, specifically 
an amino acid polymorphism Arg38Gln. Association at this locus has also been 
implicated in several auto-immune disorders (The Wellcome Trust Case Control 
Consortium 2007; Barrett, Hansoul et al. 2008).  IL-23R is located on chromosome 
1q31 and the IL-23 receptor is a heterodimeric membrane receptor to the IL-23 
cytokine. It forms in complex with the IL-12RB subunit, which has also been found 
to be a susceptibility gene for CD. Interestingly two other components of the IL-23 
signalling pathway have also been found to be associated with IBD. Janus kinase 2 
(JAK2), a proximal kinase and downstream target, and signal transducer and 
activator of transcription 2 gene (STAT3) are both associated with CD and UC 
indicating that the IL-23 signalling pathway is important in the inflammation in IBD 
(Barrett, Hansoul et al. 2008; Ishihara, Aziz et al. 2009) (Figure 1.5). JAK2 and 
STAT3 are also activated in other signalling pathways, including IL-10, which has 
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Figure 1.5: Illustration of the IL-23 pathway 
(Budarf, Labbe et al. 2009). This figure highlights the genes that are associated with 
IBD in the IL-23 inflammatory pathway, demonstrating how the use of GWAS 
studies have identified novel pathways involved in IBD. Gene variants in IL-23R, IL-
12RB, JAK3 and STAT3 have been shown to be significantly associated with either 
CD or UC. 
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1.2.2.4 Autophagy pathway 
The finding that IBD is associated with autophagy-related (ATG) 16L1 gene has 
generated much interest in the field. It is located on chromosome 2q37.1 and was 
found that ATG16L1 is associated with an increased risk for CD, with the strongest 
association at a non-synonymous amino acid change, alanine to threonine (Budarf, 
Labbe et al. 2009). It is a key component in the modulation of the autophagy 
pathway. The autophagy pathway involves enclosing cellular content in the 
autophagosome, a double membrane organelle, which is then delivered to the 
lysosome for degradation. It is now thought to play an important role in the innate 
immune system by delivering intracellular bacteria to the lysosome (Hampe, Franke 
et al. 2007; Barrett, Hansoul et al. 2008).  
 
Interestingly two other components of this pathway are thought to be associated with 
CD, IRGM located on chromosome 5q33.1 and leucine-rich repeat kinase 2 (LRRK2) 
located on chromosome 12q12 (The Wellcome Trust Case Control Consortium, 
2007; Barrett, Hansoul et al, 2008). NOD1 and NOD2 have been shown to be co-
localised with ATG16L1, and it has been suggested that this localisation at the cell 
membrane is an essential step in the initiation of the autophagy pathway after 
bacterial infection (Travassos, Carneiro et al. 2010). 
 
1.2.2.5 Nucleotide-binding Oligomerization Domain 2 (NOD2) 
CARD15 was the first candidate gene to be identified for IBD. It is located at 
chromosome 16q12 and polymorphisms in NOD2, encoded by CARD15, were found 
to be significantly associated with CD in western populations (Ogura, Bonen et al. 
2001). NOD2 polymorphisms have not been found in Japanese or Asian populations. 
NOD2 is cytoplasmic protein, which is activated upon recognition of the bacterial 
ligand, muramyl dipeptide (MDP), a component of both Gram-positive and Gram-
negative bacteria. It is involved in the regulation of the inflammatory process and 
upon MDP recognition, NOD2 activates a signalling pathway that results in the 
transcription of the inflammatory mediator NF-%B and the activation of the MAPK 
pathway (Strober, Murray et al. 2006). NOD2 has also been found to be activated by 
 
  31 
viral ssRNA, activating IRF3 and production of IFN-! (IL-6) suggesting a role in the 
immune response to viral infection as well as bacterial (Sabbah, Chang et al. 2009). 
 
NOD2 is a member of the large protein NLR (NOD-like receptor) family which 
share three structural domains, a leucine-rich repeat (LRR) domain which is involved 
in ligand recognition, a nucleotide oligomerisation (NOD) domain involved in self-
oligomerisation and a caspase activation recruitment domains (CARD) or PYRIN 
domain that is involved in protein-protein interactions. NOD2 contains two CARD 
domains located at the N-terminal and is known to be involved in protein-protein 
interactions with several proteins such as RIPK2. It also contains a central NOD 
domain which is important for self-oligomerisation that is necessary for NF-%B 
activation and a C-terminal LRR domain which is required for MDP recognition 
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Figure 1.6: Structure of NOD2 gene and protein 
(Gaya, Russell et al. 2006). This illustrates the structure of the gene and the protein 
of NOD2. The gene structure highlights the location of the three NOD2 
polymorphisms associated with CD. The protein structure demonstrates the three 
structural domains of NOD2, two CARD domains, a central NOD binding domain 
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MDP activation of NOD2 causes recruitment of receptor-interacting serine/threonine 
kinase (RICK) via the CARD domain. This results in the activation of the NF-%B 
pathway and gene transcription. It has been demonstrated in intestinal epithelial cell 
lines that membrane localization of NOD2 is necessary for the activation of NF-%B 
in response to MDP recognition (Barnich, Aguirre et al. 2005). Disruption of actin 
cytoskeleton has been shown to increase NOD2 mediated NF-%B transcription after 
stimulation by MDP (Legrand-Poels, Kustermans et al. 2007). Activation of NOD2 
by MDP can also activate the MAPK signaling pathway through phosphorylation of 
JNK, p38 and ERK (Abraham and Cho 2006). 
 
The majority of NOD2 mutations are localised in the C-terminal LRR domain, which 
is involved in ligand recognition (Figure 1.6). There are three mutations associated 
with CD, Arg702Trp, Gly908Arg and Leu1107fsinsC (3020insC). The 
Leu1107fsinsC is a frameshift mutation, resulting in a truncated short terminal 
protein, and tends to carry an increased disease risk than the other two mutations. A 
study by Maeda et al, 2007, produced a mouse with a NOD2 3020insC mutation. The 
mice were healthy, with no abnormalities present in the intestines, however they 
showed that this mutation had a gain of function observed as an increase in NF-"B 
activation after MDP treatment. After treatment with DSS, the mice displayed an 
increase in bacteria-induced inflammation and an increase in proinflammatory 
cytokines, especially Il-1! (Maeda, Hsu et al. 2005). However in human 
macrophages, the three NOD2 mutations do not appear to respond to MDP 
stimulation resulting in a decrease in the NF-%B inflammatory response (Tanabe, 
Chamaillard et al. 2004). It has been shown that the Leu1107fsinsC protein cannot 
localise to the cell membrane as the deletion causes the loss of the final 33 COOH-
terminal amino acid residues, the region that is responsible for the membrane 
targeting of NOD2 (Barnich, Aguirre et al. 2005). The Leu1107fsinsC protein has 
also been shown to inhibit the expression of IL-10, an anti-inflammatory cytokine, in 
human monocyte cells (Noguchi, Homma et al. 2009).  
 
Patients with IBD have an increased risk of developing CRC (discussed in the 
following section) and one study identified a potential association between the 
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NOD2 mutation Leu1107fsinsC and an increase in the risk of developing CRC at an 
older age (Kurzawski, Suchy et al. 2004). A meta-analysis conducted by (Tian, Li et 
al. 2010) looked at eight studies, consisting of 3,524 CRC cases and 2,364 controls 
and found that the three NOD2 polymorphisms (Arg702Trp, Gly908Arg and 
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1.2.3 IBD and CRC 
 
There is strong a link between IBD and CRC, where patients with IBD have a greater 
risk of developing CRC, which is increased with duration of symptoms and severity 
of inflammation and dysplasia, and accounts for 15% of all deaths in patients with 
IBD (Ekbom, Helmick et al. 1990; Munkholm 2003; Jess, Gamborg et al. 2005). 
Although patients with IBD only account for ~2% of all CRC patients, there is an 
increased incidence rate of 2.64 for CD and 2.75 for UC patients (Bernstein, 
Blanchard et al. 2001). A meta-analysis of 116 studies showed that the risk of UC 
patients developing CRC is ~2% after 10 years of disease, increasing to 8% after 20 
years and 18% at 30 years (Eaden, Abrams et al. 2001). Chronic inflammation can 
promote carcinogenesis, by inducing gene mutation, epigenetic changes, promoting 
cell growth and angiogenesis. Both positive and negative regulators of inflammation 
have been implicated in the development of CRC, including TNF", IL-1, IFN-!, Il-
10, COX-2, TLR4, NF-%B and TGF! (Kraus and Arber 2009; Danese and 
Mantovani 2010). 
 
The development of colitis-associated CRC has several differences than the models 
of CRC development discussed in the previous section (Section 1.1). One difference 
is the stage of cancer in which the APC gene is mutated. As discussed previously, the 
mutation of APC is an early event in the development of sporadic CRC and is 
considered the initiation event of the adenoma-carcinoma pathway. In colitis-
associated CRC, it appears that APC mutation is a rarer and much later occurring 
event in the development of the cancer (Kern, Redston et al. 1994; Aust, Terdiman et 
al. 2002) and mutation of p53, followed by LOH, is an early event (Holzmann, 
Klump et al. 1998; Hussain, Amstad et al. 2000) (Figure 1.7). Mouse models with 
p53 knockout (p53-/-), p53+/+ and p53+/- do not develop CRC, however after 
treatment with dextran sulphate sodium (DSS), which causes acute intestinal 
inflammation, 20% of the p53+/+ and p53+/- mice developed cancers which increased 
to 57% in the p53 knockout mice and the studies showed that the loss of p53 
enhanced the development of colitis-associated cancer in these models (Chang, 
Coudry et al. 2007).  
 






Figure 1.7: Development of sporadic CRC versus colitis-associated CRC 
(Xie and Itzkowitz 2008). Illustration of a simple adenoma-carcinoma progression of 
sporadic CRC compared with a progression model of colitis-associated CRC. As 
illustrated APC mutation is an early event in CRC development, however it occurs at 
a much later stage in the colitis-associated cancer. Conversely p53 mutation is a late 
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1.3 Early Growth Response 1 (EGR1) 
 
 
Early growth response EGR1 (also know as Krox-24, NIGFI-A, TIS8, and Zif268) is 
a transcription factor first described in 1988 (Sukhatme, Cao et al. 1988). EGR1 is a 
member of the early growth response (EGR) family, which also contains EGR2, 
EGR3 and EGR4. They share a conserved DNA binding sequence, a zinc finger 
motif, with between 81 and 93% homology. EGR1 is located at chromosome 5q31. 
Expression of EGR1 is seen throughout fetal mouse development, however knockout 
of EGR1 is not embryonic lethal and mice demonstrate normal growth (Sukhatme 
1990; Lee, Tourtellotte et al. 1995). However one study found that EGR1 null mice 
were smaller in size, with defects in the pituitary glands resulting in a lack of 
luteinizing hormone (LH) and in the case of the females, defects were also seen in 
the ovaries. In these EGR1 knockout mice, both sexes were sterile (Topilko, 
Schneider-Maunoury et al. 1998). 
 
 
EGR1 was initially recognised as a serum-induced transcription factor involved in 
cell growth and differentiation. However many different cellular functions have since 
been attributed to EGR1 as well as its ability to be rapidly and transiently induced by 
many different environmental signals. EGR1 has become of increasing interest as it 
was found to be differentially expressed in many different cancers and play a role in 
the regulation, either directly or indirectly, of several tumour suppressor genes 
including p53 and PTEN (Thiel and Cibelli 2002).  It has also been shown that there 
is an increase in EGR1 protein levels in the inflamed mucosa of IBD patients 
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1.3.1 Structure and promoter of EGR1 
 
EGR1 is a zinc-finger transcription factor whose motif consists of three Cys2-His2 
type zinc fingers (Pavletich and Pabo 1991). This region acts as a DNA-binding 
domain, and binds to a specific GC-rich sequence, 5’-GCGGGGGCG-3’ (Christy 
and Nathans 1989). This sequence is also found in the EGR1 promoter, suggesting 
that EGR1 can activate its own gene expression. EGR1 also contains a nuclear 
localisation signal, which is located in a basic region near the zinc finger motif. This 
basic region is also conserved in the other members of the EGR family, EGR2 and 




The EGR1 protein has an inhibitory domain situated between the transcriptional  
activation domain, which is localised at the amino terminus and the DNA-binding 
domain (Russo, Sevetson et al. 1995) (Figure 1.8 A). This inhibitory domain binds 
two transcriptional co-factors, NGF1-A-binding protein (NAB) 1 and 2 (NAB1, 
NAB2), which block the biological activity of EGR1. NAB1 was first identified as 
an interacting protein of EGR1 by yeast-two hybrid screen using a mouse embryo 
cDNA library, where it was found to interact via the inhibitory domain and suppress 
transcriptional activity of EGR1 (Russo, Sevetson et al. 1995).  
 
 
The 5’ genomic flanking region of the EGR1 promoter contains five serum response 
elements (SREs) (Christy, Lau et al. 1988) (Figure 1.8 B). The serum response 
elements require binding of two transcription factors, the serum respone factor (SRF) 
and a ternary complex factor Ets-like-1 (ELK1) protein. The EGR1 promoter also 
contains a cyclic AMP response element which binds CREB. CREB is constitutively 
bound to the EGR1 promoter and the phosphorylation of CREB is also necessary for 
activation of EGR1.The EGR1 promoter contains a SP1 binding site and a NF-%B 
binding site as well as an EBS site which can bind EGR1 (Thiel and Cibelli 2002; 
Tur, Georgieva et al. 2010). 
 




Figure 1.8: Illustration of EGR1 domains and promoter region 
(Adapted from Thiel and Cibelli 2002; Tur, Georgieva et al. 2010). A. Demonstrates 
the domains of EGR1, an activation domain, an inhibitory domain which binds two 
transcriptional co-factors NAB1 and NAB2 and a DNA-binding domain that contains 
a zinc-finger motif. B. An illustration of the EGR1 promoter with the regulatory 
binding regions highlighted. The EGR1 promoter has several serum response 
elements (SREs), a cyclic AMP site, transcription factor binding regions for SP1 and 
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1.3.2 Induction of EGR1 expression 
 
The expression of EGR1 is rapidly induced by many environmental signals, such as 
growth factors, hormones, cytokines and neurotransmitters, as well as serum and 
phorbol 12-myristate 13-acetate (PMA) (DeFranco, Damon et al. 1993). It has been 
shown that activation of EGR1 by serum, PMA, EGFR and LPS is mediated by the 
mitogen-activated protein kinase (MAPK) signalling pathway, via Ras-Raf-MEK-
ERK with ERK1/2 causing phosphorylation of Elk1 which forms a complex with 
SRF on the EGR1 promoter (DeFranco, Damon et al. 1993; Whitmarsh, Shore et al. 
1995; Guha, O'Connell et al. 2001; Maegawa, Arao et al. 2009; Tur, Georgieva et al. 
2010) (Figure 1.9). 
 
EGR1 is also induced by stress stimuli such as the chemotherapeutic drugs cisplatin 
and etoposide, DNA damaging agents, genotoxic stress, UV, and bacteria 
Helicobacter pylori (Virolle, Adamson et al. 2001; Xu, Dziarski et al. 2001; Yu, de 
Belle et al. 2004; Matsunoshita, Ijiri et al. 2011). It has been shown that induction of 
EGR1 by growth factors leads to a transient expression, whereas UV-induced 
expression of EGR1 leads to a sustained expression (Yu, de Belle et al. 2004). The 
EGR1 promoter has a NF-%B binding site, and EGR1 expression is induced by NF-
%B in prostate cancer cells, with full induction of EGR1 by NF-%B requiring the 
E2F1 transcription factor. Both NF-%B and E2F1 are over-expressed in prostate 
cancer, as is EGR1 (Zheng, Ren et al. 2009). 
 
The induction of EGR1 by anisomycin, a drug which inhibits DNA and protein 
synthesis, in T lymphocyte cells is mediated via the MLK2/MKK3/p38 MAPK 
signalling pathway, which causes the phosphorylated CREB and ATF1 to bind to the 
EGR1 promoter (Rolli, Kotlyarov et al. 1999) (Figure 1.9). Activation of EGR1 by 
PGE2 in macrophage cells is also mediated via p38, with CREB and ATF2 binding to 
the EGR1 promoter to induce expression (Faour, Alaaeddine et al. 2005). The 
induction of EGR1 by different stress stimuli can have opposing effects. In prostate 
cancer it was found that serum-induced EGR1 increases the transcription of p300, 
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which has several EGR1 binding sites, and this induction of p300 acetylates and 
stabilises EGR1. However activation of EGR1 by UV irradiation causes the 
induction of EGR1 phosphorylation, which leads to a downregulation of p300 (Yu, 
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Figure 1.9: MAPK pathways involved in EGR1 activation 
Illustration of the MAPK signalling pathways that regulate the activation of EGR1. 
LPS, PMA and EGFR induction of EGR1 is known to be mediated via MEK/ERK 
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1.3.3 Regulation of EGR1  
 
As an early response gene the expression of EGR1 is normally rapid and transient, 
depending on the stimulus and cell type, with mRNA levels of EGR1 increasing as 
soon as 15min after activation. The main method of regulating EGR1 expression 
appears to be in the form of the two inhibitory co-factors, NAB1 and NAB2, as well 
as EGR1 itself.  
 
1.3.3.1 NGF1-A-binding protein (NAB)-1 and 2  
NAB1, one of the two inhibitory co-factors of EGR1 is ubiquitously expressed and 
can completely block EGR1-mediated transcription. However NAB2 expression is 
induced by the same stimuli as EGR1, such as serum and growth factors (Svaren, 
Sevetson et al. 1996). NAB2 contains some EGR1 binding sites in its promoter and 
transcription of NAB2 is activated by EGR1. It has been shown in epithelial cells that 
this activation by EGR1 is repressed by NAB2 itself in a dose-dependent manner, i.e. 
EGR1 activation of NAB2 causes EGR1 transcription to be switched off suggesting 
EGR1 and NAB2 act in a negative feedback loop (Kumbrink, Gerlinger et al. 2005). 
The expression of NAB2 is also induced by other members of the EGR family, 
EGR2 and EGR3 indicating that they play a role in the regulation of NAB2 
expression (Kumbrink, Kirsch et al. 2010). NAB2 has been shown to block the 
EGR1-mediated transcription of tissue factor (TF) in HeLa cells as well as 
preventing the EGR1-mediated production of growth factors TGF1, VEGF, HGF and 
PDGF-AB (Houston, Campbell et al. 2001). 
 
NAB1 and NAB2 have the ability to multimerise with each other, forming either 
homo or hetero multimers, through a conserved domain, NAB conserved domain 1 
(NCD1). NAB1 and NAB2 contain two highly conserved domains, NCD1, which is 
also required for interaction with EGR1, and NCD2 which is though to be required 
for the repression activity of EGR1 (Svaren, Sevetson et al. 1996; Svaren, Sevetson 
et al. 1998). It has been found that the c-terminal domain of NAB2 interacts with 
chromodomain helicase DNA-binding protein 4 (CHD4), which is a component of 
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the nucleosome remodelling and deacetylase (NuRD) complex. This interaction is 
necessary for the inhibitory function of NAB2 (Srinivasan, Mager et al. 2006). 
 
EGR1 is known to be overexpressed in prostate cancer. It has been shown that NAB2 
expression is down-regulated in 80% of prostate cancers, suggesting that loss of 
NAB2 results in an unbalanced expression of EGR1, with several of EGR1 target 
genes similarly overexpressed in prostate cancer. The loss of NAB2 in prostate 
cancer appears to be an early event in the development of prostate cancer 
(Abdulkadir, Carbone et al. 2001). Interestingly studies have indicated that NAB2 
may also play a role as a co-activator of EGR1. It has been shown that NAB2 is a co-
activator of EGR1-mediated transcription of luteinizing hormone ! (LH!) in CV-1 
cells and of IL-2 transcription in Jurkat cells (Sevetson, Svaren et al. 2000; Collins, 




It is known that changes in cytosine DNA methlyation are one cause for epigenetic 
changes in cancer. These changes occur within the dinucleotide CpG. Areas that are 
rich in CpG regions, called CpG islands, are found in the 5’ region of the gene, and 
are usually unmethyated (Esteller 2007). CpG island hypermethlyation of genes can 
cause silencing of the gene and it has been found that several tumour suppressor 
genes are hypermethylated in human cancer, indeed several genes have been found to 
be CpG methylated in their promoter region in prostate in breast and CRC. Genes 
that usually are methylated can also become un-methylated in cancer, thereby 
causing aberrent gene activation (Rodriguez, Frigola et al. 2006; Schuebel, Chen et 
al. 2007; Chung, Kwabi-Addo et al. 2008; Kakar, Deng et al. 2008; Toyota, Suzuki 
et al. 2008). 
 
A number of promoters regulated by EGR1 have been found to undergo altered 
methylation such as the p73 promoter, and the MDR1 promoter in prostate cancer 
(Enokida, Shiina et al. 2004; Pipaon, Real et al. 2005). It has been found that the 
heparanase promoter is CpG island hypomethylated in both bladder and prostate 
cancer (Ogishima, Shiina et al. 2005; Ogishima, Shiina et al. 2005)  and the 
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expression of heparanase is known to be regulated by EGR1 in tumour cells (de 
Mestre, Rao et al. 2005). The methyaltion of these promoters may affect the binding 
of EGR1 to its binding site of the promoter which may have an effect on gene 
activation. EGR1 has several CpG islands in its 5’ region and it has been suggested 
that CpG methylation of the EGR1 promoter may influence the transcription and 
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1.3.4 The EGR1 protein and transcription factor 
 
 
EGR1 codes for an 80kDa nuclear protein that is rich in amino acids proline and 
serine (~33%) and is endogenously expressed. It is known to have several 
phosphorylation sites, although these are not well characterised, and the protein is 
short lived when not phosphorylated. The EGR1 protein is thought to be regulated by 
the ubiquitin-proteasome pathway as EGR1 can be ubiquinated and has been shown 
to interact with PRC8, a subunit of the 20S proteasome complex (Bae, Jeong et al. 
2002). EGR1 is known to localise to the nucleus and as mentioned earlier it contains 
a nuclear localisation signal. However there is evidence to suggest that EGR1 may 
also be localised in the cytoplasm and that the cytoskeleton plays a role in shuttling 
EGR1 between the nucleus and the cytoplasm (Mora, Olivier et al. 2004). 
 
1.3.4.1 EGR1 and the Cytoskeleton 
It has been suggested that the cytoskeleton may play a role in the regulation of EGR1 
in benign prostate cells as rapid nuclear translocation of EGR1 is mediated by the 
cytoskeleton in these cells (Mora, Olivier et al. 2004). Curcumin, the active 
component of the herb Curcuma longa, was shown to inhibit cellular proliferation 
and trigger cell death partly by binding to tubulin, causing tubulin aggregation and 
perturbed microtubule assembly in epithelial cells (Gupta, Bharne et al. 2006). 
Curcumin is known to inhibit EGR1 by suppressing the induced expression of EGR1 
mRNA resulting in decreased expression of EGFR in colon cancer cell lines 
(Pendurthi and Rao 2000). Conversely, studies using rat hippocampus and primary 
neurons culture has shown that overexpression of EGR1 promotes the 
phosphorylation of Tau resulting in the destabilisation of microtubules in the brain 
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1.3.4.2 EGR1 protein interactions 
There are not many proteins that are known to interact with EGR1. The most well 
characterised EGR1 protein-protein interaction is with NAB1 and NAB2 as 
discussed. The function of EGR1 as a transcription factor is well characterised and 
the known EGR1-protein interactions appear to facilitate EGR1 in this role.  EGR1 
has been shown to interact with Yes kinase-associated protein –1 (YAP-1), which is 
a transcriptional coactivator of p73, in prostate cancer cells. After irradiation, this 
EGR1-YAP1interaction induces Bax gene expression causing apoptosis in the cell 
(Zagurovskaya, Shareef et al. 2009). As mentioned earlier serum induction of EGR1 
in prostate cancer cells causes the protein to become acetylated, after which it is able 
to directly bind to p300/CBP where it induces expression of growth genes such as 
TGF!, and IGF-2, and inhibits transcription of itself, and p300/CPB. Conversely 
induction of EGR1 by UV causes the protein to become phosphorylated, after which 
it transactivates pro-apoptotic genes p53, PTEN and Bcl-2 (Yu, de Belle et al. 2004; 
Adamson, Yu et al. 2005). 
 
1.3.4.3 EGR1 target genes 
EGR1 has been shown to activate many different genes which are involved in many 
different and even opposing cellular functions including genes involved in growth 
and differentiation, cell cycle regulation, apoptosis and tumour promoting as well as 
trannscription factors. Some interesting target genes of EGR1 include the growth 
factors and cytokines IGF2, TGF!, and VEGF and apoptotic proteins such as p53, 
PARP, PTEN and TNF-".  EGR1 activates expression of the cell cycle regulatory 
protein Cyclin D1, extracellular matrix proteins fibronection and VCAM1 as well 
other transcriptional regulatory proteins such as Fos, ATF3, PPAR#, NF-%B and 
EGR1 itself (Adamson and Mercola 2002; Fu, Zhu et al. 2003; Krones-Herzig, Mittal 
et al. 2005). EGR1 regulates genes that have been shown to be important in human 
cancer as well as genes that are involved in the immune and inflammatory response. 
The role of EGR1 in cancer and the inflammatory response will be discussed in 
detail below.  
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1.3.5 EGR1 and cancer 
 
EGR1 expression has been found to be significantly lower in a variety of cancer cells 
and human tumours including breast carcinoma, glioblastoma, osteogenic sarcoma, 
basel cell carcinoma, squamous cell carcinoma, fibrosarcoma, uterine leiomyomas 
and esophageal carcinoma (Huang, Liu et al. 1995; Huang, Fan et al. 1997; Calogero, 
Arcella et al. 2001; Wu, Chen et al. 2001; Pambuccian, Oprea et al. 2002; Fang, Wee 
et al. 2007). In contrast, EGR1 seems to be overexpressed in gastric cancer and the 
levels of EGR1 expression correlated with the clinical stage of the cancer as well as 
the tumour infiltration and invasion of the tumour (Zheng, Pu et al. 2010). The levels 
of EGR1 are also significantly higher in prostate cancer, and the increased levels of 
EGR1 may play a role in influencing the regulation of genes including signalling 
proteins, transcription regulators, neuroendrocine proteins and membrane-associated 
proteins involved in adhesion and signalling (Svaren, Ehrig et al. 2000). It has been 
suggested that EGR1 may act as either a tumour promoter or as a tumour suppressor 
as both gain and loss of EGR1 appears to be significant in human cancer.  
 
Many tumour cell lines also express little EGR1 and re-introduction of EGR1 into 
these cell lines, such as HT1080 (a fibrosarcoma cell line), inhibits the growth and 
transformation of the cells and induces expression of TGF!1 (Liu, Yao et al. 1999). 
Similarly re-introduction of EGR1 to esophageal carcinoma cell line and tissue 
resulted in a reduced growth, reduced soft agar colony formation and reduced tumour 
growth rate in SCID mice (Wu, Chen et al. 2001). In an egr1-/- mouse model, 
introduction of a Lewis lung carcinoma (LLC1) showed slower rates of tumour 
growth compared with wild-type mice (Caso, Barry et al. 2009). In a study by 
Krones-Herzig et al, in which a two-stage carcinogenesis experiment using DMBA 
and TPA was performed, it was shown that the induced tumours in EGR1 null mice 
developed significantly earlier than egr1+/+ or egr1+/- mice. This demonstrated an 
increased susceptibility for tumour development in the absence of EGR1 (Krones-
Herzig, Mittal et al. 2005). These studies indicate that there is a difference in the role 
of EGR1 in tumour development between introducing the mutation into an EGR1 
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null mouse and inducing a tumour in an EGR1 null mouse, suggesting that the 
difference in the function of EGR1 depends on the cellular or tumour environment. 
 
One mechanism by which EGR1 is thought to exert tumour suppressor or tumour 
promoter effects is by its regulation of several tumour suppressor genes, which are 
known to be involved in the induction of apoptosis. Apoptosis is an important 
mechanism in regulating cell growth, and the dysregulation of the apoptotic pathway 
is a regular occurrence in cancer. EGR1 has been proposed to have a role in inducing 
apoptosis in cancer via three main pathways; binding to the c-Jun transcription 
factor; transactivation of the PTEN gene; and through binding to the p53 promoter 
with activation of the p53 tumour suppressor gene (Thiel and Cibelli 2002). Both p53 
and PTEN are frequently mutation in cancer, and CRC, as previously discussed. The 
c-Jun transcription factor has been shown to be essential for apoptosis in neuronal 
cells (Ham, Eilers et al. 2000). 
 
1.3.5.1 EGR1 and p53 
TP53 is an essential tumour suppressor gene due to its role in regulation of cell 
growth and regulation of many mediators of the apoptotic pathway. Activation of 
p53 results in cell cycle arrest, apoptosis and senescence. Loss of p53 results in 
dysregulation of the apoptotic pathway and aberrant cell growth. EGR1 has been 
shown to regulate the expression of p53 and p73 which in turn can regulate the 
expression of EGR1, which has p53 responsive elements in its promoter region 
indicating a system of feedback loops that comes into effect in response to stress, 
resulting in prolonged expression of the p53 family of genes and apoptosis in tumour 
cells (Yu, Baron et al. 2007). There are several potential EGR1 binding sites in the 
promoter region of p53, and EGR1 binds directly to the p53 promoter (Krones-
Herzig, Mittal et al. 2005). 
 
It has been shown that UV-induced expression of EGR1 only occurred in p53-/- cells. 
EGR1 expression was not induced in cells with p53 expression, either in p53+/- or 
p53+/+ cells. Over-expression of EGR1 in p53+/+ caused transformation of the cells 
(Zhang and Chen 2001). However in egr1-/- mice, irradiation treatment does not 
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induce expression of either p53 or p73, indicating that EGR1 is necessary for the 
induction of p53 and p73 in response to radiation (Yu, Baron et al, 2007). 
 
It has been suggested that the mutation status of p53 may have an effect on the 
function of EGR1 again indicating the importance of the cellular environment on the 
function of EGR1. EGR1 can induce the expression of wild-type p53 and may 
enhance its anti-apoptotic and growth inhibitory effects. However in cells expressing 
mutant p53, EGR1 appears to have a tumour-promoting role and mutant p53 can 
induce the expression of EGR1. Loss of EGR1 in cells expressing mutant p53 
increases the rate of apoptosis after genotoxic stress, suggesting that expression of 
EGR1 in cells expressing mutant p53 contributes to its resistence to apoptosis 
(Weisz, Zalcenstein et al. 2004). Studies by Sauer et al suggest that the over-
expression of EGR1 that occurs in prostate cancer may be caused by the presence of 
mutant p53. In prostate cells, mutant p53 activates the MEK/ERK signalling 
pathway, which regulates the transcription of EGR1. Activated EGR1 then activates 
the EGFR/ERK signalling cascade, causing a positive feed back loop (Sauer, Gitenay 



















































Figure 1.10: Positive feeback loop with EGR1 and mutant p53 
(Sauer, Gitenay et al. 2010). Mutant p53 inatiates activation of the loop by induction 
of MEK, which activates trancription of EGR1, and allows activation of EGR1 target 
genes. EGR1 up-regulates the expression of EGFR ligands, which activates the EGF 
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1.3.5.2 EGR1 and PTEN 
PTEN is a lipid phosphatase that acts as a tumour suppressor gene by antagonising 
the PI3/Akt pathway (Cao, Wei et al. 2004). The PTEN promoter has several putative 
EGR1 binding sites, and it has been shown that EGR1 can directly transactivate the 
PTEN gene. A study by Virolle et al demonstrated that the presence of EGR1 is 
necessary for the induction of PTEN following radiation and etoposide treatment, as 
egr1-/- cells are unable to induce expression of PTEN, as well as being resistant to 
UV induced apoptosis. Induction of EGR1 by UV light results in the expression of 
PTEN as well as apoptosis. As EGR1 expression is lost in many cancers it has been 
suggested that EGR1 may play a part in resistance to radiation treatment (Virolle, 
Adamson et al. 2001).  
 
 
It has also been shown that induction of ARF by IGF-1 can cause phosphorylation of 
EGR1 and its ultimate translocation to the nucleolus. The resulting ARF-mediated 
sumoylation of EGR1 increases the transcriptional ability of EGR1 to induce 
transcription of PTEN. Like PTEN the ARF promoter contains EGR1 binding sites, 
with EGR1 able to induce expression of ARF. PTEN expression is not induced in 
egr1-/- or Arf -/- cells (Yu, Zhang et al. 2009).  
 
 
1.3.5.3 EGR1 and colorectal cancer  
A RNA microarray study showed that seven genes, including EGR1, were 
consistently up-regulated in the normal mucosa of CRC patients compared with the 
mucosa from healthy controls (Hong, Ho et al. 2007), indicating that EGR1 
expression is up-regulated in colorectal cancer patients.  EGR1 was also shown to be 
differentially expressed in different stages of colorectal cancer development between 
normal and adenoma tissue, and between adenoma and carcinoma also (Habermann, 
Paulsen et al. 2007).  
 
The role of apoptosis in the development of cancer is well known, with the ability of 
cancer cells to inhibit or evade apoptosis a hallmark of cancer progression. The pro-
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apoptotic role of EGR1 depends on the cell type and the nature of the stimulus used 
to induce EGR1 expression. Several studies have been undertaken to try and 
elucidate the apoptotic activity of EGR1 in epithelial and CRC cells. Survivin is an 
inhibitor of apoptosis (IAP) protein that is abberantly expressed in human cancer and 
over-expressed in several cancer cell lines including the CRC cell line SW480. It has 
been shown that EGR1 regulates the expression of survivin and binding of EGR1 to 
the survivin promoter downregulates its expression (Wagner, Schmelz et al. 2008).  
 
As well as mediating the induction of the proapoptotic proteins p53 and PTEN as 
discussed, EGR1 also mediates the induction of the proapoptotic proteins ATF3 and 
NSAID-activated gene-1 (NAG-1). Treatment of CRC cells lines (HCT116, SW480, 
LoVo and HT-29) with the NSAID, tolfenamic acid, suppressed the proliferation of 
these cells and induced apoptosis through an increase in the nuclear accumulation of 
epithelial-specific ETS-1 (ESE-1) transcription factor, resulting in the activation of 
EGR1, which in turn transactivated the expression of the pro-apoptotic protein NAG-
1 (Lee, Cho et al. 2008).  
 
Activation transcription factor 3 (ATF3) is a downstream target of EGR1, which has 
also been shown to be act as a tumour suppressor in colorectal tumours. ATF3 
appears to mediate LY29002-induced apoptosis in human colorectal cancer cell lines, 
HCT-116, SW480, Caco-2 and HT-29 and contrary to PTEN events this apoptosis 
pathway is a PI3K/Akt-independent pathway (Yamaguchi, Lee et al. 2006). Tumour 
necrosis factor-related apoptosis-induction ligand (TRAIL) induces the expression of 
EGR1 in gastric and CRC cell lines. TRAIL induces apoptosis in cells via binding to 
the death receptor 4 (DR4) and DR5. However DR4 and DR5 can also mediate 
induction of pro-survival and inflammatory signalling and EGR1 expression is 
induced after the induction of DR4 and D5R. The DR5-induced apoptosis pathway is 
inhibited by c-FLIP, which is a target gene of EGR1, indicating an anti-apoptotic role 
for EGR1 (Mahalingam, Natoni et al. 2010).  
 
Hypoxia inhibition of EGR1 prevents upregulation of EGFR, EGR1 directly induces 
EGFR transcription and it is also known that low oxygen levels and EGFR play a 
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crucial role in tumour development and progression (Nishi, Nishi et al. 2002). 
Treatment of CRC cell lines HT-29 and Caco2 with curcumin was also shown to 
result in downregulation of EGFR by inhibiting ERK signalling which significantly 
decreased EGR1 gene expression at both a transcriptional and translational level 
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1.3.6 EGR1 and inflammation 
 
EGR1 gene expression is regulated by both growth stimulatory and inhibitory 
cytokines including TNF-", TNF-!, interleukin-1, IFN-", and IFN-! (Cao, Guy et 
al. 1992; Granet and Miossec 2004). EGR1 is induced after treatment with the 
bacterial components lipopolysaccharide (LPS) and peptidogylcan (PGN), which is 
mediated by MEK/ERK signalling pathway, through binding to Elk-1 and SRF to the 
SRE-1 domain in the EGR1 promoter (Xu, Dziarski et al. 2001). The induction of 
EGR1 by LPS in macrophages is rapid and transient, with mRNA levels increased 
after 30min of treatment, and protein levels expressed after 1-2 hours (Coleman, 
Bartiss et al. 1992). TNF-"/!, IFN and IL-1 induced expression of EGR1 is similarly 
rapid and transient (Cao, Guy et al. 1992; Granet and Miossec 2004). EGR1 is also 
required for LPS-mediated induction of both TF and TNF-", both of which are also 
mediated via MEK and ERK (Shi, Kishore et al. 2002). EGR1 is thought to bind to 
the TF promoter with AP-1 and c-Rel/p65 transcription factors in order to induce 
gene expression of TF (Figure 1.11). EGR1 is also involved in the PGN-induced 
expression of TNF-", which requires the EGR1, c-Jun and NF-%B transcription 
factors (Xu, Dziarski et al. 2001).  
 
EGR1 is important in the LPS-mediated induction of IL-6, which is reduced in egr1-/- 
cells. It has been demonstrated that although EGR1 is not necessary for the initial 
expression of many inflammatory mediators, it is required for the sustained 
expression of these mediators (Pawlinski, Pedersen et al. 2003). Although the 
majority of EGR1 research in relation to the inflammatory response is conducted in 
monocytic and macrophage cells, epithelial cells do express the receptor for LPS, 
toll-like receptor 4 (TLR4) and LPS has been demonstrated to induce EGR1 
expression in epithelial cells. EGR1 has been shown to co-localise with TF in kidney 
and lung epithelial cells, and egr1-/- cells show a reduced expression of TF 
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Figure 1.11: LPS induction of EGR1 and TF in monocytes 
(Guha, O'Connell et al. 2001). Illustration of the mechanism by which LPS induces 
the expression of TF via the induction of EGR1. LPS induces the expression of 
EGR1 via the MEK/ERK signalling pathway which then activates the expression of 


















  57 
Membrane-associated prostaglandin (PG) E2 synthase (PGE2) is an inducible enzyme 
that is a mediator of inflammation, and is induced by pro-inflammatory stimuli. 
EGR1 binds to the mPGES promoter, resulting in induction of PGE2 (Naraba, 
Yokoyama et al. 2002). Dimethylcelecoxib (a derivative of the NSAID celecoxib 
used for treatment of rheumatoid arthritis and FAP) inhibits mPGES-1 
transcription by down-regulating EGR1 (Deckmann, Rorsch et al. 2010). PGE2 
can induce expression of EGR1 via the MLK2/MKK3/p38 MAPK signalling 
pathway in a concentration-dependent manner, in macrophage and fibroblast cells. 
The induction of EGR1 was mediated via binding of ATF2 and CREB transcription 
factors to the EGR1 promoter. PGE2 suppressed the induction of TNF-" expression, 
with EGR1 binding to the TNF-" promoter suppressing transcription (Faour, 
Alaaeddine et al. 2005).  
 
Helicobacter pylori has been shown to induce EGR1 expression in colon and gastric 
cell lines, and EGR1 regulates the expression of CD44, ICAM-1, and CD95L 
(APO/Fas), which are induced after infection with H.pylori (Abdel-Latif, Windle et 
al. 2004), suggesting a role for EGR1 in the innate immune system. EGR1 also 
contributes to inducible expression of the multidrug resistence-1 (MDR1) gene, 
which codes for P-glycoprotein, and in hematopoietic cells it has been suggested that 
EGR1 is necessary for MDR1 promoter activity after induction by 12-O-
tetradecanoylphorbol-13-acetate (TPA) (McCoy, Smith et al. 1995). MDR1 deficient 
mice develop large bowel inflammation and dysplasia after infection with 
Helicobacter (Annese, Valvano et al. 2006). A further link with inflammation is the 
observation that in IBD patients, there was an increase in the levels of EGR1 protein 
in the inflamed mucosa compared with the non-inflamed mucosa (Subbaramaiah, 
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1.4 Preliminary studies of EGR1 
 
EGR1 is highly likely to play a role in carcinogenetic processes involved in the 
development of colorectal cancer. As the above reviewed literature illustrates, EGR1 
plays an important role in cancer, as a regulator of either tumour suppressor or 
tumour promoter genes and also in the induction of apoptosis in cancer cells by 
various pathways. EGR1 appears to play a significant role in inflammatory pathways, 
which highlights a role in IBD also. Hence several preliminary studies were 
undertaken in the Colon Cancer Genetics Group (CCGG) (University of Edinburgh) 
and the Gastrointestinal unit (GI) (University of Edinburgh) before undertaking this 
thesis. 
 
In silico studies conducted by the CCGG identified that EGR1 expression is 
decreased in the tumour mucosa of patients with CRC compared with normal colonic 
mucosa (James Prendergast/Susan Farrington pers comm). An in silico analysis of 
tissue expression datasets was conducted, using 329 adult human EST libraries. The 
EST libraries contained a minimum of 250 sequences, were grouped according to 
disease and tissue type, and examined for differences in gene expression between 
normal and disease, e.g. normal colon and tumour colon. The study showed that 
EGR1 expression was significantly higher in normal colon (q value = 8.77e-7) and 
also in normal lung (q value = 4.36e-7). EGR1 expression was not significantly 
differentially expressed in kidney, liver or prostate tumours.  
 
A co-expression and gene ontology enrichment study was also performed. This study 
used the GNF Gene Atlas V2 Human U133A data (Su, Wiltshire et al. 2004). The 
158 Gene Atlas arrays consisting of 79 tissues (with 2 replicates of each) were 
normalised and the expression values were calculated using the PM/MM difference 
model in dChip. The expression values of replicate arrays were pooled and Pearson 
correlations were calculated between logged values. A funcational annotation term 
enrichment of the 407 probes displaying the highest co-expression with EGR1 were 
analysed using DAVID. The following five probes showing high co-expression with 
EGR1 were mapped to genes that are known to be involved in IBD; Tumour necrosis 
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factor 2 (TNF2), interleukin 1 beta (IL-1!), solute carrier family 11, intereferon 
gamma receptor 1 (INFGR) and intercellular adhesion molecule 1 (CD54). 
 
Simultaneously, experiments conducted by the GI unit examined the expression of 
EGR1 in colonic biopsies and also showed that EGR1 is differentially expressed 
between non-inflamed and inflamed mucosa. A yeast-two hybrid screen conducted 
by the GI unit using NOD2 as bait against a SW480 CRC cell line library also 
identified EGR1 as a potential novel interacting protein with NOD2 in SW480 CRC 
cells.  
 
In collaboration a large scale case-control study was conducted by both the CCGG 
and the GI unit which demonstrated an association between common variants of 
EGR1 with disease phenotype in both CRC and IBD. Three common variants of 
EGR1 (rs3813321, rs11743810, rs11748288) were genotyped in healthy controls 
(n=3011) and colorectal cancer patients (n=3012). Overall the study showed that 2 of 
the EGR1 variants gave a borderline significance for association with CRC 
(rs3813321 p=0.2967; rs11743810 p=0.0571; rs11748288 p=0.0815) and all 3 EGR1 
variants were associated with early onset (<55 years of age) colorectal cancer 
(rs3813321 p=0.0392, rs11743810 p=0.0283, rs11748288 p=0.0258). Subsequently 
the 3 variants were genotyped in IBD patients (n=990) and different healthy controls 
(n=368). This study showed a significant association with 2 of the EGR1 loci for 
IBD (rs3813321 p=0.0789, rs11743810 p=0.0329, rs11748288 p=0.0413), with a 
significant association at all three EGR1 loci for ulcerative colitis (rs3813321 
p=0.0394, rs11743810 p=0.0202, rs11748288 p=0.0062). Only one of the loci was 
significantly associated with Crohn’s disease (rs3813321 p=0.1882, rs11743810 
p=0.0357, rs11748288 p=0.1855) (Susan Farrington/Elaine Nimmo pers comm). 
 
The preliminary data collected by the CCGG and GI unit and reviewed literature 
suggests that EGR1 is a candidate susceptibility gene in colorectal disease, both in 
CRC and IBD, and thus further investigation into the activity of EGR1 in CRC and 
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What is clear from the literature is that EGR1 itself is neither a tumour suppressor 
nor a tumour promoter gene. What makes it an important gene to study in cancer is 
its role as a regulatory of gene expression of both tumour promoter and tumour 
suppressor genes, and of inflammatory genes in both cancer and IBD. As discussed, 
it has the ability to activate the transcription of many types of genes often with 
opposing functions, but what determines which genes it activates in still unclear. 
Therefore it may be that the cellular environment has an impact on the role of EGR1 
in these cells. However the mechanism of regulation of EGR1 expression in these 
cells is unknown. It is therefore necessary to determine first of all to what extent 
there is differential expression of EGR1 in colorectal cancer, and to try and 
determine by what means the expression of EGR1 is regulated. What is also evident 
is that the EGR1 protein also can have different roles to play, depending on which 
stimulus it is induced by ie it is context-dependent. This warrants a further look into 
EGR1 expression and localization in CRC cells and any potential novel protein 
interactions in these cells, especially given the potential interaction between EGR1 
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1.5 Aims and Experimental Design 
 
The aim of this project is to better understand how EGR1 is expressed in colorectal 
disease and to further investigate the localisation and function of the EGR1 protein in 
CRC cells line. This project was conducted in collaboration with the CCGG and the 
GI unit. 
 
There is little really known about the role of EGR1 in CRC. Therefore we will first 
determine the expression levels of EGR1 in matched normal mucosa and tumour 
samples and this thesis will attempt to determine if EGR1 expression is gained or lost 
in CRC. Similarly although EGR1 is known to be involved in the regulation of many 
different inflammatory mediators little is known about its role in IBD. We will 
investigate the expression of EGR1 in the normal mucosa of IBD patients along with 
its expression after stimulation with inflammatory mediators to determine if there is 
differential expression of EGR1 in IBD. This will lead to a greater understanding of 
EGR1 expression and potential role in both colorectal cancer and IBD. 
 
The mechanisms by which EGR1 is differentially expressed in cancer is still unclear 
We will attempt to determine if the EGR1 variants that were identified as being 
associated with disease phenotype in both CRC and IBD show any correlation with 
the expression of EGR1 in both diseases. Given that EGR1 expression is mediated 
via the MAPK signalling pathway, and mutation in KRAS/BRAF are a frequent 
occurrence in CRC, we will determine if mutations in this pathway demonstrate any 
correlation with EGR1 expression. We will also investigate whether EGR1 
expression is regulated via methylation of the EGR1 promoter in both the CRC and 
IBD patients.  
 
The finding by the GI unit that EGR1 may interact with NOD2 by yeast-two hybrid 
experiments is an exciting and novel interaction for both proteins and we will 
determine if an interaction does occur in CRC cells as this interaction may be 
important in understanding the role that EGR1 plays in inflammation and IBD. The 
cellular localisation of EGR1 will be investigated in CRC cells to determine if EGR1 
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does localise to the cytoplasm, which would allow it to co-localised and interact with 
NOD2 in the cell. The finding of an EGR1-NOD2 interaction led to the possibility 
that EGR1 may have many un-identified protein-protein interactions, so a further 
yeast-two hybrid screen will be conducted to determine novel interacting proteins of 
EGR1 specifically in CRC cells. It is hoped that this experiment will determine if 
EGR1 does interact with different proteins and lead to a better understanding of its 
function in cancer cells. 
 
All experimental techniques used in this thesis are described in detail in Chapter 2. 
Chapter 3 will discuss the findings in relation to the differential expression of EGR1 
in CRC and IBD patients using qRT-PCR as well as sequencing of the three EGR1 
variants and bisulfite sequencing of the EGR1 promoter in these patients. Chapter 4 
will investigate the expression and localisation of EGR1 in CRC cells using protein 
extract, Western blotting techniques and immunocytochemisstry and determine if 
EGR1 interacts with NOD2 and components of the cytoskeleton using 
immunoprecipitation. Chapter 5 will discuss the yeast-two hybrid screen to 
determine novel interacting proteins of EGR1.The yeast two hybrid screen is 
conducted using a SW480 cell line library, and a full length and truncated EGR1 
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2 Materials and Methods 
 
This chapter details the methods that are used in this thesis. Where required, more 
detailed methods are included in the relevant results chapters. Solutions and media 
denoted with an asterisk (*) have been prepared by the technical services department 
at the MRC Human Genetics Unit. Where stated, patient DNA and RNA samples 
have been prepared by members of the CCGG and GI unit. 
 
2.1  Biological Material 
 
2.1.1 Materials and Solutions 
 
Tissue Culture Medium 
Dulbecco’s modified Eagle’s DMEM (Gibco BRL, Invitrogen, UK) 
Leibovitz L-15 (Gibco BRL) 
McCoy’s 5A (Gibco BRL) 
10% w/v Foetal bovine serum (FBS)* 
1% w/v Penicillin and Streptomycin (P/S)* 




Trypsin Versene (T/V)* 
50% w/v Trypsin 
50% w/v Versene 
Freezing Media 
10% w/v Dimethyl Sulfoxide (DMSO) in FBS 
Treatments 
1mg/ml stock Lipopolysaccharide (LPS; Sigma-Aldrich) 
10mM stock Curcumin (Sigma-Aldrich) 
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2.1.2 Cell culture  
 
Cell lines are stored in the liquid nitrogen facility at MRC Human Genetics Unit. 
Cells were raised from liquid nitrogen by thawing at 37oC and resuspended in 
appropriate media (Table 1). Cells were grown in the appropriate media, which was 
supplemented with 10% foetal bovine serum (FBS)* and 1% 
penicillin/streptomycin*, and incubated in 5% CO2 at 37oC. The cells were 
maintained in the growing phases by removing the media, washing with PBS and 
treating with a solution of trypsin/versene (1:1) at 37oC for 5min to detach the cells. 
The cells were resuspended at a suitable dilution in an appropriate amount of media 
and placed in a fresh flask containing media. To preserve the cell line stock, the cells 
were centrifuged after they have been detached and the pellet re-suspended in 
freezing media. The cells were first frozen at –70oC, before transfer to the liquid 
nitrogen storage at –140oC. 
 
The cells were harvested for RNA, DNA and protein extracted by removing the 
media and washing the cells in cold PBS. The cells were detached from the flask 
using a cell scraper and collected in 1ml of PBS. The cells were centrifuged using an 
Eppendorf Microcentrifuge 5415 R, the PBS was discarded and the cell pellet was 





Cell line Cell type Media  Reference 
HRT18 Colorectal adenocarcinoma DMEM (Tompkins, Watrach et al. 
1974) 
HT29 Colorectal adenocarcinoma McCoy’s 5A  (Fogh, Fogh et al. 1977)  
HCT116 Colorectal carcinoma McCoy’s 5A (Brattain, Fine et al. 1981) 
SW480 Colorectal adenocarcinoma L-15  (Leibovitz, Stinson et al. 
1976) 
VACO425 Colorectal carcinoma DMEM (McBain, Weese et al. 1984) 
Table 2.1: Cell lines cultured and used within this thesis 
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The following cell lines are maintained within the CCGG and cell pellets for RNA 
and DNA extraction were provided by M. Walker. 
 
Cell line Cell type Reference 
SW48 Colorectal adenocarcinoma (Leibovitz, Stinson et al. 1976) 
LoVo Colorectal adenocarcinoma (Drewinko, Romsdahl et al. 1976) 
CACO2 Colorectal adenocarcinoma (Fogh, Fogh et al. 1977) 
MCF7 Breast adenocarcinoma (Soule, Vazguez et al. 1973) 
PNT Prostate adenocarcinoma (Cussenot, Berthon et al. 1991) 
PC3 Normal prostate (Kaighn, Narayan et al. 1979) 
DUI45 Prostate carcinoma (Stone, Mickey et al. 1978) 
MDC6  Lymphoblastoid Lab stock 
ConA Lymphoblastoid  Lab stock 
Table 2.2: Cell line used for DNA and RNA extraction 
 
The genetic instability status and mutations where known of the colorectal cancer 
cell lines used in this thesis are listed below (Din, Dunlop et al. 2004); S.Farrington 
pers comm). 
 
Cell line APC $-catenin P53 MMR CIN 
HRT18 Mutant Wild type Mutant Deficient (hMSH6) Negative 
HT29 Mutant Wild type Mutant Proficient  Positive 
HCT116 Wild type Mutant Wild type Deficient (hMLH1) Negative 
SW48 Unknown Unknown Wild type Deficient (hMLH1) Unknown 
SW480 Mutant Wild type Mutant Proficient Negative 
LoVo Mutant Unknowm Wild type Deficient (hMSH2) Positive 
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2.1.3 Treatment of cells 
 
Cells were grown in T25cm2 flasks until ~70% confluent and treated with LPS in a 
dose and time dependent manner, or with 1ug/ml of LPS, MDP, PGN and TNF 
(Sigma; provided by Elaine Nimmo, GI unit) for 24hours.  
 
 
2.1.4 Patient Material 
 
2.1.4.1 Colorectal normal mucosa and tumour 
Normal and tumour mucosa samples were collected by Prof. Malcom Dunlop. All 
RNA and DNA extractions on the CRC patient samples were conducted by Dr. 
Rebecca Barnetson, as detailed in the relevant sections below.  
 
2.1.4.2 Inflammatory bowel disease 
The IBD biopsy samples were prepared by the GI unit. The biopsy samples were 
collected in PBS containing 1% P/S and 1% Gentamycin. The samples were placed 
on gauze in solution of Weymouths media (Gibco BRL) containing 1% 
penicillin/streptomycin and 1% glutamine and treated with inflammatory stimuli 
(LPS, MDP, PGN and TNF). The dish containing the samples was placed over a dish 
containing H2O, sealed, and incubated at 37oC for 24hours. The samples were frozen 
in RNALater® (Applied Biosystems). All DNA and RNA extractions on the IBD 
patient material, and cDNA synthesis was conducted by members of GI unit, as 
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2.2 RNA protocols 
 
2.2.1 RNA extraction 
 
Cell line RNA and CRC patient RNA (extracted by Dr. Barnetson) was extracted 
using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions, and 
stored at –80oC. IBD patient RNA were extracted by the GI unit using AllPrep 
DNA/RNA/Protein Mini Kit (Qiagen).  
 
2.2.2 Estimation of RNA concentration 
 
RNA concentration was estimated using optical densitometry on GeneQuant Pro 
RNA/DNA calculator UV spectrometer (Amersham Pharmacia biotech, Cambridge, 
UK). RNA samples were diluted 1 in 50 with H2O, and the absorbency was 
measured at 260nm and 280nm, providing concentration in µg/ml. RNA samples 
were considered sufficiently dissolved with a A260/280 ratio of >1.8. 
 
2.2.3 DNAse I treatment 
 
Cell line and patient RNA was DNAse treated in a 10µl reaction containing 1µg of 
RNA, 1µl of DNAse1 (2 Units) and 1µl of 10x reaction buffer at 37oC for 30 min. 
The reaction was terminated by adding 1µl of DNAse stop and incubated at 65oC for 
10 min.  
 
2.2.4 cDNA synthesis 
 
DNAse treated cDNA was converted to cDNA using the 1st strand cDNA Synthesis 
kit for RT-PCR (AMV), (Roche) as per the manufacturer’s instructions. The cDNA 
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2.3 DNA protocols 
 
2.3.1 Materials and Solutions 
 
10x Tris-Acetate EDTA (TAE)* 
2M Tris 
5.7% w/v Glacial acetic acid 
50mM Na2EDTA (pH 8.0) 
Loading Buffer 
100mM Na2EDTA (pH 8.0) 
0.25% w/v Bromophenol blue 




2.3.2 DNA extraction 
 
2.3.2.1 Cell Lines 
Cell line DNA was extracted using a QIAamp DNA mini kit as per manufacturers 
instructions by myself and Marion Walker.  
2.3.2.2 Patient Material 
Colorectal normal and tumour patient DNA was extracted by Dr. Barnetson using 
using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions, and 
stored at –20oC. IBD patient DNA was extracted by the GI unit using AllPrep 
DNA/RNA/Protein Mini Kit (Qiagen). 
2.3.2.3 Bacterial plasmids 
DNA from bacterial plasmids was extracted using a QIAprep miniprep kit or a 
QIAprep maxiprep kit (QIAGEN), depending on the concentration of DNA required, 





  69 
2.3.3 Purification of DNA  
 




2.3.4 Estimation of DNA concentration 
 
DNA concentration was estimated using optical densitometry on GeneQuant Pro 
RNA/DNA calculator UV spectrometer (Amersham Pharmacia biotech, Cambridge, 
UK). DNA samples were diluted 1 in 50 with H2O, and the absorbency was 
measured at 260nm and 280nm, providing concentration in µg/ml. DNA samples 
were considered sufficient with a A260/280 ratio of >1.6  
 
 
2.3.5 Bisulfite treatment of DNA 
 
DNA samples (1µg) were bisulfite treated using the EpiTect Bisulfite Kit (Qiagen 
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Primers were supplied by Sigma as precipitates and resuspend in dH2O to a stock 
concentration of 100µM, with working stocks diluted to 20µM with dH20. PCR 
amplification was performed on a Peltier PCT225 thermal cycler (MJ research, 
Waltham USA) using the following conditions, unless indicated otherwise: 94oC - 
3min, (94oC - 45secs, 58oC - 45secs, 72oC - 45secs) x35, 72oC - 10min. All primers 

























































































































































Table 2.4: Oligonucleotides for PCR amplification 
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2.4.2 Standard PCR 
 
All PCR reactions were set up in 20µl reactions using the following conditions; 10X 
buffer (1x; Invitrogen), dNTPs (2.5mM; Invitrogen), MgCl2 (2.5mM; Invitrogen), 
Primers (100ng), Taq Polymerase (2.5 units; Invitrogen) and DNA (100ng).  
 
 
2.4.3 Nested PCR 
 
To improve the efficiency of amplification of bisulfite treated DNA, the samples 
under went an additional nested PCR reaction in order to gain more amplification, 
using 1µl of the original PCR reactions in place of the DNA, using the same 
conditions as detailed above. 
 
2.4.4 PCR using Bacterial/Yeast plasmids 
 
PCR reactions using either bacterial or yeast plasmids were performed by 
transferring a colony into the PCR reaction mix in place of DNA using a sterile 
pipette tip, followed by transfer of the residual colony into a 96 well culture plate 
containing the relevant media for storage.  
 
2.4.5 Gel Electrophoresis 
 
PCR were products were resolved on agarose gels (1-3%) using routine grade 
agarose (Biogene, Kimbolton, UK) and 0.5µg/ml of ethidium bromide (BDH, 
Electran, Poole, England) per 50ml gel in 1x TAE. 5µl of the PCR product was 
loaded onto the gel with 3µl 1x loading buffer. The 1Kb ladder (Promega) was 
loaded in a separate well to determine the size of the products. The DNA was 
electrophoresed at 40-80V for ~40min, and visualised on the BioRad Chemi Doc 
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2.4.6 Quantitative Real-time PCR 
 
qRT-PCR was performed using the Taqman Gene Expression Assay system (Applied 
Biosystems) on an ABI PRISM HT7900 Sequence Detection Systme thermal cycler 
to quantify relative levels of mRNA expression of EGR1 (Hs00152928 probe mix, 
Applied Biosystems) and NAB2 (Hs00195573-m1 probe mix). Expression of !-actin 
(Human ACTB endogenous control probe mix, Applied Biosystems) was used as a 
reference control.  
 
Each cDNA sample as prepared in 2.2.4 was amplified in triplicate in a 384 well 
plate (ABgene, Surry, UK) using the following reaction conditions: 2µl of cDNA, 
2.5µl sterile H2O, 5µl Absolute Blue QPCR ROX Mix (ABgene) and 0.5µl of probe 
mix (20x). A series of dilutions was performed using HCT116 cDNA with the !-
actin probe mix and the EGR1 probe mix to generate a standard curve. The PCR 
reaction conditions were: 50oC – 2min, 95oC – 10min, 95oC – 15secs and 60oc – 
1min. The cycle was repeated x40.  
 
The data was analysed using SDS Version 2.3 (Applied Biosystems). In order to 
determine relative expression levels a standard curve was generated from the dilution 
series by plotting the threshold cycle (Ct) against the logged quantity of the diluted 
HCT116 cDNA. 
 
The relative expression of the samples was calculated using linear regression analysis 
from the standard curve. Only standard curves with a R2 value of close to 1 were 
used. The EGR1 expression values were normalised by dividing by the !-actin 
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2.5 Sequence analysis 
 
2.5.1 Purification of PCR products 
 
The PCR products were purified using exonuclease 1 (USB, Ohio, US) and shrimp 
alkaline phosphatase (SAP; USB) in the following reaction mixture: 3.75µl of H2O, 
0.5µl SAP (0.5 U), 0.25µl Exo 1 (2.5 U) and 3µl of PCR product. The mixture was 
incubated in a Peltier PCT225 thermal cycler (MJ Research) at 37oC for 15min, 
followed by incubation at 80oC for 15min. 
 
2.5.2 DNA sequencing 
 
Sequencing of the purified DNA was performed in 10µl reactions using ABI PRISM 
Ready Big Dye Terminator cycle sequencing kit in the following reaction: 100ng of 
purified DNA, 40ng of primer (forward or reverse), 1µl of Big Dye (Applied 
Biosystems) and 5µl of H2O using the following reaction conditions 96oC – 30sec, 
50oC – 15sec, 60oC – 4min, x25 cycles.  
 
2.5.3 Precipitation of DNA from sequencing reactions 
 
Following the sequencing reaction the DNA was precipitated by adding 60µl of 95% 
ethanol and 240µl of NaOAc (0.3M final concentration), and incubating at room 
temperature for 30min. The samples were spun at 1200rpm for 30min using either 
Eppendorf Microcentrifuge 5415 R centrifuge (for reactions in eppendorfs) or a 
Heraeus Multifuge 3 Plus Centrifuge at 2000rpm (for reactions in 96 well plates). 
The pellets were washed with 70% ethanol and allowed to air dry. The DNA pellets 
were stored at –20oC.  The precipitated reaction products were re-suspended in 
HiDiTM (Applied Biosystems), heated at 90oC for 2min, and resolved on ABI 
PRISM® 3100 or 3730 genetic analysers by HGU Technical Services. 
 
 
2.5.4 Analysis of sequence data 
Sequence data was analysed using Consed sequencing program (Gordon, Abajian et 
al. 1998) and Mutation Surveyor® version 3.30 (Biogene Ltd, UK).  
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2.6 Cloning and Bacterial culture 
All centrifuge steps were done using a Heraeus Multifuge 3 Plus Centrifuge or 
Thermo Sorvall RC-5B Plus Centrifuge. 
 
2.6.1 Media and Solutions 
 
Luria Broth (L-Broth )* 
0.1% weight/volume (w/v) Tryptone (Difco) 
0.05% w/v Yeast extract (Difco) 
171 mM NaCl 
Luria Agar (L-Agar)* 
0.1% w/v Tryptone (Difco) 
0.05% w/v Yeast extract (Difco) 
171 mM NaCl 
0.15% w/v Agar (Oxoid Ltd) 
Ampicillin Stock Solution 
50mg/ml ampicillin (Sigma) 
Kanamycin Stock Solution 
50mg/ml kanamycin (Sigma) 
5-Bromo-4-Chloro-3-Indolyl-!-D-galactoside (X-gal) 






The cloning plasmids, pGBKT7-BD and pGADT7-AD, were obtained from 
Matchmaker Gal4 Two-Hybrid System 3 (Clontech Labroatories Inc). All plasmids 
were grown in 250ml L-Broth, with 20mg/ml ampicillin or 10mg/ml kanamycin, 
overnight with shaking at 37oC. The plasmids were extracted and purified using 
Maxi Prep Kit (Invitrogen or Qiagen) as per manufacture’s instructions. The 
plasmids were stored as glycerol stocks at –80oC, via addition of 1ml of overnight 
culture to 300µl sterile glycerol. 
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2.6.3 Cloning of EGR1 into pGEM-T® cloning vector 
 
Full length EGR1 (EGR1Fl) and EGR1 minus its transactivation domain 
(EGR1"Act) were amplified from CRC cell line cDNA and the PCR products were 
purified using a PCR Purification Kit (Qiagen). EGR1Fl and EGR1"Act PCR 
products were cloned into the pGEM-T® cloning vector (Promega) as per the 
manufacturer’s instructions, and transformed into 50µl of TOP10 Chemically 
Competent E.coli cells (Invitrogen).  The transformed cells were spread onto 
selective L-agar plates containing ampicillin (50µg/µl) and X-gal (40µg/ml). The 
plates were incubated at 37oC overnight and white colonies were selected and 
amplified using Sp6 and T7 primers. A colony that was successfully amplified was 
grown in 250ml L-Broth, with 20mg/ml ampicillin, overnight with shaking at 37oC. 
Plasmids containing the correct inserts were extracted as demonstrated by plasmid 




2.6.4 Cloning of EGR1 into pGBKT7 
 
The pGBKT7 vector and the constructs containing EGR1Fl and EGR1"Act in 
pGEM-T were cut using EcoR1 in a 100µl reaction at 37oC for 2 hours. Calf 
Intestine Alkaline Phosphatase (CIAP; Roche) was added to the reactions to prevent 
self re-ligation.  The restriction digest reactions were run out on an agarose gel (0.8-
1.5%), with the correct size band extracted and the DNA purified using a Gel 
Extraction Kit (Qiagen). The ligation reaction was set up using 1µg of cut pGBKT7 
vector with 3x cut insert in a 20µl reaction. The reaction was incubated at room 
temperature for 2 hours. The ligation reaction (5µl) was transformed into 50µl of 
TOP10 Chemically Competent E.coli cell (Invitrogen), plated onto selective L-agar 
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2.6.5 Colony selection and storage 
 
Colonies were selected and amplified using primers A308 and A309, which are 
present in the pGBKT7 vector, and sequenced to confirm the orientation of the insert. 
A colony with the correct sequence and orientation was grown in 250ml L-Broth, 
with 10mg/ml kanamycin, overnight with shaking at 37oC. The EGR1Fl plasmid and 
the EGR1$Act plasmid were extracted and purified using Maxi Prep Kit (Qiagen) as 
per manufacturer’s instructions, and stored as glycerol stocks at -80oC, via 1ml of 
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2.7 Yeast Culture 
All centrifuge steps were done using a Heraeus Multifuge 3 Plus Centrifuge. 
 
 
2.7.1 Media and Solutions 
 
YPD broth* 
0.01% w/v Yeast extract  
0.02% w/v Peptone (Difco) 
0.02% glucose 
0.003% w/v Adenine 
YPD agar* 
0.01% w/v Yeast extract  
0.02% w/v Peptone (Difco) 
0.02% glucose 
0.02% w/v Agar (Oxoid Ltd) 
0.003% w/v Adenine 
SD media* 
0.02% w/v Glucose 
0.0067% w/v Yeast Nitrogen Base 
SD agar* 
0.02% w/v Glucose 
0.0067% w/v Yeast Nitrogen Base 
0.02% Microagar 
10x dropout solution 
300mg/L Isoleucine (Sigma) 
1500mg/L Valine(Sigma) 
200mg/L Arginine HCl (Sigma) 
300mg/L Lysine HCl (Sigma) 
200mg/L Methionine (Sigma) 
500mg/L Phenylalanine (Sigma) 
2000mg/L Threonine (Sigma) 
300mg/L Tyrosine (Sigma) 
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200mg/L Uracil (Sigma) 
Additives 
100x Histidine - 200mg Histidine (Sigma) / 100ml H20 
100x Adenine - 200mg Adenine (Sigma) / 100ml H20 
100x Leucine - 1000mg Leucine (Sigma) / 100ml H20 







pH 7.5 with acetic acid 
PEG/LiAc 
40% PEG 4000 







Z buffer/X-gal solution 
100ml Z buffer 
0.27ml !-mercaptoethanol 
1.67ml X-gal stock solution 
Lyticase Solution (Sigma) 
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2.7.2 Yeast Culture conditions 
 
The yeast strains Y187 and AH106 were grown in YPD medium or on YPD agar 
plates. SD media and agar with appropriate nutritional additives (10x dropout 
solution; 10x histidine; 10x adenine; 10x leucine; 10x tryptophan) was used to grow 
the yeast strains to be transformed with the bait or library. All yeast were incubated 
at 30oC and grown for 3-5 days. 
 
 
2.7.3 Yeast Transformation 
 
The bait constructs in pGBKT7 were transformed into the yeast strain Y187 using a 
LiAc transformation procedure. The constructs were grown overnight in YPD media 
at 30oC with shaking. 300ml of YPD was inoculated with 30ml of this starter culture 
and grown until it reached an OD of 0.4-0.5 using optical densitometry on 
GeneQuant Pro RNA/DNA calculator UV spectrometer (Amersham Pharmacia 
biotech). The cells were harvested by centrifugation at 1000xg for 5min, resuspended 
in 50ml H2O, spun again at 1000xg for 5 min and resuspended in 1.5ml sterile 1 x 
TE/1 x LiAc solution. 
 
A solution containing 0.1µg plasmid, 100µg salmon sperm, 100µl of Y187 yeast 
cells and 0.6ml sterile PEG/LiAc was vortexed for 10sec. The cells were incubated at 
30oC for 30min, after which 70µl of DMSO was added and them placed in 42oC 
water bath for 15min to heat shock. The cells were chilled on ice for 2 min, 
centrifuged briefly at 14,000 rpm and resuspended in 0.5ml sterile 1x TE. A 1/10 
dilution of the cells (100µl) was plated on SD/-Trp (SD media with 10x dropout 
solution, 10x histidine, 10x adenine and 10x tryptohpan) plates and incubated at 
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2.7.4 Yeast Mating 
 
50ml of SD/-Trp (SD media with 10x dropout solution, 10x histidine, 10x adenine 
and 10x tryptohpan) media was inoculated with the transformed constructs and 
grown overnight at 30oC with shaking. The cultures were grown until they reached 
an OD of 0.7-1.0. When the cells were at a concentration of 4x108/ml they were 
mixed with 250µl of SW480 library cells in AH109 (2x108/ml) and plated out onto 2 
YPDA plates and incubated overnight at 30oC. 5ml of YPDA media was added to 
each plate and the cells were scraped off, centrifuged at 1000xg for 5 min and 
resuspended in 2.5ml of SD/-Leu/-Trp (SD media with 10x dropout solution, 10x 
histidine and 10x adenine) media. Dilutions were made and plated out onto SD/-His/-
Leu/-Trp (SD agar with 10x dropout solution with 10x adenine) and SD/-His/-Ade/-
Leu/-Trp plates (SD agar with 10x dropout solution). The cells were grown for 3-5 
days at 30oC. Colonies were picked from the SD/-His/-Leu/-Trp and the SD/-His/-
Ade/-Leu/-Trp plates and inoculated into 96 well plates containing YPD + 25% 
glycerol and frozen at –80oC. 
 
2.7.5 Isolation of plasmids from yeast 
 
The plasmids were isolated from the yeast cells by growing each interacting colony 
on a SD/-Leu/-Trp for 3-4 days at 30oC. The colony cells were scraped into an 
eppendorf tube containing 50µl of TE. Lyticase (10µl) was added to each tube, and 
the cells were resuspended by vortexing. The samples were frozen at –20oC, thawed, 
and vortexed again to ensure complete cell lysis.  
 
The plasmid DNA was purified using a phenol;chloroform extraction and ethanol 
precipitation. TE buffer w as added to each eppendorf to bring the volume to 200µl. 
200µl of phenol:chloroform;isoamyl alchol was added, and the sample was vortexed 
for 5 min. The eppendorfs were centrifigued at 14,000 rpm for 10min. The aqueous 
(upper) phase was transfered to a fresh tube. 10 M ammonium acetate (8µl) and 95% 
ethanol (500µl) was added, and frozen at –70oC for 1hr. The samples were 
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centrifuged at 14,000rpm for 10min, the supernatant was discarded and the dry pellet 
was resuspended in 20µl of H2O. 
 
The plasmid DNA was transformed into DH5" cells (Invitrogen) as per the 
manufacturer’s instructions and the prey pGBADT7 plasmid was selected for by 
plating the transformed cells onto selective L-agar plates containing ampicillin 
(50µg/µl). Colonies were selected and amplified using A306 and A307 primers, with 
colonies containing the correct insert extracted and amplified using a mini prep kit 
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2.8 Protein Protocols 












0.2% w/v Triton X-100 
Hypotonic Lysis buffer 
350mM NaCl 
10mM HEPES 




6x Sample Buffer 
20% w/v Glycerol 
2% w/v Sodium dodecyl sulfate (SDS) 
0.25% w/v Bromophenol blue 
1x Stacking buffer 
5% w/v !-mercaptoethanol 
4x Resolving Buffer 
1.5M Tris 




  84 
4x Stacking Buffer 
500mM Tris 
0.4% w/v SDS 
pH 6.8 
10x Running Buffer 
250mM Tris 
2M Glycine 
1% w/v SDS 
Semi-Dry Transfer buffer 
47mM Tris 
40mM Glycine 
0.037% w/v SDS 
100mM Methanol 
10% Resolving Gel 
1x resolving Buffer  
10% w/v Acrylamide  
0.15% w/v Ammonium persulfphate (APS) 
0.01% w/v N, N, N’, N’, tetramethyl-1-2-diaminomethane (TMED) 
4% Stacking Gel 
1x stacking buffer 
4% w/v Acrylamide 
0.15% w/v APS 
0.01% w/v TMED 
IP buffer 
300mM NaCL 
1% Triton X-100 
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2.8.2 Transfection of cell lines 
 
HRT18 cells and SW480 were plated equally into a 6 well plate and grown until 
~50% confluent. siRNA transfections were performed using Lipofectamine 2000 
(Invitrogen) in Optimem-1 medium (Gibco) and the StealthTM siRNA (Invitrogen) as 
per manufacturer’s instructions with primers described in Table 2.4. Cells were 
transfected in antibiotic-free media for 24-48 hours. Cells were harvested as detailed 
in 2.1.2, the protein was extracted and resolved via Western Blot procedure as 
detailed below. 
 







Table 2.5: EGR1 siRNA primers 
 
 
2.8.3 Preparation of protein extracts 
Cells were grown until ~80% confluent in a T25cm2 flask. The cells were harvested, 
washed in PBS and pelleted by centrifugation at 12,000 rpm for 5min. 
 
2.8.3.1 Preparation of Whole Cell Extracts 
To prepare whole cell extracts the cells were resuspended in 200µl of 1X Whole Cell 
Lysis Buffer (Cell Signalling Technologies) supplemented with the following 
protease inhibitors; 40µl/ml complete protease inhibitor solution (Roche, Germany), 
10µl/ml Pefabloc solution (Roche) and 1µl/ml Pepstatin solution (Roche). After 
incubation on ice for 30min the cells were centrifuged at 13,000 rpm for 5min at 4oC, 
and the lysate was transferred to fresh pre-chilled eppendorf tubes.  
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2.8.3.2 Preparation of Cytoplasmic and Nuclear Extracts: 
To prepare cytoplasmic and nuclear extracts the cells were resuspended in 100µl of 
Normal Lysis Buffer, supplemented with the same protease inhibitors as above. 
Following an incubation of 5min on ice, the cells were centrifuged at 13,000 rpm for 
20sec. The supernatant, the cytoplasmic extract, was removed and transferred to pre-
chilled eppendorf tubes. The cell pellet was then resuspended in 30µl Hypotonic 
Lysis Buffer, supplemented with protease inhibitors as above, and incubated on ice 
for 30min. The cells were centrifuged at 13,000 rpm for 5min and the supernatant, 
consisting of the nuclear extract, was removed and transferred to pre-chilled 
eppendorfs.  
 
2.8.3.3 Preparation of cellular compartments 
In order to separate the extracts into four cellular compartments (cytoplamsic, 
membrane/organelle, nuclear and cytoskeleton) the cells were grown until confluent 
in a T25cm2 flask. The cells were then extracted using the ProteoExtract Subcellular 
Proteome Extraction Kit  (Calbiochem) as per the manufacturer’s instructions. 
 
All protein extracts were stored at –80oC. The protein concentration of all extracts 
was determined using a Bradford protein assay, using BSA as a standard control. All 
samples were measured in triplicate and concentrations calculated against a BSA 
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2.8.4 Western Blot analysis 
 
Protein samples were prepared by dilution with PBS to a suitable protein 
concentration (30-50ng) and boiled in 3µl of SDS reducing buffer for 5min. The 
protein samples were separated on a 8-10% resolving acrylamide gel with a 4% 
stacking gel in 1X SDS running buffer, using 10µl of Kaleidoscope Protein Standard 
(BioRad) as a marker. The proteins were then transferred onto a PVDF membrane 
(BioRad) at 10V for 30min, followed by blocking in 5% non-fat milk in 0.15% 
Tween-10/PBS for 1 hour at room temperature.  
 
The membranes were probed with a primary antibody in milk Tween/PBS at room 
temperature for 1 hour as standard, unless indicated otherwise (Table 2.5). The 
membranes were washed in PBS/Tween, 3 times for at least 15 minutes, with 
shaking, unless stated otherwise. Membranes were incubated in appropriate species 
of secondary antibodies for 1 hour at room temperature. The membranes were 
washed in PBS/Tween 3x for 15 minutes with shaking. The protein bands were 
visualised by chemiluminescence using Luminol reagent (Santa Cruz Biotechnology) 
by placing the Luminol reagent on the membrane for 1 minute following by placing 
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Antibody Manufacturer Dilution  Conditions 
Primary Antibodies    
EGR1 Goat mAB R&D Systems (AF2818) 1:1000  4oC - 
overnight 
EGR1 (588) Rabbit 
polyclonal 
Santa Cruz Biotechnology 
(Sc-110) 
1:1000 Standard 
EGR1 (C-19) Rabbit 
polyclonal 
Santa Cruz Biotechnology 
(Sc-189) 
1:1000 Standard 
NOD2 Mouse mAB Affinity BioReagents       
(MA1-16611) 
1:200  Standard 
#-tubulin Mouse mAB Sigma Chemical (T6557) 1:5000   Standard 
"-tubulin Mouse mAB Sigma Chemical (T9026) 1:1000   Standard 
HP1-alpha Rabbit mAb Cell Signaling Technology 
(C7F11) 
1:1000  Standard 
B23-(3F291) (NPM1) Santa Cruz Biotechnology 
(Sc-70392) 
1:1000 Standard 
eEF1" Upstate (Millipore) (05-235) 1:1000 Standard 
eEF1A1 Novel- gift from Cathy 
Abbott 
1:1000 4oC - 
overnight 
eEF1A2 Novel- gift from Cathy 
Abbott 
1:1000 4oC - 
overnight 




   
Goat anti-Mouse IgG-
HRP 





Santa Cruz Biotechnology   
(Sc-2056) 
1:2500  Standard 




1:2000  Standard 
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1:2000  Standard 




SW480 cells were seeded into a T25cm2 flask and grown until 80-90% confluent. 
The cells were harvested and the protein was extracted in 200µl of lysis IP buffer 
with protease inhibitors added and the protein concentration was determined by 
Bradford assay. The protein extracts were pre-cleared in washed (IP buffer) agarose 
G beads for 1 hour at 4oC and 500µg of protein lysate was incubated in 2µg of 
antibody overnight at 4oC while rotating. 15µl of pre-washed agarose G beads was 
added and incubated at 4oC for 1 hour while rotating. The beads were washed and 
50µl of 2x running buffer was added. The samples were boiled for 5 min at 95oC, 
and centrifuged at 14000rpm at room temperature for 5min using an Eppendorf 
Microcentrifuge 5415 R. The supernatant was separated on a 10% resolving gel and 
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2.9 Immunofluorescence 
SW480 and HRT18 cells were seeded into a 6 well plate containing a sterile 
coverslip and grown overnight at 37oC. The media was removed and cells washed in 
5ml cold PBS. The cells were fixed with 1ml of 4% formaldehyde and incubated at 
room temperature for 20min. After removal of the formaldehyde, the cells were 
rinsed several times with PBS, and a solution of 0.5% Triton X-100 was added to the 
cells for 2min at room temperature. The cells were washed with PBS x3 for 5min 
while shaking the cells and then blocked with 5% BSA in PBS all day. 
 
The cells were then washed with PBS x3 for 5min as before and incubated with a 
primary antibody in 5% BSA in PBS overnight at 4oC (Table 2.6). After washing 
with PBS x3 for 5min, the cells were incubated with a secondary antibody in 5% 
BSA for 1hr at room temperature in the dark. The cells were washed x3 for 10min as 
before and the coverslips were placed onto microscope slides containing a few drops 
of DAPI-Vectashield® (Vector Laboratories Inc., USA), containing 1µg/ml 4’,6-
diamidino-2-phenylindole (DAPI). The slides were stored in the dark at 4oC and the 
images were visualised using fluorsecence microscopy.  
 
 
Antibody Manufacturer Dilution used 
Primary Antibodies   
EGR1 Goat mAB R&D Systems AF2818 1:50  
NOD2 Mouse mAB Affinity BioReagents MA1-16611 1:200  
#-tubulin Mouse mAB Sigma Chemical T6557 1:200 
"-tubulin Mouse mAB Sigma Chemical T9026 1:200   
Secondary Antibodies   
Texas Red-AffiniPure 










Table 2.7: Antibodies for immunocytochemistry analysis 
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The expression of EGR1 has been found to be dysregulated in numerous types of 
cancers including breast carcinoma, glioblastoma, osteogenic sarcoma, fibrosarcoma, 
and esophageal carcinoma (Huang, Liu et al. 1995; Huang, Fan et al. 1997; Calogero, 
Arcella et al. 2001; Wu, Chen et al. 2001). In contrast, EGR1 expression was found 
to be increased in gastric cancer compared with normal mucosa (Kobayashi, Yamada 
et al. 2002) and EGR1 is known to be over-expressed in prostate cancer, with 
differential expression observed between prostate epithelial and stromal tissue 
(Svaren, Ehrig et al. 2000; Gregg, Brown et al. 2010).  
 
In silico studies in the Colon Cancer Genetics Group (CCGG) (University of 
Edinburgh) identified that EGR1 is downregulated in the tumour mucosa of patient 
with CRC compared with normal colonic mucosa, indicating a role in carcinogenesis 
(James Prendergast/Susan Farrginton pers comm).  
 
A microarry study by Hong et al (2007) describes an up-regulation of EGR1 
expression in early onset CRC patients, where they observed higher EGR1 
expression levels in the normal mucosa of 21 CRC patients compared with mucosa 
from 10 healthy controls indicating that EGR1 expression is up-regulated in the 
normal mucosa of colorectal cancer patients. They suggest that as they observed 
differential gene expression in seven genes between the mucosa from patients and 
controls, that although the normal mucosa appears morphologically normal in 
patients it is “already primed for carcinogenesis” (Hong, Ho et al. 2007). Given this 
finding an analysis was conducted using Oncomine (Rhodes, Yu et al. 2004) in order 
to compare the expression of EGR1 in normal and tumour mucosa in published 
microarray data. This analysis showed that there is a significant difference in EGR1 
expression, with a 7.539 fold higher expression of EGR1 in colon tissue (n=12) 
compared with colorectal carcinoma (n=70) (Hong, Downey et al. 2010). A smaller 
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study saw significantly higher EGR1 expression in colon (n=10) compared with 
carcinoma with a 3.459 fold increase, and a 3.428 fold higher expression from colon 
(n=10) to adenoma (n=5) (Skrzypczak, Goryca et al. 2010). However several studies 
showed lower expression of EGR1 in normal colon compared with colorectal 
adenocarcinoma. The most significant result was the study by Skrzypczak, which 
showed that there was significantly lower expression in colorectal tissue (n=24) 
compared with colorectal adenocarcinoma, with a 3.373 fold difference. This study 
however showed no significant difference in the EGR1 expression in normal and 
colorectal carcinoma. Three further studies showed a significant difference in EGR1 
expression from colon to colorectal adenocarcinoma. This analysis in oncomine 
showed that there is differential expression of EGR1 in normal tissue and colorectal 
tissue, with an indication that EGR1 expression is lower in colorectal adenomas 
compared to normal, but that expression may be gained in invasive carcinomas. 
 
It is known that patients with IBD are at an increased risk of developing CRC, and 
this risk further increases with duration of symptoms and severity of inflammation 
and dysplasia. Although IBD associated cancer only accounts for 1-2% of overall 
CRC cases, it accounts for 10-15% of all deaths in patients with IBD (Munkholm 
2003). Interestingly, Subbaramaiah et al (2004) observed that in both Crohn’s disease 
and ulcerative colitis patients, there was an increase in the levels of EGR1 protein in 
the inflamed mucosa compared with non-inflamed (Subbaramaiah, Yoshimatsu et al. 
2004).  Experiments conducted by the Gastrointestinal unit (GI) (University of 
Edinburgh), examined the expression of EGR1 in colonic biopsies and also showed 
that EGR1 is differentially regulated between un-inflamed and inflamed mucosa. In 
collaboration a large scale case-control study was conducted by both the CCGG and 
the GI unit which demonstrated an association between common variants of EGR1 
with disease phenotype in both CRC and IBD.   
 
Therefore it is of interest to determine why EGR1 may be differentially regulated in 
colorectal disease and to what extent this differential regulation occurs in the Scottish 
population. The aim of this chapter is to examine the differential expression of EGR1 
in colonic mucosa of healthy controls, uninflamed mucosa of patients with IBD and 
from matched normal mucosa and tumour tissue of colorectal cancer patients. We 
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investigated whether genetic variation correlated with altered gene expression by 
looking at the common EGR1 variants identified. Given that EGR1 has a large CpG 
promoter region that may undergo methylation, the methylation status of the EGR1 
promoter was examined. EGR1 expression is regulated via the MAPK signalling 
pathway and given the importance of RAF and RAS mutations in CRC the somatic 
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3.2 Methods 
 
3.2.1 Quantitative RT-PCR 
In order to determine the relative expression of EGR1 qRT-PCR was performed. In a 
single experiment each assay was conducted in triplicate, with each experiment 
conducted three times. A standard curve was generated for !-actin and EGR1 in 
order to estimate relative expression levels, using linear regression analysis. All the 
standard curves used to calculate the relative expression levels had a R2 value close 
to 1 (>0.92). The EGR1 expression values were normalised by dividing by the 
relevant !-actin expression values (as described in ABI PRISM 7700 Sequence 
Detection System publications). 
 
3.2.2 CRC patients 
Colonic biopsies from patients with colorectal cancer (CRC) were available for 
EGR1 expression analysis, from matching normal mucosa and tumour. The RNA and 
DNA was extracted using TRIzol (by Rebecca Barnetson), and the expression of 
EGR1 was analysed using qRT-PCR.  
 
3.2.3 IBD patients 
Colonic biopsies from patients with ulcerative colitis (UC) and Crohn’s disease (CD) 
were available for EGR1 and NAB2 expression analysis. All biopsies were taken 
from un-inflamed tissue. The samples were treated with various inflammatory 
agents, LPS, MDP, PGN and TNF, at 1µg/ml for 24hrs, to stimulate an inflammatory 
response. Biopsies were also available from ‘healthy’ controls (HC) who are healthy 
individuals undergoing screening for a family history for CRC. The IBD biopsy 
samples were prepared by the GI unit, using an ex vivo tissue culture protocol 
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3.2.4 Statistical analysis 
All of the data was tested for normality using the Shapiro-Wilk test. In the case of the 
CRC data, as it did not meet the conditions for normality a log transformation was 
used. The Student paired t-test was used in order to determine differences in EGR1 
expression between the matched normal and tumour samples. For the IBD data, 
which again did not meet the conditions of normality several different methods of 
analyzing the data were discussed with quantitive statistical geneticists (Albert 
Tenesa, Stephane Ballereau, Andy Sims and Jennifer Huffman). Initially the data 
was analysed using ANOVA but as ANOVA requires parametric data, the non-
parametric Kruskal-Wallis rank sum test was then considered. However this model 
does not allow for an unbalanced data set, which excluded a lot of the data. It also 
did not account for the repeated measures in the experimental design. Finally a 
mixed model ANOVA was decided on, which would account for the repeated 
measures in the data and allow an unbalanced data set. Several transformations were 
tested on the data, including log and square-root, however only a rank transformation 
transformed the data sufficiently to a normal distribution. The IBD patient data was 
therefore transformed using a rank transformation and analysed using a mixed effect 
ANOVA. All of the data analysis was done using ‘R’ (R Development Core Team 
2009), using the following packages; ‘lme4’, ‘nlme’ and ‘multcomp’ (Hothorn, Bretz 
et al. 2008; Pinheiro, Bates et al. 2009). Individual patient analysis was conducted 
using the Wilcoxon rank sum test, comparing each treatment against the untreated 
value, on non transformed data.  Data was considered to be significant at a p value 
<0.05, which is denoted by a * symbol, a p value of <0.01 is denoted by **, and 
p=<0.001 denoted by ***. 
 
3.2.5 Genotype analysis 
All of the CRC and IBD patients were genotyped for three EGR1 variants. DNA was 
extracted from the biopsies (as in 2.2 and 2.3) and amplified by PCR. Variants in the 
three SNPs (rs3813221, rs11734810 and rs11748488) were identified using the 
sequencing software Mutation Surveyor and polyphredPhrap/Consed.  
 
 
  96 
3.2.6 KRAS/BRAF mutation analysis 
The KRAS and BRAF mutation status of the CRC patients was determined. DNA was 
extracted and amplified by PCR and visualised using Mutation Surveyor. HT29 CRC 
cell line was used as a previously reported positive control for the BRAF V600E 
mutation (Davies, Bignell et al. 2002; Seth, Crook et al. 2009). 
 
3.2.7 Bisulfite sequencing 
The methylation status of the EGR1 promoter was investigated using bisulfite 
sequencing. Changes in the methylation of DNA can occur on cytosine residues, 
within CpG rich regions of the gene. Bisulfite treatment of DNA causes the cytosine 
residues to become converted to uracil residues, however cytosines that are 
methylated remain unchanged. This DNA is then amplified using PCR primers that 
are specific to unmethylated DNA, the PCR product is then sequenced, where the 
non-methylated regions displayed as thymines and the methylated regions remaining 
cytosines (Figure 3.1). 
 
Primers were designed using Methprimer (Li and Dahiya 2002), which covered 80% 
of the promoter CpG island and allowing sequencing of ~75% of the CpGs, 
corresponding with the predicted CpG island using UCSC genome browser. A 
normal mucosa sample was treated with a DNA methylase enzyme, S-(5’-Adenosyl)-
L-homocysteine (SAM), as a methylated positive control, which cuases the cytosine 
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Figure 3.1: Illustration of bisulfite sequencing of DNA 
Bisulfite treatment of DNA causes the cytosine residues to become converted to 
uracil residues (U, denoted in blue). Cytosines that are methylated (mC, denoted in 
red) remain unchanged. DNA is then amplified using PCR primers and the PCR 
product is sequenced. Non-methylated CpGs are displayed as thymines (T, denoted 
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3.3 Results  
 
3.3.1 Relative EGR1 mRNA expression levels in CRC cell lines and 
tissue specific expression levels 
 
A series of CRC cell lines were initially analysed to determine their relative EGR1 
mRNA expression levels (Figure 3.2 A). There is relatively low EGR1 expressed in 
all of the eight colorectal cancer cell lines examined, with the lowest levels evident in 
HRT18 and HCT116 cells. Vaco425 and SW480 have the highest level of EGR1. In 
order to determine if there is any correlation with the three associated variants for 
EGR1, the CRC cell lines were genotyped for the three SNPs (rs3813321, 
rs11734810 and rs11748488). SNPs rs3813321 is 856 base-pairs upstream of EGR1, 
rs11734810 is intronic (1.235 base-pairs from the start of the coding regions of 
EGR1) and rs11748488 is 579 base-pairs downstream from EGR1. LoVo, HCT116 
and HT-29 are heterozygous for the three risk variants. Vaco425 and SW480 are 
homozygous for all three variants and HRT18 and SW48 are homozygous wild-type. 
 
Other cell lines were examined for EGR1 expression to assess differences in tissue 
expression (Figure 3.2 B). There are considerably higher levels of EGR1 expression 
in cell lines derived from lymphocytes (MDC6 and ConA), compared to the CRC 
cell lines. The two prostate cell lines, DUI 145 and PNT show expression levels 
similar to Vaco425 with the breast cancer cell line MCF7 expressing much lower 
EGR1 levels, similar to HRT18 and HCT116. These data agrees with published data 
where it has been reported that there are higher levels of EGR1 in prostate cancers, 
with down-regulation of EGR1 in breast cancer (Huang, Fan et al. 1997; Svaren, 
Ehrig et al. 2000). These results show that EGR1 is differentially expressed in 
different tissues with extremely high levels being observed in the lymphocyte 
lineages and relatively low levels in cancer tissue of breast, colon and prostate. The 




  99 





















Figure 3.2: Expression and genotyping of EGR1 in cancer and non-cancer cell 
lines 
A. RNA from several different CRC cell lines was isolated and the relative mRNA 
expression levels were determined by quantitative real-time PCR. The values show 
EGR1 expression levels relative to !-actin. B. RNA from several different cell lines 
was isolated and analysed as above. MCF-7 is a breast adenocarcinoma, DUI145 a 
prostate carcinoma, PC3 a prostate adenocarcinoma, PNT a normal prostate cell 
lines, and ConA and MDC6 cell lines are derived from lymphocytes.  C. Cell line 
DNA was isolated, amplified by PCR and sequenced to determine the genotype of 
three EGR1 variants. The sequencing demonstrates an example of homozygous wild-
type, homozygous variant and heterozygous variant of SNP rs11748288.  
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3.3.2 Relative EGR1 mRNA expression in CRC patients 
 
The relative EGR1 mRNA expression was analysed in 30 patients with CRC, using 
matched normal mucosa and tumour. A student’s paired t-test was used to determine 
if there was any significant difference in the expression of EGR1 in the matched 
normal mucosa and tumour. Interestingly there appears to be differential expression 
of EGR1 between the normal mucosa and tumour, with a population of the patients 
showing higher levels of EGR1 in the tumour (group H) compared with the normal 
and the other population showing lower levels of EGR1 in the tumour (group L) 
(Figure 3.3 A). Of the 30 patients, 13 show a significantly higher level of EGR1 in 
the tumour compared with the matched normal using a paired student t-test, 10 show 
a significantly lower level of EGR1 in the tumour and 7 samples do not show a 
significant difference (group N) (Figure 3.3 B).  
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Figure 3.3: Differential expression of EGR1 in matched normal mucosa and 
tumour 
A. RNA from 30 matched normal and tumour patient samples was isolated and the 
relative mRNA expression levels were determined by quantitative real-time PCR. 
The values show EGR1 expression levels relative to !-actin. The values were 
transformed using log to normalise the data for statistical analysis. Student’s paired t-
test was used to determine significant changes, with significance set at < 0.05. B. 
Illustration of the three groups showing differential EGR1 expression levels in the 
CRC patient samples between normal and tumour. 
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When looking at the expression of EGR1 in the normal mucosa it varies between the 
patient samples, ranging from low levels comparable with the cell lines and relatively 
much higher levels (Figure 3.4 A). It appears that, save for a few outliers, that the 
normal mucosa levels in those patients in Group H have relatively low EGR1 levels 
compared with Group L. Interestingly Group L, the group of patients with higher 
levels of EGR1, have EGR1 expression levels comparable to the EGR1 expression in 
normal healthy mucosa. 
 
Plotting the relative EGR1 mRNA levels against whether they show higher or lower 
levels in the matching tumour illustrates that, on average, those patients which show 
higher levels of EGR1 in the tumour do have significantly lower levels of EGR1 
compared with the patients that have lower levels in the tumour (Figure 3.4 C). 
Overall it appears that if there are low levels of EGR1 in the normal mucosa the 
corresponding level of EGR1 in the tumour will be higher and conversely if there are 
high levels of EGR1 in the normal mucosa, the tumour will have low levels of EGR1 
(Figure 3.4 D). The patients that show no significance difference between the normal 
and tumour tended to have low levels of EGR1 in the normal mucosa.    
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Figure 3.4: Relative EGR1 mRNA expression levels in normal mucosa 
The data was divided based on differences in expression between normal mucosa and 
tumour. A. The relative EGR1 mRNA expression values of 30 CRC patients normal 
mucosa was plotted. The average EGR1 expression of healthy controls (n=17) is 
plotted (HC) to illustrate the level of EGR1 expression in healthy mucosa B. The 
relative EGR1 mRNA expression values of 30 CRC patients tumour was plotted. 
C.The average values of the normal mucosa are shown to determine the EGR1 
expression level of the population.  A mixed effect ANOVA model was used to 
determine the significant difference with the significance set at < 0.05. D. The 
average values of the normal mucosa and tumour in the three populations.  
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3.3.3 Genotype of EGR1 variants in matched normal and tumour 
patient samples 
 
Variation at the genomic level can alter transcriptional activity, hence three common 
SNPs of EGR1 were genotyped in the matched normal and tumour samples, the 
results of which are presented in Table 3.1. Three patients are homozygous wild-type 
of all three SNPs, 12 patients are heterozygous variants for all three SNPs and 5 
patients are homozygous variant. Two patients (#9 and #7) show loss of 
heterozygosity for all three variants in the tumour. There are 5 patients in which 
show recombination in both the normal mucosa and tumour, for example patient 5 is 
heterozygous variants for rs3813221 but homozygous variant for both rs11743810 
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No change in expression   Higher EGR1 expression in tumour  Lower EGR1 expression in tumour  
  rs3813221 rs11743810 rs11748288    rs3813221 rs11743810 rs11748288    rs3813221 rs11743810 rs11748288 
20N CC CC AA   17N CC CC AA  18N CT CT AG 
20T CC CC AA   17T CC CC AA  18T CT CT AG 
        31N CC CC AA  22N CT CT AG 
4N CT CT AG   31T CC CC AA  22T CT CT AG 
4T CT CT AG          25N CT CT AG 
8N CT CT AG   10N CT CT AG  25T CT CT GG 
8T CT CT AG   10T CT CT AG  30N CT CT AG 
6N CT CT AG   11N CT CT AG  30T CT CT AG 
6T CT CT AG   11T CT CT AG        
        14N CT CT AG  12N TT TT GG 
3N TT TT GG   14T CT CT AG  12T TT TT GG 
3T TT TT GG   28N CT CT AG        
23N TT TT GG   28T CT CT AG  7N CT CT AG 
23T TT TT GG   24N CT CT AG  7T TT CC GG 
       24T CT CT AG        
5N CT TT GG         15N CT TT GG 
5T CT TT GG  19N TT TT GG  15T CT TT GG 
     19T TT TT GG  16N CT TT GG 
     29N TT TT GG  16T CT TT GG 
     29T TT TT GG  26N CC CT AG 
            26T CC CT AG 
     9N CT CT AG  21N TT TT GG 
     9T TT TT GG  21T CT TT GG 
                
     1N TT CC GG      
     1T TT CC GG      
     2N TT CC AA      
     2T CC CC AA      
     27N TT CT AG      
     27T CT CT AG      
Table 3.1: Genotype of EGR1 variants in CRC patient samples 
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Figure 3.5 A shows the frequency of the alleles of the three SNPs in the three 
populations, i.e. those samples that have no change in expression between normal 
and tumour (Group N), those that have higher levels of EGR1 in the tumour (Group 
H) and those that have lower levels of EGR1 in the tumour (Group L). There does 
not appear to be any difference in the frequency of the alleles in the three groups, 
however there are no homozygous wild type alleles present for rs11743810 and 
rs1748288 in group L, (the group with significantly lower levels of EGR1 in the 
tumour and high EGR1 expression levels in the normal mucosa comparable with the 
health controls, Figure 3.4) suggesting again that perhaps the presence of the EGR1 
variants correlates with differential EGR1 expression. However when the alleles of 
the three variants were plotted against the EGR1 gene expression (Figure 3.5 B) there 
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Figure 3.5: Genotype analysis of EGR1 variants in CRC patients 
DNA from matched normal and tumour of 30 CRC patients, was isolated, amplified 
by PCR and sequenced to determine the genotype of three EGR1 SNPs, rs3813221, 
rs11743810 and rs11748288. A The data was grouped based on differences in 
expression between normal mucosa and tumour as before, illustrating what 
percentage of alleles is present for each SNP in the three groups. B The relative 
EGR1 expression levels of the normal mucosa are plotted against the alleles of the 
three SNPs to determine if there is a correlation with gene expression and presence 
of the EGR1 variants. 
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3.3.4 KRAS and BRAF mutation status of CRC patients 
 
The mutation of two oncogenes, KRAS and BRAF, are early events in the 
development of CRC. Both KRAS and BRAF are members of the MAP kinase 
pathway and are mutated in ~30-50% and ~10-18% of all CRC respectively (Fearon 
and Vogelstein 1990; Ilyas, Straub et al. 1999; Davies, Bignell et al. 2002). 
Activating mutations of KRAS most often occur codon 12 and 13 (~90%), although 
mutation can be present at other codons such as 61 and 146, and result in a 
constitutively active Ras protein (Nagasaka, Sasamoto et al. 2004; Lee, Cho et al. 
2008). Activating BRAF mutations are found at exon 11 and 15, and most commonly 
occur at codon 600 (~80%) resulting in an amino acid change from a valine to a 
gluatmate. It has been reported that this change greatly increases the kinase activity 
of BRAF (Davies, Bignell et al. 2002; Nagasaka, Sasamoto et al. 2004; Wan, Garnett 
et al. 2004).  
 
The somatic tumour mutations status of KRAS and BRAF of the CRC patients was 
determined using PCR. Of the 30 patients, nine have a mutation in codon 12 of the 
KRAS protein. Three types of mutations were seen in codon 12 (Figure 3.6 A, Table 
3.2), the most common being a substitution from a GGT -> GAT, resulting in a 
change from a glycine (G) to an asparatic acid (D). There were three patients with a 
GGT -> GTT, resulting in a valine (V) and one patient with a GGT -> TGT 
substitution that results in a cysteine (C). As BRAF V600E mutations are relatively 
uncommon, the CRC cell line HT29 was used as a reported positive control for this 
mutation (Davies, Bignell et al. 2002; Seth, Crook et al. 2009).  Two patients were 
found to have a V600E mutation in BRAF (Figure 3.6 B). There were no KRAS or 
BRAF mutation detected in the normal mucosa of any of the CRC patients. 
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Figure 3.6: KRAS and BRAF mutation status of CRC patients 
DNA from matched normal and tumour of 30 CRC patients was isolated, amplified 
by PCR and sequenced to determine the mutation status of KRAS and BRAF. A. 
Sequencing from CRC tumours indicating the three types of KRAS mutations that 
were found in the CRC patients (n=30). All mutations found (n=9) were in exon 12 
of the KRAS gene. B. Sequencing from the two CRC tumours that have a V600E 
mutation in BRAF. HT29 cell line DNA was used a positive control for this mutation. 
C. Illustration of the percentage of BRAF and KRAS mutations found in tumours of 



































KRAS codon 12 G -> T 
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Patient BRAF mutation KRAS mutation cDNA change 
IT wt G12D-KRAS GGT -> GAT 
2T wt wt   
3T wt wt   
4T wt G12D-KRAS GGT -> GAT 
5T wt wt   
6T wt G12V-KRAS GGT -> GTT 
7T wt wt   
8T wt G12V-KRAS GGT -> GTT 
9T wt G12D-KRAS GGT -> GAT 
10T wt wt   
11T wt wt   
12T wt wt   
13T wt wt   
14T wt wt   
15T wt wt   
16T wt wt   
17T V600E wt GTG -> GAG 
18T wt wt   
19T wt G12V-KRAS GGT -> GTT 
20T wt G12D-KRAS GGT -> GAT 
21T wt wt   
22T wt wt   
23T wt wt   
24T wt G12D-KRAS GGT -> GAT 
25T wt wt   
26T wt G12A-KRAS GGT -> TGT 
27T wt wt   
28T wt wt   
29T V600E wt GTG -> GAG 
30T wt wt   
31T wt wt   
 






  112 
 
It was observed that 6/11 patients with either a KRAS or a BRAF mutation have 
higher expression of EGR1 in the tumour and the other 5/11 patients with BRAF and 
KRAS mutations are in the CRC patients that shows no significant difference 
between normal and tumour mucosa. Only one patient that shows decreased 
expression of EGR1 in the tumour harbouring BRAF or KRAS mutations. Therefore 
we looked to see if there was any association between the expression of EGR1 and 
the muation status of KRAS or BRAF.  
 
It is clear from Figure 3.7, that patients with either a KRAS or BRAF mutation in the 
tumours have high levels of EGR1 in the tumour, and most belong to the group 
which shows low levels of EGR1 in the normal mucosa. The group of patients with 
EGR1 expression levels similar to those of the healthy control population have 
higher levels of EGR1 in the normal mucosa and signicantly lower levels in the 
tumour, with no KRAS or BRAF mutations. It could be therefore that presence of a 
KRAS/BRAF mutation is associated with low EGR1 levels in the normal mucosa 
with higher levels of EGR1 in the tumour. 
 
In order to determine if the expression EGR1 correlates with either a BRAF or 
KRAS mutations, the expression graphs from Figure 3.4 were annotated as regards 
KRAS or BRAF mutation status (Figure 3.7). Graph A illustrates the EGR1 
expression in the normal mucosa, with patients who have KRAS mutations in the 
matched tumour illustrated in red, with patients who have BRAF mutation in blue. 
Graph B illustrates the EGR1 expression in the tumour, with the corresponding 
KRAS and BRAF muations denoted in red and blue respectively. This figure further 
illustrates that KRAS and BRAF mutations are found in patients with higher levels of 
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Figure 3.7: KRAS and BRAF mutation status with relative EGR1 mRNA 
expression levels in CRC patients.  
The data was divided a before based on difference in expression between normal 
mucosa and tumour, Group N have no difference in EGR1 expression levels, Group 
H have significantly higher levels in the tumour compared with normal and Group L 
have significantly lower levels of EGR1 in the tumour. A. Illustrates the EGR1 
expression levels in the normal mucosa, patients with KRAS mutations in the 
matched tumour are denoted in red, patients with BRAF mutations in the tumour are 
denoted in blue. B. Illustrates the EGR1 expression levels in the tumour, with the 
presence of KRAF mutations  in red and BRAF mutations in blue.
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3.3.5 Methylation status of the EGR1 promoter 
 
Aberrant methylation of CpG islands in promoter regions frequently occurs in CRC 
and is associated with gene silencing, so the hypothesis that the differential 
expression of EGR1 in the normal and tumour is associated with aberrant 
methylation of the EGR1 promoter was tested as it may be that the group of patients 
that show much lower levels of EGR1 in the tumour have aberrant methylation of the 
promoter. The methylation status of EGR1 was determined using bisulfite 
sequencing of the EGR1 promoter, which has a large CpG island, containing 205 
CpG dinucleotides (Figure 3.7 A). Primers were designed using Methprimer (Li and 
Dahiya 2002), covering 80% of the CpG island and allowed sequencing of ~75% of 
the CpGs, and corresponds with the predicted CpG island using UCSC and the 
regions previously reporting EGR1 promoter methylation (Seyfert, McMahon et al. 
1990) . A normal mucosa sample was treated with a DNA methylase enzyme, SAM, 
as a positive control for the assay. 
 
Bisulfite sequencing was conducted on the CRC cell lines and all of the 30 normal 
mucosa and tumour CRC patient samples. However no methylation of the EGR1 
promoter was found in any of these samples (Figure 3.7 B). Therefore the differential 
expression of EGR1 that is observed is not associated with aberrant methylation of 
this region of the EGR1 promoter.
 






























Figure 3.8: Bisulfite sequencing of matched normal and tumour samples 
A. Primers were designed using MethPrimer (Li and Dahiya 2002) to cover the CpG 
island in the EGR1 promoter as described in UCSC genome browser (highlighted in 
green). The primers covered 80% of the region and amplified 75% of the CpGs in the 
EGR1 promoter. B. CRC patient normal and tumour DNA was isolated and bisulfite 
treated. The samples were amplified and sequenced to demonstrate any methylation 
in the EGR1 promoter region. A sample was treated with S-(5’-Adenosyl)-L-
homocysteine as a positive control for methylation as seen by the non-conversion of 
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3.3.6 Relative EGR1 mRNA expression levels in IBD patients 
 
The relative EGR1 expression in IBD was investigated using qRT-PCR. Expression 
of EGR1 in a healthy control population, as well as the two disease groups, ulcerative 
colitis patients and Crohn’s disease patients was determined. The colonic biopsies 
were all taken from apparently un-inflamed tissue. An inflammatory condition was 
mimicked by culturing the biopsies with several different inflammatory mediators. 
The treatments used were LPS, MDP, PGN and TNF, all at a concentration of 
1µg/ml and treated overnight.  
 
 
3.3.6.1  EGR1 expression is significantly lower in IBD patients compared 
with healthy controls 
 
The relative EGR1 mRNA levels were examined in 17 healthy controls, 17 patients 
with Crohn’s disease and 24 patients with ulcerative colitis to determine if there is 
any difference in the levels of EGR1 in the three patient groups (Figure 3.8). By 
plotting the average of the EGR1 levels for the three patient groups it demonstrates 
that there are considerably lower levels of EGR1 expression in the both the ulcerative 
colitis and Crohn’s disease patient groups. Using a mixed effect ANOVA model it 
was determined that these differences were statistically significant. Further analyses 
were preformed to determine which patient groups were significantly different from 
each other. There is a significant difference between the healthy controls and the 
Crohn’s disease patients with a p value of 0.04437 (Figure 3.8 A). The decrease in 
EGR1 expression is between the healthy controls and ulcerative colitis patients is not 
significant.  There is also no significant difference between the Crohn’s disease 
patients and the ulcerative colitis patients.  
 
It should be noted that outliers were removed at a >3x the interquartile distance. 
There were no outliers present in the healthy controls but a single patient with 
Crohn’s disease and two patients with ulcerative colitis were removed as outliers. 
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However, the values are still significant when the data is analysed with the outliers 
included. Therefore it is evident that there are significantly lower levels of EGR1 
being expressed in the colon of Crohn’s disease patients compared with the healthy 
controls.  
 































Figure 3.9: Relative EGR1 mRNA expression levels in untreated IBD samples 
RNA from biopsies of healthy controls (n=17), ulcerative colitis patients (n=24) and 
Crohn’s disease patients (n=17) was isolated and the relative mRNA expression 
levels were determined by quantitative real-time PCR. The values show EGR1 
expression levels relative to !-actin. The experiment was performed in triplicate and 
repeated three times.  A. The average value for each of the patient groups was 
plotted. The data was normalised using a rank transformation with the significance 
difference determined by a mixed effect ANOVA, significance was set at <0.05. B. 
A boxplot demonstrating the range of values obtained for the three patient groups, 
with the median and quartile distances illustrated. Outliers >3x the interquartile 
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3.3.6.2 EGR1 expression in CRC cell lines after inflammatory treatment 
 
Having established that non-inflammed colonic tissue from the different patient 
groups expressed EGR1 to different relative levels, we wanted to test the effect of 
inflammatory mediators of EGR1 expression in those tissues. As EGR1 is a stress 
response gene it was expected that the expression of EGR1 would be induced by any 
treatment with inflammatory stimuli, and it is well documented that both LPS and 
TNF induce EGR1 expression in several cell types (Cao, Guy et al. 1992; Coleman, 
Bartiss et al. 1992; Yao, Mackman et al. 1997; Kadl, Huber et al. 2002; Granet and 
Miossec 2004; Luyendyk, Schabbauer et al. 2008). The relative EGR1 mRNA 
expression levels after treatment with LPS, MDP, PGN and TNF were initially 
looked at in the CRC cell lines HRT18 and SW480. The cells were treated with 
1µg/ml of each inflammatory mediator for 24hrs, following which the RNA was 
extracted and the expression of EGR1 determined by qRT-PCR. As previously 
found, the levels of EGR1 in HRT18 are very low (Figure 3.9 A), and there appears 
to be induction of expression after PGN and TNF treatment. The expression of EGR1 
in SW480 cells is higher, and as expected there is an increase in EGR1 expression 
after treatment will all of the inflammatory mediators, particularly MDP and TNF 
(Figure 3.9 B). 
 


























Figure 3.10: Relative EGR1 mRNA expression levels in CRC cell lines after 
inflammatory treatment 
HRT18 (A) and SW480 (B) CRC cell lines were treated with LPS, MDP, PGN and 
TNF (1 µg/ml) for 24hrs, the RNA was isolated and the relative mRNA expression 
levels were determined by quantitative real-time PCR. The values show EGR1 
expression levels relative to !-actin. The experiment was conducted in triplicate and 
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3.3.6.3 EGR1 expression is significantly induced by inflammatory 
mediators in healthy controls 
 
The relative EGR1 mRNA levels after treatment by inflammatory mediators was first 
examined in the healthy control population to determine what effect the treatments 
would have on expression levels in healthy mucosa. In the healthy control patients 
EGR1 expression appears to be induced by both LPS and TNF treatments, with very 
little difference evident after treatment with MDP and PGN, (Figure 3.10). The 
mixed effect ANOVA gave a p value of < 0.0001, and again as this was significant, 
multiple comparison tests were preformed. EGR1 expression is significantly induced 
by both LPS and TNF in the healthy controls, with p values of < 1x10-4 for both. 
MDP slightly induces EGR1 expression although not to a significantly different 
level. PGN is the only treatment that does not appear to induce any EGR1 expression 
(Figure 3.10 B).  This suggests that EGR1 is induced in normal mucosa as part of an 
inflammatory response to both LPS and the TNF cytokine. 
 
 




















Figure 3.11: Relative EGR1 mRNA expression levels in healthy controls 
Biopsies of healthy controls (n=17) was isolated and the relative mRNA expression 
levels were treated with LPS, MDP, PGN and TNF (1µg/ml) for 24hrs, the RNA was 
extracted and the relative mRNA expression levels were determined by quantitative 
real-time PCR. The values show EGR1 expression levels relative to !-actin. The 
experiment was performed in triplicate and repeated three times.  A. A boxplot 
demonstrating the range of values obtained for the five treatments, with the median 
and quartile distances illustrated. B. The average value for each of the patient groups 
was plotted. The data was normalised using a rank transformation with the 
significance difference determined by a mixed effect ANOVA, significance was set 
at <0.05. Outliers >3x the interquartile distance were removed from the analysis.  
 
                                                 *** 
              
       *** 
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In order to look more closely at the individual patients rather than the overall 
population, each patient was analysed using Wilcoxon rank sum test, comparing each 
treatment against the untreated (Table 3.3). Figure 3.11 A illustrates the effect of 
treatment with each inflammatory mediator, showing the percentage of how the 
healthy controls were affected. Using the Wilcoxon test, each patient was grouped 
based on the effect, i.e. if the treatment caused EGR1 to be increased, increased 
significantly, decreased, decreased significantly or showed little or no effect at all. 
This correlates quite well with the population analysis, as it is clear that the majority 
of patients show a significant increase after both LPS and TNF treatment, whereas 
patients show a decrease as well as an increase after MDP treatment.  
 
Figure 3.11 B illustrates the fold increase or decrease of each patient after each 
treatment. The untreated value is set 1, with the treated values adjusted accordingly 
and plotted on a logarithmic scale. It is clear from this graph that for the majority of 
patients who show increased levels of EGR1 after treatment do so after treatment 
with all the inflammatory mediators, as in most cases if there is an increase in EGR1 
after LPS, there is an increase after MDP, PGN and TNF treatment also. The same is 
true for the patients that show a decrease in EGR1 after treatment. There are few 
exceptions, and it would be interesting to determine why some patients respond in 
the opposite manner to the majority, i.e. those that show a decrease in EGR1 
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Healthy Controls        
         
  +  LPS +  MDP +  PGN +  TNF 
  Increase Decrease Increase Decrease Increase Decrease Increase Decrease 
5JN 0.06396   0.0004883 ***     0.03418 *     
9CD 0.003906 **   0.09766     0.003906* No change  - 0.6523 
13CS 0.003906 **     0.003906 ** 0.003906 **   0.003906 **   
17GF   0.007812 **   0.003906 **   0.003906 **   0.003906 ** 
24PK 0.1641     0.003906 **   0.003906 **   0.003906 ** 
26MW   0.007812 **   0.003906 **   0.003906 **   0.003906 ** 
34CM 0.01172 *     0.003906 **   0.09766 0.007812 **   
35WM 0.003906 **   0.003906 **     0.25 0.003906 **   
38GW 0.003906 **   0.02734 *   0.003906 **   0.003906 **   
39TT 0.003906 **   0.003906 **   0.003906 **   0.003906 **   
42FD 0.02734 *   0.09766     0.003906 ** 0.003906 **   
44JH No change  - 0.4238 No change - 0.129 No change  - 0.1294 0.0004883 ***   
48EC 0.0004883 ***   No change  - 0.4238 0.0004883 ***   0.0004883 ***   
50JB-S 0.01953 *   0.25   0.2031   0.007812 **   
51AW 0.003906 **   0.003906 **   0.003906 **   0.003906 **   
55HC 0.003906 **   0.003906 **     0.02734 * 0.003906 **   
57HC   0.003906 **   0.003906 **       0.003906 ** 
62HC 0.003906 **     0.09766 0.003906 **   0.003906 **   
 






















Figure 3.12: Fold induction of EGR1 after treatment of healthy control tissue 
An illustration of the effect of treatment with inflammatory mediators on EGR1 
expression levels in healthy controls. A. Demonstrates the proportion of healthy 
controls (n=17) showing an increase or decrease in EGR1 after treatment. Each 
patient analysis was done using the Wilcoxon rank sum test (paired with untreated), 
with significance set at <0.05. B. The untreated biospy values were set to 1, with 
each group representing a patient after the four treatments. The plot illustrates the 
fold increase or decrease in EGR1 expression after treatment with inflammatory 
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3.3.6.4 EGR1 expression is induced by inflammatory mediators in 
ulcerative colitis patients 
 
In the ulcerative colitis patients the effect of the inflammatory mediators seems 
similar to that of the healthy control, except after PGN treatment, which actually 
appears to decrease the level of EGR1 expression in these patients (Figure 3.12). The 
mixed effect ANOVA test gave a p value of < 0.0001, and once analysed further it 
showed that although LPS and MDP treatment appear to induce EGR1 expression it 
is not to a significant level (Figure 3.12 B). There is again a significant increase in 
EGR1 expression after treatment with TNF (p = 0.00171). However the PGN 
treatment causes the EGR1 level in these patients to significantly decrease (p = 
<0.0001). 
 




















Figure 3.13: Relative EGR1 mRNA expression levels in ulcerative colitis patients 
RNA from biopsies of ulcerative colitis patients (n=24) was isolated and the relative 
mRNA expression levels were determined by quantitative real-time PCR. The values 
show EGR1 expression levels relative to !-actin. The experiment was performed in 
triplicate and repeated three times.  A. A boxplot demonstrating the range of values 
obtained for the five treatments, with the median and quartile distances illustrated. B. 
The average value for each of the patient groups was plotted. The data was 
normalised using a rank transformation with the significance difference determined 
by a mixed effect ANOVA, significance was set at <0.05. Outliers >3x the 
interquartile distance were removed from the analysis.  
                                                                  ** 
 
                                                    *** 
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Investigating the patients on an individual basis indicates that the majority of the 
patients show a significant increase after TNF treatment, correlating with the 
population analysis, whereas after LPS and MDP treatment approximately half the 
patients show a decrease in EGR1 expression after treatment (Table 3.4; Figure 3.13 
A). Unlike the healthy controls only ~45% show an increase in EGR1 after LPS 
treatment. After PGN treatment, the majority of patients show a decrease in EGR1 
expression, which is again significant in the population analysis of the UC patients. 
Hence when the fold induction is plotted for the UC patients the results demonstrate 
a different pattern to the HC graph (Figure 3.13 B). A few patients do show 
similarity to the HC samples in that if EGR1 increases after one treatment, it 
increases after all, however this is not the case for most of the patients and indicates 
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Ulcerative Colitis        
  +  LPS +  MDP +  PGN +  TNF 
  Increase Decrease Increase Decrease Increase Decrease Increase Decrease 
2HF 0.0009766 ***   0.0009766 ***     0.05371   0.0009766 *** 
4PM 0.003906 **   0.007812 **     0.003906 ** 0.003906 **   
6CP   0.0009766 ***   0.0009766 *** No change  -0.5771     
8BS   0.9102  0.02734 *   0.05469    0.1641 
12DK 0.007812 **     0.003906 ** 0.003906 **   0.003906 **   
13CS 0.003906 **     0.003906 ** 0.003906 **   0.003906 **   
18AB   0.003906 ** 0.003906 **   0.003906 **   0.003906 **   
19SU   0.003906 ** 0.09766     0.003906 ** 0.003906 **   
21RR 0.003906 **     0.003906 **   0.003906 ** 0.003906 **   
22JC No change  - 0.9102 0.05469       0.003906 **   
23JG No change  - 0.1614 0.003906 **     0.007812 ** 0.003906 **   
25HW   0.0002441 ***   0.1531   0.04944 *   0.04944 * 
29GM   0.003906 **   0.003906 **   0.006104 **   0.003906 ** 
33SK 0.01343 *   0.008057 **   0.00524 **   1   
36GE   0.003906 **   0.007812 **   0.01172 *   0.003906 ** 
40AG 0.003906 **   0.003906 **     0.1289   0.1641 
41WB 0.003906 **     0.003906 ** 0.007812 **   0.25   
45RB 0.004883 **   0.002441 **     0.004883 ** 0.004883 **   
47WD 0.01172 *   0.09766   0.1641   0.003906 **   
52DB   0.007812 **   0.003906 ** 0.003906 **   0.003906 **   
54SK 0.003906 **   0.003906 **           
63UC 0.003906 **   0.003906 **   0.05469   0.003906 **   
64UC No change - 0.5703   0.003906 ** 0.1289     0.003906 ** 
65UC   0.003906 **   0.25   0.003906 ** 0.003906 **   
66UC   0.003906 **   0.003906 **   0.003906 **   0.003906 ** 











Figure 3.14: Fold induction of EGR1 after treatment of ulcerative colitis tissue 
An illustration of the effect of treatment with inflammatory mediators on EGR1 
expression levels in ulcerative colitis patients. A. Demonstrates the proportion of 
ulcerative colitis patients (n=24) showing an increase or decrease in EGR1 after 
treatment. Each patient analysis was done using the Wilcoxon rank sum test (paired 
with untreated), with significance set at <0.05.  B. The untreated was set a value of 1 
to illustrate the fold increase or decrease in EGR1 expression after treatment with 
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3.3.6.5 EGR1 expression is reduced after treatment with inflammatory 
mediators in Crohn’s disease patients 
 
The effect of the inflammatory mediators on the patients with Crohn’s disease 
showed a different pattern to the HC and UC samples. In the CD patient the 
expression of EGR1 is decreased after treatment with LPS and TNF compared with 
the untreated samples (Figure 3.14). Similar to the healthy controls, there appears to 
be little difference after treatment with MDP and PGN, but the other two treatments 
decrease the expression of EGR1. The mixed model ANOVA test gave a p value of < 
1x10-4, and the multiple comparison tests showed that EGR1 is significantly reduced 
after LPS (p = 0.00619). Interestingly although TNF treatment appears to reduce the 
expression of EGR1 in the population analysis, when looked at on an individual 
basis, this is not reflected in the ANOVA analysis. However 66% of patients show a 
decrease in EGR1expression after TNF treatment, with 46% of these patients 
showing a significant decrease (Table 3.5; Figure 3.15 A). Similarly 65% of patients 
show a significant decrease after treatment with MDP, but there is no difference in 
the average levels of EGR1 after MDP treatment in the population analysis. Similar 
to the HC population, the majority of patients respond similarly to all treatments.  
 





















Figure 3.15: Relative EGR1 mRNA expression levels in Crohn’s disease patients 
RNA from biopsies of Crohn’s disease patients (n=17) was isolated and the relative 
mRNA expression levels were determined by quantitative real-time PCR. The values 
show EGR1 expression levels relative to !-actin. The experiment was performed in 
triplicate and repeated three times.  A. A boxplot demonstrating the range of values 
obtained for the five treatments, with the median and quartile distances illustrated. B. 
The average value for each of the patient groups was plotted. The data was 
normalised using a rank transformation with the significance difference determined 
by a mixed effect ANOVA, significance was set at <0.05. Outliers >3x the 
interquartile distance were removed from the analysis. 
** 
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Crohn's Disease        
         
  +  LPS +  MDP +  PGN +  TNF 
  Increase Decrease Increase Decrease Increase Decrease Increase Decrease 
3NB 0.007813 **   0.007813 **   0.007813 **       
7LH   0.0009766 ***   0.004883 **   0.0009766 ***   0.0009766 *** 
11SF   0.003906 **   0.003906 **   0.25 0.25   
14TS   0.003906 **   0.003906 **   0.003906 **   0.003906 ** 
15MR   0.07422 0.01953 *     1   0.4961 
16JS   0.3594   0.003906 **   0.05469  0.01953 *   
20KS 0.003906 **     0.003906 **   0.003906 **     
27KH   0.004883 **   0.004883 ** 0.01611 *     0.004883 ** 
31AM 0.003906 **   0.02734 *   0.05469    0.007812 **   
32MC 0.3594   0.4258   0.007812 **   0.003906 **   
46RP   0.0009766 *** 0.0009766 ***   0.04199 *     0.0009766 *** 
53LL   0.003906 **   0.003906 **   0.07422   0.3008 
56CD   0.003906 **   0.01953 * 0.003906 **     0.003906 ** 
58CD   0.003906 **   0.003906 **   0.003906 **   0.003906 ** 
60CD 0.02734 *   0.003906 **   0.003906 **   0.003906 **   
61CD   0.003906 **   0.003906 **   0.01172 *   0.003906 ** 
 



















Figure 3.16: Fold induction of EGR1 after treatment of Crohn’s disease tissue 
An illustration of the effect of treatment with inflammatory mediators on EGR1 
expression levels in Crohn’s disesase. A. Demonstrates the proportion of Crohn’s 
disease (n=17) showing an increase or decrease in EGR1 after treatment. Each 
patient analysis was done using the Wilcoxon rank sum test (paired with untreated), 
with significance set at <0.05.  B. The untreated biopsy samples were set to a value 
of 1 to illustrate the fold increase or decrease in EGR1 expression after treatment 
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3.3.7 Genotype analysis of IBD patients for EGR1 variants 
 
To address whether EGR1 variation was affecting gene expression the IBD patient 
samples were genotyped for the three EGR1 variants in order to determine if there is 
any correlation with EGR1 variants and the lower levels of EGR1in both Crohn’s 
disease and ulcerative colitis (Table 3.6). Figure 3.16 A shows that there is no 
difference in the frequency of the alleles in the three EGR1 SNPs in the patient 
groups, nor is there any difference in gene expression with the presence of the 
different alleles in any of the three SNPs (Figure 3.16 B). Interestingly, however, in 
the healthy controls, there is only 1 patient with the homozygous wild-type genotype. 
The healthy controls have the highest EGR1 expression, with expression levels 
similar to that of the group L, from the CRC patients, where there was no wild-type 
genotypes present (Figure 3.4, 3.5). 
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Healthy Controls   Ulcerative Colitis   Crohn's Disease  
                      
  rs3813221 rs11743810 rs11748288    rs3813221 rs11743810 rs11748288    rs3813221 rs11743810 rs11748288 
5JN CC CC AA  6CP CC CC AA  28CD CC CC AA 
       18AB CC CC AA  31AM CC CC AA 
26MW CT CT AG  36GE CC CC AA  56CD CC CC AA 
34CM CT CT AG  49UC CC CC AA        
35WM CT CT AG         7LH CT CT AG 
44JH CT CT AG  8BS CT CT AG  32MC CT CT AG 
50JB-S CT CT AG  2HF CT CT AG  58CD CT CT AG 
51AW CT CT AG  4PM CT CT AG        
55HC CT CT AG  19SU CT CT AG  3NB TT TT GG 
62HC CT CT AG  29GM CT CT AG  20KS TT TT GG 
       33SK CT CT AG  61CD TT TT GG 
9CD TT TT GG  41WB CT CT AG        
17GF TT TT GG  47WD CT CT AG  11SF CC CT AG 
24PK TT TT GG  52DB CT CT AG  14TS CT TT GG 
42FD TT TT GG  54SK CT CT AG  15MR CC CT AG 
67HC TT TT GG  66UC CT CT AG  16JS TT CT GG 
              27KH CT TT GG 
13CS CT TT GG  22JC TT TT GG  46RP CT TT GG 
38GW CT TT GG  23JG TT TT GG  53LL CC TT GG 
39TT CC CT AG  63UC TT TT GG      
57HC CT TT GG  65UC TT TT GG      
                
     12DK CC TT GG      
     21RR CT TT GG      
     25HW CC CT AG      
     40AG TT TT AG      
     45RB CT TT GG      
     64UC CC CT AG      
Table 3.6: Genotype of IBD and healthy control patients
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A.                                                                            B. 
  













































Figure 3.17: Genotyping of IBD patients and healthy controls 
DNA from biopsies of healthy controls (n=17), ulcerative colitis patients (n=24) and 
Crohn’s disease patients (n=17) was isolated, amplified by PCR and sequenced to 
determine the genotype of three EGR1 variants. A. Illustrates what percentage of 
alleles is present for each of the three SNPs in the three patient groups. B. The 
relative EGR1 expression levels are plotted against the alleles of the three SNPs to 






  139 
3.3.8 Methylation status of the EGR1 promoter in IBD 
 
The EGR1 promoter was investigated to determine if there was any methylation of 
the CpG’s that may correlate with the differential gene expression in the patient 
groups. The DNA from all of the healthy controls, ulcerative colitis patient and 
Crohn’s disease patients was bisulfite treated and sequenced at the EGR1 promoter 
as in section 3.3.5. There was no CpG methylation evident at the EGR1 promoter in 
























































Figure 3.18: Bisulfite sequencing of healthy controls and IBD patients 
DNA was isolated from all the healthy controls, ulcerative colitis patients and 
Crohn’s disease patients and bisulfite treated. The samples were amplified and 
sequenced to demonstrate any methylation in the EGR1 promoter regions. A sample 
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3.3.9 NAB2 mRNA expression  
 
One of the main mechanisms by which the expression of EGR1 is regulated is by 
means of two co-repressors. Both NAB1 and NAB2 can block the biological activity 
of EGR1. NAB1 is a constituently expressed protein but NAB2 has been reported to 
be activated by the same stimuli as EGR1 and can be activated by EGR1 itself 
(Kumbrink, Gerlinger et al. 2005). It therefore acts in a negative feedback loop with 
EGR1. One hypothesis is that in the Crohn’s disease patients, the inflammatory 
condition of the disease is over-stimulating the expression of the NAB2 inhibitor, 
leading to lower levels of EGR1 in the patients and a dysregulation of the feedback 
loop. This hypothesis was tested by examining expression of NAB2 in the IBD 




3.3.9.1 The relative NAB2 expression levels in CRC cell lines 
 
The NAB2 mRNA expression levels were first examined in CRC cell lines HRT18 
and SW480 after treatment with the inflammatory mediators in order to ensure that 
NAB2 expression could be detected. Figure 3.18 A. illustrates that the levels of 
endogenous NAB2 in both cell lines is very low and although there does appear to be 
significant induction of expression after treatment in the cell lines this does not cause 
the NAB2 levels to greatly increase overall when compared with the EGR1 levels 
(Figure 3.18 B) 
 





























Figure 3.19: Relative NAB2 mRNA expression in CRC cell lines after 
inflammatory treatment  
HRT18 and SW480 CRC cell lines were treated with LPS, MDP, PGN and TNF (1 
µg/ml) for 24hrs, the RNA was isolated and the relative mRNA expression levels 
were determined by quantitative real-time PCR. The experiment was conducted in 
triplicate and repeated three times. The values show NAB2 expression levels relative 
to !-actin. A. The relative NAB2 mRNA expression levels in HRT18 and SW480 
cell, untreated and after treatment with inflammatory mediators. B. EGR1 and NAB2 
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3.3.9.2 Relative NAB2 expression levels in IBD  
 
The relative NAB2 mRNA expression levels were examined in healthy controls 
(n=19), ulcerative colitis patients (n=19) and patients with Crohn’s disease (n=14) 
representing 89.89%, 76% and 77.78% respectively of the total patients in each 
group. Figure 19.A. shows that there are relatively low levels of NAB2 present, and 
much lower levels of NAB2 compared with EGR1 in all three of the patient groups. 
Figure 19.B illustrates the level of NAB2 compared to EGR1 (where EGR1 value=1), 
plotted on a logarithmic scale. In the healthy controls none of the patients have 
higher levels of NAB2 than EGR1. Three patients have higher levels of NAB2 in 
ulcerative colitis (15.79%) and two Crohn’s disease patients have higher levels of 
NAB2 compared with EGR1 (14.29%). There appears to be no differential expression 
of NAB2 in ulcerative colitis or Crohn’s disease although the patient numbers are 
small and the low expression of NAB2 may be an issue.  
 





















Figure 3.20: Relative NAB2 mRNA expression levels in IBD and healthy 
controls  
RNA from biopsies of healthy controls (n=16), ulcerative colitis patients (n=19) and 
Crohn’s disease patients (n=14) was isolated and the relative mRNA expression 
levels were determined by quantitative real-time PCR. The values show NAB2 and 
EGR1 expression levels relative to !-actin. The experiment was performed in 
triplicate and repeated twice. A. The average value of NAB2 expression for each of 
the patient groups was plotted, along with the average value of EGR1 expression. B. 
The EGR1 values were set to 1 to illustrate the fold increase or decrease in 
endogenous NAB2 expression compared with the endogenous EGR1 levels for each 
patient. 
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3.4 Discussion 
 
It is clear that there is differential expression of EGR1 in diseased colon. We looked 
at the expression of EGR1 in matched normal mucosa and tumour and found that 
there is significantly different expression in 23/30 CRC patients. Given that EGR1 is 
differentially expressed in so many different cancers this was not an unexpected 
result. What is surprising however is that there appears to be two different 
populations of patients, with respect to EGR1 expression. Thirteen of the CRC 
patients show over-expression of EGR1 in the tumour (group H), whereas 10 patients 
show decreased expression of EGR1 in the tumour (group L). We have shown that 
the patients that have over-expression of EGR1 have relatively low levels of EGR1 in 
the normal mucosa, compared with the expression of EGR1 in healthy controls. 
Conversely the patients that have decreased expression of EGR1 in the tumour, have 
relatively high levels of EGR1, on a par with the EGR1 expression levels seen the 
healthy control population. The paper described by Hong et al 2007, described an 
over-expression of EGR1 in the normal mucosa from CRC patients compared with 
healthy controls which we do not observe in this study. The group with high levels of 
EGR1 in the normal mucosa do not have higher EGR1 levels than the healthy 
controls. It should be kept in mind however that the study mentioned above was 
conducted on patients with early onset CRC and from a Chinese population. 
Unfortunately the patient set used here were anonymous and therefore there is no 
patient data available for our group of patients, however they are unlikely to be early 
onset in general as they were collected from the Western General Hospital surgical 
list, and this possible age difference in study set could explain the differences seen in 
the two studies.  
 
However, the observance of two different populations with regards their EGR1 
expression in this study is consistent with published data and our Oncomine analysis 
of EGR1 expression in normal tissue and tumour of colorectal ancer patients. These 
studies showed that there is differential expression of EGR1 in the different stages of 
tumour development. The first study (Habermann et al, 2007), observed significantly 
lower levels of EGR1 in adenoma samples compared with normal tissue, with a 
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significant increase in EGR1 from adenoma to carcinoma. As Oncomine analysis 
showed that lower EGR1 expression was detected in colorectal adenoma than in 
normal tissue (Hong et al, 2010), with higher expression of EGR1 in colorectal 
carcinoma than in normal tissue (Skrzypcak et al) These results could account for 
why we see two difference groups of EGR1 expression between normal and tumour 
in our matched samples.  
 
Given the differential expression seen in the CRC patients we then investigated 
whether there is any association between the three EGR1 variants that were 
determined to have an association with disease phenotype from the case control 
study conducted by the CCGG. We do not see any correlation with the EGR1 
variants and the differential expression of EGR1, however the sample size in this 
study was small and a study conducted with much larger numbers would be required 
to conclusively prove or disprove any possible correlation of EGR1 expression with 
these variants. However, it is interesting that one group, group L, showed a lack of 
homozygous wild-type alleles. This group had the highest level of EGR1 in 
expression in the normal mucosa, with expression levels comparable to the healthy 
controls. It should also be noted that there was only one homozygous wild-type 
genotype present in the healthy control group, which showed the highest levels of the 
EGR1 in the study. It would be of interest to conduct a haplotype analysis and to 
determine if there is a genetic change on this haplotype background influencing 
expression. 
 
 Somatic tumour mutations of KRAS and BRAF in the patients was also investigated 
to determine if they could explain the three observed patient groups. We observed 
KRAS mutations in 9/30 patients and BRAF mutations in 2/30 patients. The 
frequency of the KRAS and BRAF mutations observed in our group of patients agrees 
with published data (Ilyas, Straub et al. 1999; Davies, Bignell et al. 2002), with all of 
the mutations being identified in the two most common mutated codons in both 
KRAS and BRAF, codon 12 of KRAS and codon 600 in BRAF. BRAF mutations are 
associated with both a sporadic onset microsatellite instability (MSI) phenoytpe and 
with the CpG island methylator (CIMP) phenotype (Weisenberger, Siegmund et al. 
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2006). BRAF mutations have also been shown to be associated with other features of 
sporadic MSI-H cancers including advanced age at diagnosis and female sex. KRAS 
mutations are rarely observed in MSI-H phenotype cancers (Kambara, Simms et al. 
2004) but are associated with the CIMP phenotype (Toyota, Ahuja et al. 1999).  As 
mentioned we observed that the patients with a KRAS or BRAF mutation have 
relatively low levels of EGR1 expression in the normal mucosa, with 6/11 patients 
with a mutation showing increased expression of EGR1 in the tumour. This is very 
interesting given that the expression of EGR1 is mediated via the MAPK signalling 
pathway (Chapter 1.3.2, Figure 1.9).  
 
We investigated whether the differential expression of EGR1 is associated with 
aberrant methylation of the EGR1 promoter. A number of promoters regulated by 
EGR1 have been found to undergo altered methylation such as the p73 promoter, and 
the MDR1 promoter in prostate cancer (Enokida, Shiina et al. 2004; Pipaon, Real et 
al. 2005). It has been found that the heparanase promoter is CpG island 
hypomethylated in both bladder and prostate cancer (Ogishima, Shiina et al. 2005) 
and the expression of heparanase is known to be regulated by EGR1 in tumour cells 
(de Mestre, Rao et al. 2005). EGR1 has several CpG islands in its 5’ region (Li and 
Dahiya 2002) and it has been suggested that CpG methylation may influence the 
transcription and expression of EGR1 (Seyfert, McMahon et al. 1990) which made it 
a reasonable mechanism to be involved in the differential expression of EGR1 in 
these patients. However, here there is no evidence to suggest that there is any 
methylation of the EGR1 promoter in the CRC cell lines, or any of the CRC patients, 
either in the normal mucosa or in the tumour in the region of the EGR1 promoter that 
we investigated. There was also no evidence of methylation of the EGR1 promoter in 
any of the patients in the IBD study. Therefore it can be assumed that aberrant 
methylation of EGR1 does not occur in the mucosa of CRC or IBD patients at this 
region. However it is possible that the expression of EGR1 is being regulated in a 
different manner such as the deacetylation of histones, which is mediated by HDACs 
(Jones and Baylin 2002). There is evidence to show that changes in histone 
acetylation has an important role in the regulation of EGR1 and that it is necessary to 
have a repression chromatin structure in order to prevent the constitutive activation 
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of EGR1 (Tur, Georgieva et al. 2010).  It would be interesting to further investigate 
chromatin modifications in the regulation of EGR1 in CRC patients.  
 
As mentioned previously one of the main mechanisms by which the expression of 
EGR1 is regulated is by means of its two co-repressors NAB1 and NAB2, which 
prevent the constitutive activation of the EGR1 target genes. The NAB proteins 
regulate the activity of EGR1 by binding to the RI domain of EGR1 and form a 
complex that binds to the EGR1 binding site. This does not prevent EGR1 from 
binding to DNA but does inhibit the activation of the target genes (Swirnoff, Apel et 
al. 1998), EGR1 has been shown to active NAB2 transcription, which can then be 
repressed by the NAB proteins and appears to act in a negative feedback loop 
(Kumbrink, Gerlinger et al. 2005). However there are conflicting reports that indicate 
that NAB2 can act as a positive activator of gene transcription as it has been shown 
that NAB2 can enhance the EGR1 transcription of IL-2 (Collins, Wolfraim et al. 
2006). NAB2 has been shown to be over-expressed in a variety of melanomas 
(Kirsch, Korradi et al. 1996) and down-regulation of NAB2 is seen in advance 
prostate cancer (Abdulkadir, Carbone et al. 2001). The NAB proteins could 
potentially have a role in the regulation of the differential expression see in the CRC 
patients. Unfortunately there was insufficient RNA available to investigate this in the 
CRC patients.   
 
One other important investigation of these patient samples would be to look at 
whether there is differential expression of the EGR1 protein to the same extent as 
EGR1 mRNA. It would also be important to determine whether there is any effect on 
the activation of the downstream targets of EGR1 such as PTEN and TF. EGR1 is 
known to regulate the expression of a variety of genes including several tumour 
suppressor genes such as TGF!1, PTEN, TP53 and fibronectin (Baron, Adamson et 
al. 2006) and the differential expression of EGR1 may have an impact on its 
transcriptional activity and ultimately the expression of its downstream target genes. 
Given the absence of patient data for these patients an analysis into the mutation 
status of some of these key tumour suppressor genes, such as p53 and PTEN, would 
be very informative. Similarly it would be possible to determine if these patients are 
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MSI or MSS and given that MSI and CIN are usually mutually exclusive, this would 
allow us to determine they type of genetic instatility that exists in these patients and 
whether it correlates in any way to the differential EGR1 gene expression that we 
have observed. 
 
Analysis of a group of healthy controls and IBD patients also demonstrated 
differential expression EGR1. The expression of EGR1 was found to be decreased in 
the un-inflamed tissue of ulcerative colitis and to a significant level in Crohn’s 
disease. As EGR1 is known to be involved in the regulation of several different 
genes involved in inflammation it is interesting that the expression of EGR1 is 
decreased in un-inflamed mucosa in IBD especially as it has been observed that 
EGR1 is over-expressed in the inflamed mucosa of both Crohn’s disease and 
ulcerative colitis patients (Subbaramaiah, Yoshimatsu et al. 2004). It was possible to 
investigate the hypothesis that expression of the NAB2 repressor protein plays a role 
in the differential expression of EGR1 in the healthy controls and IBD patients, 
however there does not appear to be any over-expression of NAB2 that may account 
for lower levels of EGR1 in these patients. 
 
In order to determine how EGR1 responds under inflammatory conditions in IBD 
patients, biospies were cultured overnight in several different inflammatory 
mediators, LPS, MPD, PGN and TNF. Both LPS and TNF mediators have published 
links with EGR1 expression and activity. Lipopolysaccharide (LPS) is a component 
of the outer membrane of gram-negative bacteria and it induces inflammatory 
response through the TLR4 receptor and is known to induce EGR1 expression in 
many different cell types including monocytes, endothelial cells and macrophages 
(Coleman, Bartiss et al. 1992; Yao, Mackman et al. 1997; Kadl, Huber et al. 2002; 
Luyendyk, Schabbauer et al. 2008). It has been shown that EGR1 mediates the LPS 
induced activation of TNF-! in monocytes (Yao, Mackman et al. 1997). TNF is pro-
inflammatory cytokine that is secreted upon activation and has been shown to have 
increased expression in IBD (Bosani, Ardizzone et al. 2009; Roda, Sartini et al. 
2010). EGR1 was induced by treatment with TNF-! in human fibroblasts and 
osteosarcoma cells (Cao, Guy et al. 1992; Granet and Miossec 2004). Muramyl 
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dipeptide (MDP) is the major component of peptidoglycan (PGN) and is found in 
both gram-positive and gram-negative bacteria. MDP induces and inflammatory 
response through the activation of NOD2, which activates the NF-!B and IL-12 
production. PGN is recognised by the TLR2 receptor.  There is little known about the 
effect of treatment with MDP and PGN of the expression of EGR1.  
 
EGR1 is an early response gene and in most cell types the activation of EGR1 
expression is usually seen by 30min, with a return to basal levels by 4hr. However 
preliminary experiments conducted by the GI unit indicted that EGR1 expression is 
induced up to 24hrs in SW480 cells after treatment with all of the inflammatory 
mediators and this was replicated in my own data. It is known that the induction of 
EGR1 by different stress stimuli can have opposing effects depending on the stimuli 
and cell type (Yu, de Belle et al. 2004). Interestingly in endometrial carcinoma cells 
EGR1 protein expression was shown to be induced up to 24hrs after treatment with 
ER-!, and constitutive activation of the EGFR/ERK1/2 pathway can result in 
constant high levels of EGR1 protein in prostate cells, indicating that the induction of 
EGR1 can be sustained in some cell types (Saegusa, Hashimura et al. 2008; Sauer, 
Gitenay et al. 2010).  
 
In the mucosa of the healthy controls EGR1 expression is significantly induced after 
LPS and TNF treatment and the majority of patients show induction of EGR1 after 
these treatments, indicating that EGR1 is induced by inflammatory mediators in 
healthy normal mucosa as expected. Interestingly there is little or no induction of 
EGR1 expression after MDP or PGN treatment, indeed 35% of patients show a 
decrease in EGR1 expression after MDP treatment and 57% show a decrease after 
PGN. It could be that EGR1 is not activated to the same extent after exposure to 
MDP or PGN, or that unlike after LPS and TNF, the expression of EGR1 is more 
transient in response to these treatments in normal mucosa. It should also be kept in 
mind that the sample numbers for each patient group in this study are small and 
larger numbers would be required to get a more accurate picture. 
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The un-inflamed mucosa in ulcerative colitis patients show significant induction of 
EGR1 after treatment with TNF as in the healthy controls. However EGR1 
expression does not seemed to be induced to the same extent after LPS treatment, 
indeed only 49% of the UC patients show an induction of EGR1 after LPS. 
Interestingly the treatment of UC mucosa with PGN actually seems to cause a 
significant decrease in the levels of EGR1. However it is surprising that there is such 
a difference after treatment with MDP and PGN in these patients, as MDP is a 
component of PGN. 
 
In the Crohn’s disease patients there is a significant decrease in EGR1 expression 
after LPS treatment, with 70% of the patients showing lower levels of EGR1 after 
treatment with LPS. Although in the overall population analysis only LPS shows a 
significant decrease, 66% of patients show a decrease after TNF treatment and 66% 
show a significant decrease after MDP treatment. It is interesting that the Crohn’s 
disease patients show such an aberrant response after MDP treatment. NOD2 is the 
main susceptibility gene for Crohn’s disease and has been shown to be activated by 
MDP (Strober, Murray et al. 2006). A yeast two-hybrid screen conducted by the GI 
unit identified EGR1 as a novel binding protein with NOD2, which will be 
investigated in the next chapter. However it is intriguing that the Crohn’s disease 
patients show such an aberrant response of EGR1 induction after MDP treatment 
given this link with NOD2.  
 
It is clear however that in the un-inflamed tissue of the IBD patients there is an 
aberrant induction of EGR1 after inflammatory treatments. It would interesting to 
determine if the protein levels of EGR1 are similarly effected, and whether the 
aberrant response of EGR1 to these inflammatory stimuli has an effect on the 
downstream inflammatory targets of EGR1 such as mPGES-1. It has been suggested 
that there is an important role for prostaglandin E2 (PGE2) in inflammatory bowel 
disease, and it has been shown that there are increased levels of mPGES-1, which is 
important for the synthesis of PGE2, in inflamed intestinal mucosa in both CD and 
UC (Subbaramaiah, Yoshimatsu et al. 2004). EGR1 is known to regulate the 
transcription of the mPGES-1 promoter (Naraba, Yokoyama et al. 2002), and it has 
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been shown that EGR1 is necessary for the TNF!-mediated induction of mPGES-1. 
Interestingly mPGE2 is over-expressed in CRC (Yoshimatsu, Golijanin et al. 2001). 
It would therefore be of considerable interest to determine if the EGR1-mediated 
transcription of mPGES-1 is aberrant in IBD.  
 
In conclusion, we have shown that there is differential expression of colonic EGR1 in 
diseased colon, in both CRC and IBD. In CRC there is both increased expression and 
suppression of EGR1 in the tumour and it is unknown how this differential 
expression is regulated. We know that it is unlikely to be associated with aberrant 
methylation of the EGR1 promoter in normal mucosa or tumour or with the EGR1 
common variants in the germline, although almost half of those patients with lower 
EGR1 expression in the tumour has a mutation in the RAF signalling pathway. There 
is also differential expression of EGR1 between healthy controls and patients with 
IBD, with the IBD patients also showing an aberrant EGR1 response to inflammatory 
mediators. It is unlikely that this differential expression is associated with aberrant 
methylation of the EGR1 promoter or with the expression of the EGR1 co-repressor 
protein NAB2. Future work would be to determine how the differential expression of 
EGR1 is regulated in diseased colon and understanding what effect this differential 
expression has on the downstream targets of EGR1 in CRC and IBD would be of 
great interest.  
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EGR1 is a transcription factor that is known to be localised in the nucleus, but has 
also been shown to localise in the cytoplasm. EGR1 contains a bipartite nuclear 
localisation signal located in the zinc-finger domain of EGR1 (Gashler, Swaminathan 
et al. 1993), and it has been suggested that the components of the cytoskeleton may 
have a role to play in the nuclear translocation of EGR1 (Mora, Olivier et al. 2004). 
EGR1 has been shown to localise with microtubules, with both !- and "-tubulin, in 
benign prostate cells, whereas no interaction is visible in malignant prostate cells 
(Mora, Olivier et al. 2004). Similarly preliminary results by the CCGG demonstrated 
that EGR1 co-localises with the cytoskeleton in skin fibroblasts and CRC cells by 
immunocytochemistry and have demonstrated a potential interaction with #-tubulin 
by IP. Therefore further work was required to investigate the potential interaction 
with cytoskeleton components such as #-tubulin and !-tubulin in CRC cell lines. 
 
An interesting finding by the Gastrointestinal Unit was that EGR1 is an interacting 
partner of the IBD susceptibility NOD2 protein by yeast-two hybrid. It was decided 
to investigate this interaction in colorectal cancer cell lines and ultimately to 
determine whether or not this interaction was localised in the cytoplasm or nucleus, 
and whether it was altered upon stimulation of EGR1 by stress stimuli such as LPS. 
The aim of this chapter was to investigate the cellular role of EGR1 in colorectal 
disease by advancing preliminary work preformed by the CCGG and GI groups, 
including specific cellular localisation and interaction with other proteins. The 
cellular localisation of EGR1 in CRC cells by western blot and 
immunoctyochemistry is investigated and whether NOD2 localisation coincides with 
EGR1 in these cells. The interaction between EGR1 and NOD2 is investigated using 
immuoprecipitation in both untreated and LPS treated cells. The interaction between 
EGR1 and tubulin components are also confirmed using immuoprecipitation in 
SW480 cells. 
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4.2 Methods 
 
4.2.1 Cell Culture 
Cell culture was conducted as detailed in the methods section (2.1.2).  
 
4.2.2 siRNA knockdown of EGR1  
HRT18 cells were plated in equal amounts into a 6 well tissue culture plate and 
grown until ~80-90% confluent. siRNA transfections were performed using 
Lipofectamine 2000 reagent (Invitrogen) in Optimem-1 medium (Gibco) and the 
Stealth siRNA (Invitrogen) as per manufacturer’s instructions. Cells were transfected 
in antibiotic-free media for 48 hours. Cells were subsequently harvested, the protein 
was extracted and resolved by Western Blot analysis as detailed in methods (2.8). 
 
Stealth siRNA Primers  
EGR1HSS103117 (1) UCU CCC AGG ACA AUU GAA AUU UGG U 
AGC AAA UUU CAA UUG UCC UGG GAG A 
EGR1HSS103118 (2) GAU CUC UGA CCC GUU CGG AUC CUU U 
AAA GAA UCC GAA CGG GUC AGA GAU C 
EGR1HSS103119 (3) CCA UGG ACA ACU ACC CUA AGC UGG A 
UCC AGC UUA GGG UAG UUG UCC AUG G 
Scrambled control – 
mutant SOCS-1  
CUA UCU AAG UUA CUA CCC CUU TT 
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4.2.3 Treatment of cells  
HRT18 and SW480 cells were treated with various concentrations of Curcumin 
(Sigma Aldrich, UK) ranging from 10nM to 15µM, for time points between 30min to 
22 hours. The stock solution of Curcumin was prepared in dimethyl sulfoxide 
(DMSO) at a concentration of 10mM, and all subsequent concentrations of Curcumin 
were prepared in DMSO to a final volume of 500µl of media. DMSO only controls 
were included in all experiments. 
 
HRT18, SW480 and Vaco425 cells were also treated with concentrations of LPS 
ranging from 100ng/ml to 10µg/ml, for various time lengths between 30min to 22 
hours. The stock solution of LPS was prepared in PBS at a concentration of 1mg/ml 
and all subsequent concentrations of LPS were prepared in PBS. 
 
4.2.4 Preparation of protein extracts 
Two methods of nuclear and cytoplasmic extraction were tested as detailed below, 
with longer extraction times for the cytoplasmic extract in protocol (B). 
 
4.2.4.1  Preparation of Cytoplasmic and Nuclear Extracts (A) 
To prepare cytoplasmic and nuclear extracts the cells were resuspended in 100µl of 
Normal Lysis Buffer, supplemented with protease inhibitors. Following an 
incubation of 5min on ice, the cells were centrifuged at 13,000 rpm for 20sec. The 
supernatant, which is the cytoplasmic extract, was removed and transferred to pre-
chilled eppendorf tubes. The cell pellet was then resuspended in 30µl Hypotonic 
Lysis Buffer, supplemented with protease inhibitors (2.8.3.1) and incubated on ice 
for 30min. The cells were centrifuged at 13,000 rpm for 5min and the supernatant, 
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4.2.4.2  Preparation of Cytoplasmic and Nuclear Extracts (B) 
To prepare cytoplasmic and nuclear extracts the cells were resuspended in 100µl of 
Normal Lysis Buffer, supplemented with the same protease inhibitors (2.8.3.1). The 
cells were then centrifuged at 6,000 rpm for 20min. The rest of the protocol 
continues the same as above from this stage. 
Ultimately both extraction methods resulted in the same localisation of EGR1 in the 
CRC cell lines and the data in this chapter illustrates nuclear and cytoplasmic 
extracts prepared as detailed in the (A) protocol.  
 
4.2.4.3 Preparation of cellular extracts into more distinct cellular 
compartments 
In order to separate the extracts into four cellular compartments (cytoplasmic, 
membrane/organelle, nuclear and cytoskeleton) the cells were grown until confluent 
in a T25cm3 flask. The cells were then extracted using the ProteoExtract Subcellular 
Proteome Extraction Kit  (Calbiochem) as per the manufacturer’s instructions. 
 
4.2.5 Western Blotting 
Protein extracts were resolved by western blot analysis as detailed in the methods 
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4.2.6 Antibodies 
The following antibodies were used in this chapter: 








4oC - overnight 
EGR1 (588) 
Rabbit polyclonal 




4oC - overnight 
EGR1 (C-19) 
Rabbit polyclonal 

































Santa Cruz Biotechnology 
sc-48416 








Santa Cruz Biotechnology 
sc-40 





   
Goat anti-Mouse 
IgG-HRP 
Santa Cruz Biotechnology   
(Sc-2005) 
1:2000 (WB) Standard 
Donkey anti-Goat 
IgG-HRP 
Santa Cruz Biotechnology   
(Sc-2056) 
1:2500 (WB) Standard 
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Goat Anti-Rabbit 




1:2000 (IC) Standard 
Sheep Anti-





1:2000 (IC) Standard 
Table 4.2: Primary and secondary antibodies 
WB indicates dilution used in Western blotting techniques, IC indicates dilution used 




SW480 cells were seeded into a T75cm3 flask and grown until 80-90% confluent. 
The cells were harvested and the proteins were extracted in 500µl of lysis IP buffer 
with protease inhibitors added. The protein concentration was determined by 
Bradford assay. The agarose G beads where blocked in lysis buffer containing BSA 
(100µg/ml tRNA, 100µg/ml BSA, 100µ/ glycogen). The agarose G beads were 
washed 3 times in IP buffer and the protein extracts were pre-cleared in washed 
agarose G beads for 1 hour at 4 oC. 500µg of protein lysate was incubated in 2µg of 
antibody overnight at 4 oC while rotating. 15µl of pre-washed agarose G beads was 
added and incubated at 4 oC for 1 hour while rotating. The beads were washed and 
50µl of 2 times running buffer was added. The samples were boiled for 5 min, and 
centrifuged at 14,000rpm at room temperature for 5min. The supernatant was 
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 Salt Detergent Buffer 
IP lysis buffer 1 150mM NaCl 0.5% NP40 50mM Hepes (pH 7.4) 
IP lysis buffer 2 150mM NaCl 0.5% Tween 50mM Hepes (pH 7.4) 
IP lysis buffer 3 300mM NaCl 0.5% Tween 50mM Hepes (pH 7.4) 
IP lysis buffer 4 300mM NaCl 1% Triton x100 50mM Hepes (pH 7.4) 
IP lysis buffer 5 400mM KCl 1% NP40 25mM Tris 




Initially two methods of immunocytochemistry were tested.  
 
4.2.8.1 Immunocytochemistry method using methanol:acetone 
Cells were spilt and 500µl of cell suspension was plated into a 6 well plate 
containing a sterile coverslip and grown overnight at 37oC. The medium was 
removed and cells/coverslip washed in 5ml cold PBS. The cells were fixed with 3ml 
of methanol:acetone (1:1) and incubated at –20oC for at least 30min. After removal 
of the methanol:acetone the cells were washed with PBS while shaking for 10mins, 3 
times. A blocking solution of 10% donkey serum in PBS was added to the cells for 
30min at room temperature. After removal of the donkey serum, the cells were 
incubated with primary antibody in 10% donkey serum and incubated at room 
temperature for 1 hour. After washing with 0.15% Tween-10/PB for 10min while 
shaking, the cells were incubated with a secondary antibody in 1.5% donkey serum 
for 30min at room temperature in the dark due to the use of fluorescent secondary 
antibody. The cells were washed 3 times for 10min as before and the cover slips 
were placed cell side down onto microscope slides containing a few drops of DAPI-
Vectashield. The slides were stored in the dark at 4oC and the images were visualised 
using fluorescence microscopy. 
 
  160 
 
4.2.8.2 Immunocytochemistry method using formaldehyde 
Cells were spilt and plated as above. The cells were fixed with 1ml of 4% 
formaldehyde and incubated at room temperature for 20min. After removal of the 
formaldehyde, the cells were rinsed several times with PBS, and a solution of 0.5% 
Triton-x was added to the cells for 2min at room temperature. The cells were washed 
with PBS 3 times for 5min while shaking and then the cells were blocked with 5% 
BSA in PBS all day. The cells were then washed with PBS 3 times for 5min as 
before and incubated with a primary antibody in 5% BSA in PBS overnight at 4oC. 
After washing with PBS 3 times for 5min while shaking, the cells were incubated 
with a secondary antibody in 5% BSA for 1hr at room temperature in the dark. The 
cells were washed 3 times for 10min as before and the cover slips were placed cell 
side down onto microscope slides containing a few drops of DAPI-Vectashield. The 
slides were stored in the dark at 4oC and the images were visualised using 
fluorescence microscopy. 
 
The immunocytochemistry method using formaldehyde to fix the cells gave much 
better immunostaining and consistent results. All of the immunofluorescence 
experiments detailed in this chapter were conducted using the formaldehyde 
protocol. 
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4.3 Results 
 
4.3.1 Determination of accurate tools for EGR1 protein analysis  
 
A number of different antibodies for EGR1 are commercially available and had been 
used with mixed results previously in the lab. Whole cell extracts of four colorectal 
cancer cell lines (HRT18, HCT116, SW480 and Vaco425) were prepared, resolved 
on a Western blot and probed with three different commercially available antibodies. 
Two antibodies that had been used previously in the lab are EGR1 anti-rabbit 
available from Santa Cruz Biotechnology (Table 4.2). A third antibody tested was 
EGR1 anti-goat from R&D Systems (AF2818). Figure 4.1 illustrates the membrane 
probed with the three different antibodies. Antibody A (Figure 4.1 A) is EGR1 !-
rabbit (sc-110), however EGR1 expression is barely evident in any of the three cell 
lines. Using antibody B (EGR1 !-rabbit, Santa Cruz Biotechnology, Sc-189) 
demonstrates expression in the cell lines, however in HCT116 and Vaco425 multiple 
bands are evident, and only a weak band is evident in HRT18 and SW480 cells 
(Figure 4.1 B). The final EGR1 antibody (EGR1 !-goat, R&D Systems) gave a clear 
single band in HCT116 and SW480 cells, and a weak band evident in HRT18 cells 
located at the correct position for EGR1 at ~ 80kDa (Figure 4.1 C). Therefore it was 
decided to use the third antibody for all future experiments. After further 
optimisation it was determined that for best results the EGR1 antibody requires 
overnight incubation in milk PBS/Tween along with washing the membrane for 1 
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Figure 4.1: EGR1 antibody in CRC cell lines 
Whole cell extracts were prepared from HRT18, HCT116, SW480 and Vaco425, 
resolved on a 10% acrylamide gel and probed with three different anti-EGR1 
antibodies A. The anti-EGR1 antibody (Santa Cruz Biotehcnology, sc-110) gave a 
weak band of EGR1 expression in all three cell lines.  B. The anti-EGR1 (Santa Cruz 
Biotechnology, sc-189) shows a stronger a band but there appears to be multiple 
bands. C. The third anti-EGR1 (R&D systems, AF2818) gave a clear single band for 
EGR1 expression at the correct size of ~80kDa. 
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In order to confirm the presence and the detection of EGR1 by the antibody chosen, 
the expression of EGR1 was knocked down in HRT18 cells using three different 
siRNA primers for 48 hours. Whole cell extracts were prepared, resolved on a 
Western blot and probed with the anti-EGR1 antibody. The membranes were 
subsequently probed with an anti-actin antibody to verify protein loading. It is clear 
from figure 4.2 that both siRNA primer 1 and 2 reduces EGR1 expression after 48 
hours. This confirmed that the antibody being used for analysis is detecting the 
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Figure 4.2: Knockdown of EGR1 
HRT18 cells were transfected with three different siRNA primers for 48 hours. Cells 
were also transfected with a scrambled control and a lipofectamine only control. 
Whole cell extracts were prepared (30µg) and resolved on a 10% acrylamide gel. The 
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This clearly demonstrated that the EGR1 antibody chosen detects a band of correct 
size for EGR1, with EGR1 siRNA reducing this expression. However we wanted to 
ensure that the EGR1 protein being detected responds to induction by stress stimuli. 
As it has been shown that different cell lines respond differentially to treatment with 
stress stimuli the experiment was conducted using both HRT18, which has low levels 
of EGR1 expression, and SW480 cells which has higher levels of EGR1 at both the 
mRNA and a protein level (Figure 3.1; Section 3.3.1). 
 
SW480 (A) and HRT18 (B) cells were treated with various concentrations of 
curcumin, ranging from 100nM to 15µM, for a 3 hour time period and using a 
concentration of 1µM of curcumin over a time period ranging from 30 minutes to 21 
hours (Figure 4.3 A, B). There is an increase in the levels of EGR1 protein in both 
cell lines, after treatment of 500nM of curcumin or higher. In SW480 cells, there is 
an increase at 1µM, taking into account differences in protein loading and the 
induction of EGR1 with 1µM of curcumin appears to occur after 30 minutes to 6 
hours (Figure 4.3 A). In HRT18 cells the protein levels are increased at 
concentrations 500nM to 10µM with EGR1 levels increasing after treatment with 
1µM between 1 hour and 3 hours (Figure 4.3 B). 
 
The experiment was repeated using LPS to induce expression of EGR1. The cells 
were treated with concentrations of LPS ranging from 100ng/ml to 10µg/ml for 6 
hours, and treated with 1µg/ml over a time period, ranging from 30min to 21 hours 
(Figure 4.3 C, D). In SW480 cells there is an increase in EGR1 protein levels as the 
concentration of LPS increases, and an increase in EGR1 after 1 hour with 1µg/ml 
LPS (Figure 4.3 C). There is no clear increase of EGR1 in HRT18 at any particular 
concentration, but an increase in EGR1 protein levels after 1 hour with 1µg/ml 
treatment LPS (Figure 4.3 D). This experiment demonstrates that there is induction 
of EGR1 evident using the !-EGR1 antibody at the correct band size of ~80kDa 












Figure 4.3: CRC cells treated with Curcumin and LPS 
Cells were treated with curcumin and LPS over a range of concentrations and over a 
time period as detailed below. Whole cell extracts were prepared (30ng) and probed 
with anti-EGR1 and anti-actin. A. SW480 cells and B. HRT18 cells were treated 
with various concentrations of curcumin (100nM, 500nM, 1µM, 10µM and 15µM) 
for 3 hours and treated with 1µM curcumin for over a time period (20 hrs, 6 hrs, 3 
hrs, 1hr and 30 min). C. SW480 cells and D. HRT18 cells were treated with various 
concentrations of LPS (100ng/ml, 500ng/ml, 1µg/ml, 2µg/ml and 10µg/ml) for 6 
hours and then treated with 1µg/ml of LPS over a time course (21 hrs, 6 hrs, 3 hrs, 
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4.3.2 Expression of EGR1 in CRC cells 
 
In order to determine the protein levels of EGR1 in various colorectal cancer cell 
lines, whole cell extracts of HRT18, HCT116, SW480 and Vaco425 were prepared 
with 30µg of protein, resolved on an acrylamide gel and probed with the anti-EGR1 
antibody (Figure 4.4). High protein levels of EGR1 are observed in both HCT116 
and SW480 cells, but lower protein levels in HRT18 and Vaco425. Interestingly 
Vaco425 has the highest relative EGR1 mRNA expression levels in the qRT-PCR 
analysis from the previous chapter but shows the least amount of protein in this case. 
The next investigation was to determine the localisation of the EGR1 protein in CRC 
cells, hence cytoplasmic and nuclear protein extracts of the four CRC cell lines 
above were prepared at a concentration of 30µg of protein. This again shows lower 
levels of EGR1 in HRT18 and Vaco425 cells. It appears that EGR1 is localised in the 
nucleus and the protein is also detected strongly at times in the cytoplasm in all cell 
lines tested except for Vaco425. Indeed EGR1 is possibly increased in the cytoplasm 
of HRT18 cells rather than the nucleus, which is intriguing as the HRT18 cell line 
contains the wild-type allele for all three EGR1 SNPs. 
 












Figure 4.4: Expression of EGR1 in CRC cell lines 
Protein extracts (30µg) were prepared from HRT18, HCT116, SW480 and Vaco425, 
resolved on a 10% acrylamide gel and probed with anti-EGR1 antibody and stripped 
and re-probed with anti-actin antibody as a loading control. A. Illustrates EGR1 
protein levels in whole cell extracts B. EGR1 levels in nuclear (N) and cytoplasmic 
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Immunofluorescence experiments were conducted to visualise the localisation of the 
EGR1 protein in HRT18 and SW480 cells. It was decided to further investigate the 
expression and localisation of EGR1 in these two cell lines specifically, as they have 
different genotypes of the three EGR1 SNPs that were investigated in the previous 
chapter. HRT18 is homozygous wild type for the three EGR1 SNPs and SW480 is 
homozygous variant.  
 
As figure 4.5 illustrates, EGR1 is localised in both the nucleus and the cytoplasm in 
both these cells, with stronger cytoplasmic staining evident in the HRT18 cells, in 





















Figure 4.5: Localisation of EGR1 in CRC cell lines using immunofluorescence 
HRT18 and SW480 cells were grown on cover slips and fixed with formaldehyde. 
The cells were immunostained with EGR1 anti-goat and TxRed-conjugated Goat 
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As EGR1 is a transcription factor, it was expected that the protein would be 
predominantly localised in the nucleus. However, as discussed there is also evidence 
to suggest that EGR1 may shuttle between the cytoplasm and the nucleus and so a 
subcellular localisation kit was used to further determine the exact localisation of 
EGR1. The protein extract can be separated into four subcellular fractions, the 
cytosol fraction, a membrane bound/organelle fraction, the nuclear fraction and the 
cytoskeleton fraction. Figure 4.6 A illustrates that, as expected in the SW480 cells, 
EGR1 is predominantly localised in the nucleus with protein evident in the cytosol 
and membrane bound/organelle fraction also. The membrane was subsequently 
probed with anti-HP1 as a nuclear control to determine correct separation of the 
protein fractions. There is a strong band in the nuclear fraction for HP1 as expected, 
however there are also faint bands present in the cytoplasmic and 
organelle/membrance bound fraction, indicating a slight contmination of nuclear 
protein the the cytoplasmic fractions. Figure 4.6 B shows the localisation of EGR1 
over a 16-hour time period.  
 
Due to inconsistency and low levels of EGR1 obtained from HRT18 cells when 
using the subcellular localisation kit it was not possible to conduct all experiments in 
this cell line as hoped. Similarly low levels of NOD2 is also observed in HRT18 cells 
(as will be demonstrated in Figure 4.7) so SW480 will used in the majority of the 
future experiments. 
 









Figure 4.6: Localisation of EGR1 in cellular sub-compartments  
A. SW40 cells were extracted into four cellular sub-compartments, the cytosol, 
membrane bound/organelle, nuclear and cytoskeleton and 30µg of protein was 
resolved on a 10% gel and probed with anti-EGR1 antibody. The membrane was 
stripped then probed with anti-HP1 as a positive control for nuclear protein. B. 
SW480 cells were extracted into the four cellular compartments as above at several 
different time points, starting at time point 0hr (23 hours after splitting). 30µg of 
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4.3.3 Investigation into a potential interaction of EGR1 and NOD2 
 
4.3.3.1 Localisation and expression of NOD2 in CRC cells 
In order to confirm a potential interaction between EGR1 and NOD2, we first wanted 
to characterise the expression and localisation of NOD2 in CRC cell lines and 
determine if NOD2 localisation coincides with EGR1. Whole cell extracts were 
prepared from HRT18, HCT116, SW480 and Vaco425 cells, 30µg of protein were 
resolved on an acrylamide gel and probed with the anti-NOD2 antibody (Figure 4.7 
A) The protein levels of EGR1 as demonstrated in Figure 4.1.2 are included in the 
figure also. There are low levels of NOD2 expressed in HRT18 cells, with higher 
levels evident in HCT116, SW480 and Vaco425 cells.  
 
Nuclear and cytoplasmic extracts from the same four cell lines were used to 
determine the cellular localisation of NOD2 (Figure 4.7 B). As expected from the 
literature the majority of NOD2 is localised in the cytoplasm in HRT18, HCT116 
and SW480 cell lines. However in the Vaco425 cells, NOD2 is detected equally in 


































Figure 4.7: Expression of NOD2 in CRC cell lines 
Protein extracts (30µg) were prepared from HRT18, HCT116, SW480 and Vaco425, 
resolved on a 10% acrylamide gel and probed with anti-EGR1 antibody, anti-NOD2 
and anti-actin antibody as a loading control. The membranes were stripped and re-
probed A. Illustrates EGR1 and NOD2 protein levels in whole cell extracts B. EGR1 
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There has been evidence published to suggest that NOD2 localises to the membrane 
in intestinal epithelial cells and this localisation is necessary for the MDP induction 
of NOD2-mediated activation of NF-!B (Barnich, Aguirre et al. 2005). Therefore a 
subcellular localisation experiment was used to determine if NOD2 is localised in 
any other cellular compartment in the SW480 cells. The protein extracts were 
separated into four subcellular fractions, the cytosol fraction, a membrane 
bound/organelle fraction, the nuclear fraction and the cytoskeleton fraction and 
probed with anti-NOD2 antibody. The membrane was also probed with EGR1 to 
determine if EGR1 and NOD2 may be localised in the same compartment (Figure 4.8 
A). Again it is evident that NOD2 is localised in the cytoplasm in SW480 CRC cells, 
with some protein detected in the membrane bound/organelle fraction also. 
Immunofluorescence shows that NOD2 is localised in cytoplasm in both HRT18 and 
SW480 cells (Figure 4.8 B). The cells were stained with FITC labelled "-mouse 
secondary antibody to visualise NOD2.  
 









Figure 4.8: Localisation of NOD2 in CRC cell lines 
A. SW40 cells were extracted into four cellular compartments, the cytosol, 
membrane bound/organelle, nuclear and cytoskeleton and 30µg of protein was 
resolved on a 10% gel and probed with anti-NOD2 and anti-EGR1 antibody. The 
membrane was then probed with anti-HP1 as a positive control for nuclear protein. 
The membrane was stripped and re-probed with all antibodies. B. HRT18 and 
SW480 cells were grown on cover slips and fixed with formaldehyde. The cells were 
immunostained with NOD2 anti-mouse and FITC-conjugated Mouse AntiSheep IgG 
- Horseradish Peroxidase, with DAPI to stain the nuclei (magnification x40). 
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4.3.3.2 EGR1 and NOD2 co-localises in CRC cells 
Although EGR1 is predominantly localised in the nucleus, it is evident from the 
previous results and the literature that EGR1 can localise in the cytoplasm, so further 
immunocytochemistry experiments were conducted to determine if EGR1 and NOD2 
co-localise in CRC cells. SW480 and HRT18 cells were grown on cover slips and 
fixed using formaldehyde. The cells were co-stained with FITC-conjugated NOD2 
(1:200) and TxRed-conjugated EGR1 (1:50). As figure 4.9 illustrates, it does appear 













Figure 4.9: Co-localisation of EGR1 and NOD2 in CRC cell lines 
HRT18 (A) and SW480 (B) cells were grown on cover slips and fixed with 
formaldehyde. The cells were immunostained with NOD2 anti-mouse and FITC-
conjugated Mouse Anti-Sheep IgG - Horseradish Peroxidase and EGR1 anti-goat and 
TxRed-conjugated Goat Anti-Rabbit IgG - Horseradish Peroxidase, with DAPI to 
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4.3.3.3 Optimisation of Immunoprecipitation of EGR1 and NOD2 
A potential interaction had been identified between EGR1 and NOD2 by yeast two-
hybrid analysis, hence we needed to confirm that this interaction was real and 
therefore developed an immunoprecipitation protocol to assess the interaction. 
Initially the experiments were conducted using a c-Myc-tagged NOD2 construct that 
was transfected into SW480 cells using Lipofectamine for 24 hours and 
immunoprecipitated using anti-EGR1 and agarose G beads (Figure 4.10). The 
membranes were then probed with anti-Myc to determine if any interaction occurs. 
Although there does appear to be a band in the EGR1 IP at the correct size for c-
Myc, this band is also visible to a lesser extent in the IgG goat IP, which should act 
as a negative control for the anti- EGR1 goat antibody (Figure 4.10 A). Due to the 
presence of these non-specific bands in the IgG negative control, a range of 
experimental conditions were investigated. A control sample containing only agarose 
G beads was used, which showed a high level of background in the bead only sample 
(Figure 4.10 B). To eliminate this non-specific binding, the agarose G beads were 
blocked in a buffer containing BSA. (Figure 4.10 C) This resulted in a reduction of 
the non-specific background. The experiments were also conducted using agarose A 
beads which showed no difference in the levels of non-specific backgrounds. 
 














Figure 4.10: Optimisation of immunoprecipitation 
SW480 cells were transfected with a c-Myc tagged NOD2 construct using 
Lipofectamine. Cells were extracted using lysis buffer 1 and immunoprecipitated 
using agarose G beads and anti-EGR1. IgG goat was used as a negative control. A. 
The immunoprecipitated complexes were run on a 10% resolving gel and probed 
with anti-c-Myc. B. A sample containing beads only was included as a negative 
control. C. The agarose G beads were cleared in a lysis buffer containing BSA to 
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Although the results in general indicated that there was indeed an interaction 
between EGR1 and NOD2, it was apparent however that using the c-Myc-tagged 
NOD2 construct was resulting in a high level of background in the IgG control. As 
such it was decided to continue the experiments looking at the endogenous NOD2 
protein. Due to the poor quality of the NOD2 antibodies available, the 
immunoprecipitation was conducted by pulling down with NOD2 and probing the 
membrane with anti-EGR1. A series of different buffers was investigated using 
varying concentrations of different salts (NaCl and KCl) and different detergents 
(NP40, Triton x100 and Tween) in order to eliminate any non-specific binding while 
retaining the interaction (Section 2.6, table 2). Two of the buffers, buffer 2 and 4, 
showed greatly reduced background in the IgG control with a faint band being 
detected as Figure 8.A illustrates for buffer 4. In order to increase the protein levels 
of both EGR1 and NOD2, the cells were treated with 1µg of LPS for 24 hours before 
extraction. As Figure 8.B illustrates the treatment with LPS does increase the 
endogenous EGR1 levels, and there is a faint interaction detected using buffer 2. 
There is also an interaction detected with buffer 4, although there is once again 
background in the IgG mouse control. However it was decided to continue the 
experiments using buffer 4, coupled with a more rigorous washing step following 
formation of the immuno-complex. Buffer 4 contains 300mM NaCl, with 1% Triton 
x100 and 50mM Hepes buffer (pH 7.4) with the addition of protease inhibitors. As 
Figure 8.C illustrates there is an interaction detected between EGR1 and NOD2 in 


























Figure 4.11: EGR1 immunoprecipitates with NOD2  
A. Cells were extracted using lysis buffer 4 and immunoprecipitated using agarose G 
beads and anti-EGR1. IgG goat was used as a negative control. Immunoprecipitated 
complexes were run on a 10% resolving gel and probed with anti-EGR1. The agarose 
G beads were blocked in a lysis buffer containing BSA to eliminate non-specific 
binding. B. Cells were treated with 1µg LPS for 24 hours, extracted using lysis 
buffer 2 and 4 and immunoprecipitated as above.  C. Cells were extracted as above 
using buffer 4 and pulled down with several antibodies.  
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4.3.4 Investigation into EGR1 interaction with the cytoskeleton 
 
4.3.4.1 EGR1 co-localises with tubulin in CRC cells 
EGR1 has been shown to localise with microtubules, with both the !- and "-tubulin, 
in benign prostate cells, whereas no interaction is visible in malignant prostate cells 
(Mora, Olivier et al. 2004). To determine if EGR1 localises with components of the 
cytoskeleton in CRC cells, immunofluorescence experiments were performed. 
SW480 cells were co-stained with tubulin (!- and #-tubulin) and EGR1. As can be 
see in Figure 4.12 EGR1 co-localises with both !- and #-tubulin in SW480 cells. In 
the previous stainings of EGR1 the staining appears similar both when stained only 
with EGR1 and while co-staining with EGR1 and NOD2 and to some extent with the 
co-staining of EGR1 and #-tubulin. However in Figure 4.12 A below the pattern of 
EGR1 staining when co-stained with !-tubulin appears to be quite different, both 
from the previous staining as seen in this chapter and from the EGR1/!-tubulin seen 
in the Mora, et al (Mora, Olivier et al, 2004). The difference in staining of EGR1 
between these studies and ones conducted by Mora et al may be in part accounted for 
by the use of a different cell line as well as the use of the different antibody (Santa-
Cruz sc110). However it is also likely that there is some “bleed through” of the !-
tubulin antibody into the TxRed channel, giving rise to the slightly different pattern 
of EGR1 staining as seen in figure A below. 
 
 







Figure 4.12: EGR1 co-localises with tubulin 
A. SW480 cells were grown on cover slips and fixed with formaldehyde. The cells 
were immunostained with !-tubulin anti-mouse and FITC-conjugated Mouse Anti-
Sheep IgG - Horseradish Peroxidase and EGR1 anti-goat and TxRed-conjugated 
Goat Anti-Rabbit IgG - Horseradish Peroxidase , with DAPI to stain the nuclei. B. 
Cells were grown as above and immunostained with "-tubulin anti-mouse and FITC-
conjugated Mouse Anti-Sheep IgG - Horseradish Peroxidase and EGR1 anti-goat and 
TxRed-conjugated Goat Anti-Rabbit IgG - Horseradish Peroxidase (magnification 
x100).  
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4.3.4.2 EGR1 can form a complex with microtubule components 
In order to confirm a localisation/interaction with EGR1 and the microtubules 
components, !- and "-tubulin, immunoprecipitation experiments were performed 
using the conditions that were optimised in the previous section (4.3.3.3). SW480 
cells were treated with LPS for 24 hours before extracting with lysis buffer 4. The 
cellular protein extracts were precleared in BSA blocked beads, and pulled down 
with !- or "-tubulin overnight. The immuno-complex was formed by adding Agarose 
G beads (pre-blocked in BSA). The samples were run on a 10% resolving gel and 
probed with anti-EGR1. As can be seen in figure 4.13 A. there is a clear interaction 
with EGR1 and !-tubulin in the treated cells, and a faint interaction evident with "-
tubulin. However by stimulating and inducing EGR1 levels with LPS treatment there 



































Figure 4.13: EGR1 immunoprecipitates with !- and "-tubulin 
SW480 cells were treated with 1µg LPS for 24 hours, extracted using lysis buffer 4 
and immunoprecipitated using agarose G beads and anti-!-tubulin and anti-"-tubulin. 
IgG mouse was used as a negative control. Immunoprecipitated complexes were run 
on a 10% resolving and probed with anti-EGR1. The agarose G beads were blocked 
in a lysis buffer containing BSA to eliminate non-specific binding. A. 
Immunopreciptation with untreated SW480 cells. B. Immunoprecipitation with LPS 
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4.4 Discussion 
 
The results in this chapter show that there is a high level of EGR1 protein in SW480 
and HCT116 colon cancer cell lines, with lower levels in HRT18 and Vaco425 colon 
cancer cell lines. For the most part, this is in agreement with the qRT-PCR 
expression data in the previous chapter, where there are higher relative EGR1 mRNA 
expression levels in SW480 than HRT18. However Vaco425 cells had the highest 
relative EGR1 mRNA expression levels, but there appears to be less EGR1 protein 
expressed although it does appear to be present evenly in the cytoplasm and the 
nucleus of Vaco425 cells. SW480 was chosen as the main cell line in which to 
conduct the majority of the experiments in this chapter due to the fact that it was a 
SW480 cell line library that was used in the original yeast-two hybrid screen that 
pulled out an interaction with EGR1 and NOD2. Ideally the subcellular localisation 
and IP experiments would be repeated using other cell lines, in particular HRT18, 
which has strong levels of cytoplasmic EGR1, and Vaco425, which shows high 
EGR1 mRNA expression levels but lower protein levels. Due to technical difficulties 
and time constraits it was not possible to conduct the experiments using these cell 
lines but it would be important to ultimately conduct these experiments after further 
optimisation of the techniques. It may be possible to further stimulate expression of 
EGR1 and NOD2 in these cells lines, which may allow for better detection of the 
protein in order to look at the subcellular localisation and conduct IP experiments. 
 
As expected EGR1 is localised predominantly in the nucleus in the CRC cells lines 
however there is strong cytoplasm staining evident, especially in HRT18 cells. This 
is in agreement with published data that demonstrates that EGR1 can localise in the 
cytoplasm also. EGR1 contains a bipartite nuclear localisation signal, that is located 
in the zinc-finger domain of EGR1 (Gashler, Swaminathan et al. 1993), and it has 
been suggested that the cytoskeleton may have a role to play in the nuclear 
translocation of EGR1 in prostate cells (Mora, Olivier et al. 2004). Mora et al, 2004 
showed that EGR1 interacts with microtubules in benign prostate cells only and this 
interaction is necessary for the nuclear translocation of EGR1 and subsequent 
transcription of EGR1-mediated genes. In SW480 cells there does appear to be 
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higher levels of EGR1 in the cytoplasm at some time points suggesting that EGR1 
may actively translocate between the cytoplasm and nucleus in CRC cells also. It is 
therefore of interest that we demonstrated an interaction between EGR1 and !- and 
"-tubulin in SW480 cells. The interaction between EGR1 and tubulin is observed 
using high salt buffer conditions, which is in contrast to the published data describing 
an interaction with EGR1 and tubulin, where low salt with no detergent was used in 
prostate cells (Mora, Olivier et al. 2004). Experiments were conducted to determine 
if EGR1 also localises with #-tubulin, however we were unable to demonstrate an 
interaction. As EGR1 has been previously demonstrated to interact with #-tubulin 
(Mora, Olivier et al. 2004), it may be that further optimisation or an alternative #-
antibody is required, or that this particular interaction does not occur in CRC cells. 
 
As mentioned, the staining of EGR1 in some experiments is not consistent, and 
therefore should be interpreted with caution. For the most part the pattern of EGR1 
expression in the immunflorescence is consistent and similar. However, there are 
some differences between experiments, particularly when EGR1 is co-stained with 
!-tubulin. The staining of EGR1 here is not consistent with the EGR1 staining in the 
study by Mora et al. However, as mentioned, they have conducted their experiments 
using prostate cancer cells, PC-3, LNCaP and DU-145. It is likely that there is some 
“bleed through” of the !-tubulin staining into the EGR1 staining. Both of the 
secondary antibodies were test alone to ensure that they did not show any sign of 
fluorescnec in the absence of a primary antibody, but it may be that the !-tubulin 
staining of the cells is too strong and the antibody needs to be tested using a lower 
concentration. One significant difference between the two studies is the EGR1 
antibody. The Mora et al study used the Santa Cruz antibody Sc-110 for their 
immunoflorescence. In this study the same antibody (EGR1, R&D Systems 
AF2818) was used for both the western blotting and the immunofloorescence, and 
although the sc-110 EGR1 antibody did not produce good results using a Western 
Blot method (Figure 4.1) it could be that this antibody does not work well to detect 
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Further experiments would be needed to indicate whether the cytoskeleton actively 
translocates EGR1 to the nucleus in CRC cells or if there is aberrant translocation of 
EGR1 to the nucleus in CRC cells similar to prostate cells. Indeed it has been shown 
that aberrant abnormal centrosomes form in HCT116 cells (Kuriyama, Bettencourt-
Dias et al. 2009). It would be interesting to disrupt the microtubules using a 
microtubule polymerisation agent such as nocodazole, which has been shown to 
prevent the translocation of EGR1 to the nucleus in prostate cells (Mora, Olivier et 
al. 2004), to determine if this has an effect on the localisation of EGR1 or the 
transcriptional activity and activation of EGR1 downstream targets in colorectal 
cancer cells. There are several luciferase reporter plasmids containing the promoter 
of genes with an EGR1 transcription factor binding site, including p300, TF and 
EGFR, available as a resource in the lab which could be utilised to study the effect of 
microtubule disruption on the transcriptional effect of EGR1. It would also be 
interesting to determine if there is an association with EGR1 localisation and cell 
cycle in CRC cells as it is known that EGR1 is involved in the regulation of genes 
involved in cell cycle and cell proliferation including cyclin D and thymidine kinase 
(Molnar, Crozat et al. 1994; Yan, Nakagawa et al. 1997).   
 
The CD susceptibility gene/protein NOD2 is localised in the cytoplasm with some 
localisation apparent in the membrane bound/organelle fraction, which is in 
agreement with published data that suggests that NOD2 can be targeted to the cell 
membrane in epithelial cells after MDP stimulation, and this membrane association 
is necessary for NF-!B activation (Barnich, Aguirre et al. 2005). There have been 
several mutations of NOD2 reported (Leung, Hong et al. 2007; Rosenstiel, Huse et 
al. 2007; McCarroll, Huett et al. 2008), the most common being a truncated protein 
caused by a frame shift mutation, Leu1007fins, which is associated with Crohn’s 
disease and does not respond to MDP or activate NF-!B (Ogura, Bonen et al. 2001). 
This CD-associated mutation has an impaired ability to activate NF-!B, and fails to 
associate with the cell surface membrane.  The two other commonly CD-associated 
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As discussed in the previous chapter there is significantly less EGR1 transcript 
present in CD patients compared with healthy controls, and a majority of patients 
show a reduction in EGR1 expression after treatment with LPS (70%), MDP (65%) 
and TNF (66%), suggesting that there is aberrant inflammatory response in these 
patients. It is interesting then that we have demonstrated an interaction between 
EGR1 and NOD2 in SW480 cells. The interaction between EGR1 and NOD2 is 
observed using high salt buffer conditions, in both untreated and LPS treated cells. It 
should be noted that the LPS used in the immunoprecipitation experiment is known 
to be contaminated with MDP, unlike the LPS that was used for the qRT-PCR 
expression analysis and therefore could be MDP stimulation that was influencing the 
EGR1/NOD2 interaction. It is probable that the interaction between EGR1 and 
NOD2 occurs in the cytoplasm, however there is evidence to suggest that NOD2 is 
membrane associated and as EGR1 is also present in the membrane bound/organelle 
fraction there is the possibility that the interaction is membrane associated also. To 
further investigate this it would be interesting to determine if EGR1 interacts with 
any of the three CD-associated NOD2 polymorphisms. HA-tagged constructs of the 
three common NOD2 mutations are available as a resource (gift from Colin Stevens). 
Preliminary experiments conducted to transfect these constructs into CRC cells to 
determine an interaction with EGR1 by immunoprecipitation were unsuccessful, 
however if conditions were optimised to reduce the non-specific binding that 
occurred using transfected constructs, it would be interesting to determine if EGR1 
co-localises and/or interacts with any of the NOD2 mutants. This would also provide 
more information as to whether or not the LRR domain of NOD2 is required for the 
EGR1-NOD2 and it would also be interesting to identify the physical regions that are 
necessary for the EGR1-NOD2 interaction. Construsts lacking domains or regions of 
either protein could be used to determine which domains are necessary for the 
interaction.  
 
EGR1-protein interactions can be complicated and it has been shown that the stimuli 
under which EGR1 is induced can have different effect on its post-translational 
modification, indeed sometimes with opposing effects. For example in prostate cells, 
serum-induced EGR1 can be acetylated which then can bind to p300 /CBP and 
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results in the inhibition of p300/CBP and EGR1 itself (Yu, de Belle et al. 2004; 
Adamson, Yu et al. 2005). However if EGR1 is induced by UV irradiation, the 
protein become phosphorylated which then transactivates p53, p73 and PTEN and 
inhibits NF-kB. It would appear that acetylated EGR1 is growth promoting and anti-
apoptotic whereas the opposite is true for phosphorylated EGR1. It would be very 
interesting to determine if either acetylation or phosphorylation of EGR1 is necessary 
for EGR1-NOD2 interaction. It is also unknown as to what effect the EGR1-NOD2 
interaction may have on either EGR1 or NOD activation of downstream targets, 
whether stimulatory, inhibitory or indeed if it has any effect on the activation of the 
EGR1 or NOD2 dependent pathways. An interesting experiment would be to 
determine what effect loss of NOD2 would have on the ability of EGR1 to activate 
gene transcription using the EGR1 luciferase reporter plasmids with EGR1 binding 
sites or whether loss of EGR1 effects the MDP-mediated NOD2 dependent activation 
of a NF-!B reporter assay. This could lead to a greater understanding of the role of 
both EGR1 and NOD2 in inflammatory pathways that are known to be important in 
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Little has been reported on the protein-protein interactions of EGR1, particularly in 
epithelial cells and CRC cells. However EGR1 protein interactions are known to 
have important cellular functions. EGR1 interacts with its inhibitor proteins, 
NAB1/NAB2, which helps regulate EGR1 expression levels in cells (Swirnoff, Apel 
et al. 1998). As previously discussed (Ch. 4), EGR1 is also known to interact with 
components of the cytoskeleton in prostate cancer which has been suggested to play 
a role in EGR1 translocation (Mora, Olivier et al. 2004). Finally acetylated EGR1 is 
known interact with p300/CBP, also in prostate cells, and inhibit its function 
(Adamson, Yu et al. 2005).  
 
We have demonstrated that EGR1 is differentially expressed in colonic epithelial 
cells, in both CRC and IBD patients, as well as confirming a novel EGR1-NOD2 
interaction in SW480 cells, which was first identified by yeast-two hybrid screen. 
Therefore it is of interest to investigate other potential EGR1-protein interactions in 
epithelial cells in order to identify novel interactions and new pathways which may 
be involved in colorectal disease to further our understanding of disease. 
 
It was decided to investigate whether potential EGR1 protein interactions could be 
indentified using a yeast-two hybrid screen, using EGR1 as bait and with a SW480 
cDNA library in order to determine any novel EGR1 interacting proteins in cancer 
epithelial cells. The screen identified 22 potential novel interactions with EGR1. Two 
interesting proteins identified by the screen, NPM1 and eEF1A1 were further 
investigated. The localisation and expression of both proteins was determined in 
CRC cells and the interactions confirmed by immunoprecipitation.  
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5.2 Methods 
The yeast-two hybrid screen was conducted using Clontech MatchmakerTM system. 
 
5.2.1 Background of a yeast two-hybrid screen 
 
The yeast two hybrid screen is an assay to detect protein-protein interactions. It 
works by utilising the binding of the GAL4 transcription factor to an upstream 
activating sequence (UAS) activating the transcription of downstream reporter genes 
such as lacZ. The GAL4 transcription factor consists of a DNA binding domain (BD) 
which binds to the UAS and a activating domain (AD) which is responsible for the 
activation of the transcription factor (Figure 5.1 A).  
 
A yeast two hybrid screen takes advantage of this system by fusing a ‘bait’ protein of 
interest, in this case EGR1, to the GAL4 DNA-binding domain, and a cDNA library 
‘prey’ is fused to the GAL4 activation domain. Expression of either the bait+DNA 
BD or the prey+AD in yeast cells is inadequate to activate gene transcription (Figure 
5.1 B,C). Upon interaction of the bait protein with a prey protein, this brings the BD 
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Figure 5.1: Illustration of GAL4 mediated activation of reporter genes in yeast 
two-hybrid system 
Diagram of the activation of reporter genes by the GAL4 transcription factor in yeast 
two hybrid. A. GAL4 DNA binding domain (BD) and activation domain (AD) are 
both required for activation of reporter gene transcription. B. ‘Bait’ protein is fused 
to the DNA-BD, but cannot activate reporter genes. C. ‘Prey’ protein fused with the 
AD domain and also cannot activate gene transcription. D. If a protein-protein 
interaction occurs with the bait and prey proteins, the BD and AD domains can then 
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The bait (EGR1) was cloned into the vector pGBKT7 and transformed into the Y187 
yeast strain (Figure 5.2 A). The Y187 yeast strain has a GAL1 UAS, a GAL1 TATA 
box and a lacZ reporter gene.  The pGBKT7 vector contains the GAL4 DNA BD, a 
kanamycin resistance gene and the nutritional reporter TRP1, indicating that it is 
selected for in the absence of the amino acid tryptophan. The cDNA library (SW480 
– prepared by GI unit) was cloned into the vector pGADT7 which has the GAL4 AD, 
an ampicillin resistance gene and the nutritional reporter LEU2, for the amino acid 
leucine, using the yeast stain AH109 (Figure 5.2 B). AH109 has three reporter genes, 
ADE2, HIS3 and MEL1 (lazZ), in order to reduce the number of false positives 
detected. The nutritional reporters are used to select for the approprioate vectors, the 
‘bait’ protein in Y187 grows in the absence of tryptophan (-Trp), the ‘prey’ protein in 
AH109 grows in the absence of leucine (-Leu). Once the two yeast are mated, the 
presence of an interaction will active the lacZ reporter as well as the other two 
nutritional reporters, so will only grow in the absence histidine (-His), with more 

















































Figure 5.2: Map of the vectors pGBKT7 and pGADT7 
Restriction map and multiple cloning sites of pGBKT7 (A; for the ‘bait’) and 
pGADT7 (B; for the ‘prey’) vectors that are use in the yeast two hybrid screen. 
Vector maps are from Clontech Laboratories Inc (Clontech Laboratories Inc 2008; 
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5.2.2 Cloning of EGR1 into yeast vector pGBKT7 
 
5.2.2.1  Cloning of EGR1 into pGEM-T cloning vector 
As transcription factors can activate transcrisption of the reporters in the yeast 
without the presence of an interacting protein, an EGR1 construct without its 
transactivation domain as well as a full length EGR1 construct were cloned into the 
pGBKT7 vector. Full length EGR1 cDNA (EGR1Fl) and EGR1 minus its 
transactivation domain (EGR1!Act) were amplified from CRC cell line cDNA and 
the PCR products were purified using a PCR Purification Kit (Qiagen). EGR1Fl and 
EGR1!Act PCR products were cloned into the pGEM-T cloning vector (Promega), 
and transformed into 50µl of TOP10 Chemically Competent E.coli cell (Invitrogen).  
Colonies were selected and amplified using Sp6 and T7 primers (Ch.2.4.1).  A 
colony that was successfully amplified, producing a single band, was grown in 
250ml L-Broth, with 20mg/ml ampicillin, overnight with shaking at 37oC. Both 
plasmid inserts were extracted, sequenced to confirm correct construct and purified 
using a Maxi Prep Kit (Qiagen) as per manufacturer’s instructions. 
 
5.2.2.2 Cloning of EGR1 into pGBKT7 
The constructs containing EGR1Fl and EGR1!Act in pGEM-T and the pGBKT7 
vector were cut using EcoR1 in a 100µl reaction at 37oC for 2 hours. Calf Intestine 
Alkaline Phosphatase (CIAP) (Roche) was added to the reactions to prevent self re-
ligation.  The restriction digest reactions were run out on an agarose gel (0.8-1.5%), 
with the correct band extracted and the DNA purified using a Gel Extraction Kit 
(Qiagen). A ligation reaction (20µl) was set up using 1µg of cut pGBKT7 vector and 
3µ of cut insert. The reaction was incubated at room temperature for 2 hours. 5µl of 
this ligation reaction was transformed into 50µl of TOP10 Chemically Competent 
E.coli cells (Invitrogen) and grown overnight at 37oC. Colonies were selected and 
amplified using primers A308 and A309 (section 2.4.1), and then sequenced to 
confirm the orientation of the insert. A colony with the correct sequence and 
orientation was grown in 250ml L-Broth, with 10mg/ml kanamycin, overnight with 
shaking at 37oC. The EGR1FL plasmid and the EGR1!Act plasmid were extracted 
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and purified using Maxi Prep Kit (Qiagen) as per manufacturer’s instructions, and 
accurate plasmid colonies stored as glycerol stocks at –80oC, via addition of 1ml of 
overnight culture to 300µl sterile glycerol. 
 
 
5.2.3 Yeast-two hybrid screen 
 
The yeast strains Y187 and AH106 were grown in YPD medium or on YPD agar 
plates. SD media and agar with appropriate nutritional additives were used to grow 
the yeast strains transformed with the bait or library. All yeast was incubated at 30oC 
and grown for 3-5 days. Details of the nutritional additives are found in chapter 2.7, 
with a summary below. 
 
 
SD yeast media/agar SD media/agar with 10x dropout solution + 
10x histidine, 10x adenine, 10x leucine, 10x 
tryptophan 
SD/-Trp  media/plates SD media/agar with 10x dropout solution + 
10x histidine, 10x adenineand 10x leucine 
SD/-Leu/-Trp media/plates SD media/agar with 10x dropout solution + 
10x histidine and 10x adenine 
SD/-His/-Leu/-Trp media/plates SD media/agar with 10x dropout solution + 
10x adenine 
SD/-His/-Ade/-Leu/-Trp media/plates SD media/agar with 10x dropout solution  




5.2.3.1 Lithium Acetate (LiAc) Yeast Transformation 
The EGR1Fl and EGR1!Act constructs in pGBKT7 were transformed into the yeast 
strain Y187 using a LiAc transformation. The constructs were grown overnight in 
YPD media at 30oC with shaking. 300ml of YPD was inoculated with 30ml of this 
starter culture to give an Optical Density (OD at 600nm) of ~0.2-0.3. The culture was 
grown until it reached an OD of 0.4-0.5. The cells were harvested by centrifugation 
at 1000xg for 5min, resuspended in 50ml H2O, spun again at 1000g for 5 min and 
resuspended in 1.5ml sterile 1 x TE/1 x LiAc solution. 
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0.1µg plasmid was added to 100µg salmon sperm, 100µl of Y187 yeast cells and 
0.6ml sterile PEG/LiAc solution and vortexed for 10sec. The cells were incubated at 
30oC for 30min, after which 70µl of DMSO was added and then placed in 42oC 
water bath for 15min to heat shock. The cells were chilled on ice for 2 min, 
centrifuged briefly at 14,000 rpm and resuspended in 0.5ml sterile 1x TE. A 1/10 
dilution of the cells (100µl) was plated on SD/-Trp plates and incubated at 30oC for 3 
days. 
 
5.2.3.2 Test Mating    
50ml of SD/-Trp media were inoculated with the transformed constructs and grown 
overnight at 30oC with shaking. The cultures were grown until they reached an OD 
of 0.7-1.0. The cells at a concentration of 4x108/ml were mixed with 250µl of SW480 
library cells in AH109 (2x108/ml) and plated out onto 2 YPDA plates and incubated 
overnight at 30oC. The SW480 library cells in AH109 were provided by E.Nimmo 
from the GI unit. 5ml of YPDA media was added to each plate and the cells were 
scraped off, centrifuged at 1000g for 5 min and resuspended in 2.5ml of SD/-Leu/-
Trp media. The following dilutions were made and plated out onto the relevant plates 
(Table 5.2). The mated cells will grow on the SD/-Leu/-Trp, SD/-Leu and SD/-Trp 
plates, which will be used to calculate the mating efficiency, but only colonies 
containing interaction proteins will activate transcription of the reporter genes and 




Dilution Amount Plates: 
Undiluted 240ul SD/-His/-Leu/-Trp; SD/-His/-Ade/-Leu/-Trp 
1/10 100ul SD/-Leu/-Trp 
1/1000 100ul SD/-Leu/-Trp; SD/-Leu; SD/-Trp 
1/100000 100ul SD/-Leu; SD/-Trp 
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The cells were grown for 3-5 days at 30oC and the mating efficiency was calculated. 
Colonies were picked from the SD/-His/-Leu/-Trp and the SD/-His/-Ade/-Leu/-Trp 
plates and inoculated into 96 well plates containing YPD + 25% glycerol and frozen 
at –80oC. 
 
5.2.3.3 Products of Yeast Mating 
Colonies resulting from the yeast mating of the strain containing the SW480 library 
and strain containing the EGR1Fl and EGR1!Act constructs were amplified by PCR 
and visualised on an agarose gel. PCR products which produced a single band were 
purified and sequenced. The DNA sequences were translated into protein sequences 
and put into BLAST (Basic Local Alignment Search Tool; NCBI) to identify the 
proteins whose sequence was amplified from the mated yeast colonies.  
 
 
5.2.4 Detection of false positives 
 
Although the use of the three reporter genes, LacZ, ADE2 and HIS3 reduce the 
number of false positives detected, it is still important to ensure that the ‘prey’ 
protein detected does not activate transcription of the reporter genes by itself. The 
interacting prey plasmids were isolated from the yeast (Chapter 2.17.5) and were co-
transformed into AH109 yeast cells with the pGBKT7-pGBKT7 construct, and with 
a pGBKT7 construct only using a LiAc transformation as before. Transformed cells 
were plated onto SD/-Leu/-Trp/x-gal and SD/-Ade/-Leu/-Trp/x-gal plates to 
determine if the prey only constructs activate the reporter genes. 
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5.3 Results 
 
5.3.1 Cloning of EGR1 constructs into the pGBKT7 vector 
 
Two EGR1 proteins constructs were investigated in the yeast-two hybrid system, a 
full length EGR1 (EGR1Fl) and a truncated EGR1 protein lacking the transactivation 
domain (EGR1!Act) as it is known that the transactivation domain of transcription 
factors can bind to the GAL4 UAS and activate transcription of the reporter genes in 
yeast two hybrid thereby generating false positives. Studies indicate that the 
transactivation domain of EGR1 consists of amino acid 1-~285, followed by an 




Primers were designed to amplify full length EGR1 and an EGR1 construct from 
amino acid codon 283, incorporating an EcoR1 restriction enzyme site. EGR1Fl and 
EGR1Act were amplified using HRT18 cDNA and sequenced to determine accurate 
amplification. Both constructs were cloned into the pGEM-T cloning vector, and 
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Figure 5.3: EGR1Fl and EGR1!Act constructs 
Illustration of the EGR1 full length construct (EGR1Fl) and the EGR1 construct 
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5.3.2 LiAc Yeast Transformation 
 
The pGBKT7-EGR1Fl and the pGBKT7-EGR1!Act construct were transformed into 
the yeast strain Y187 using a LiAc transformation and plated on SD/-Trp agar plates, 
as the pGBKT7 vector has a selective for tryptophan (Trp). Two different clones for 
each construct were transformed, as well an empty vector. The transformation 
efficiencies of the constructs into the yeast strain were calculated using the formula 
below, where cfu is the number of colonies present (colonies forming unit).  
 
 
Equation 5.1: Transformation efficiency 
Cfu x total suspension vol. (µl) = cfu/µg DNA 




Construct Transformation Efficiency 
pGBKT7 vector only 3.5 x 104 cfu/µg DNA 
pGBKT7-EGR1Fl (1) 5.5 x 104 cfu/µg DNA 
pGBKT7-EGR1Fl (2) 6 x 104 cfu/µg DNA 
pGBKT7-EGR1!Act (1) 3.1 x 105 cfu/µg DNA 
pGBKT7-EGR1!Act (2) 2.75 x 105 cfu/µg DNA 
Table 5.3: Transformation efficiencies of pGBKT7-EGR1 constructs 
 
 
5.3.3 Preliminary Yeast-two hybrid experiments 
 
As the transformation efficiencies were within the accepted range, several control 
experiments were conducted prior to the yeast-two hybrid screen. In order to ensure 
that the transformed EGR1 constructs had no toxic effects on yeast growth, a toxicity 
assay was performed by measuring the absorbance of the transformed yeast culture 
over a period of time. The resulting measurements were used to plot a growth curve. 
The growth curves of the transformed constructs are similar to that of the Y187 strain 
alone, indicating that there are no toxic effects of the constructs. 
 





Figure 5.4: Growth curve of Y187, pGBKT7 and the EGR1 constructs 
The Y187 yeast strain, the pGBKT7 vector and the transformed EGR1 constructs 
were grown overnight in SD/-Trp media. The absorbance at 600nm of each culture 
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The second control experiment conducted was a self-activation test. This was 
performed to ensure that the transformed cells with EGR1 constructs did not activate 
transcription of the lacZ reporter as well as ensuring the cells only grow in the 
absence of tryptophan and not in the absence of histidine (His) or adenine (Ade) as 
the absence of these amino acids is required for determining whether the two proteins 
interact and the strength of this interaction. As such the transformed Y187 yeast cells 
did not grow on SD/-Trp/-His and SD/-Trp/-Ade plates, indicating that at this stage 
the transformed constructs require His and Ade to grow. Figure 5.5 demonstrates this 
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Y187 transformed with EGR1Fl construct 
  
SD/-Trp plate                        SD/-Ade/-Trp                       SD/-His/-Trp 
 
Figure 5.5: Auto-activation assay 
Y187 yeast cells transformed with EGR1 constructs in pGBKT7 vector were grown 
on SD/-Trp/x-gal, SD/-Ade/-Trp and SD/-His/-Trp plates to determine if the bait 
alone activates the two reporters, ADE and HIS3. This figure illustrates the results 
for the EGR1Fl construct, which only grows in the absence of tryptophan and still 
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5.3.4 Yeast-two hybrid mating 
 
A yeast mating was performed using one of the EGR1Fl and EGR1!Act constructs. 
The Y187 transformed constructs were mated with an AH109 yeast strain containing 
a SW480 cell line library (E.Nimmo). The SW480 library is transformed into the 
yeast vector pGADT7, which is selective for leucine (Leu). Positive interactions 
should activate the HIS3 reporter and the ADE2 reporter if the interaction is strong, 
so mated colonies were selected for growth on both SD/-His/-Leu/-Trp and SD/-His/-
Ade/-Leu/-Trp. The mating efficiency was determined by inoculating the mated yeast 
colonies onto SD/-Leu (to determine viability of the prey library) and SD/-Trp (to 
determine viability of the bait) and SD/-Leu/-Trp to determine viability of the 
diploid. The mating efficiency was determined using the following formula: 
 
Equation 5.2: Viable cfu/ml 
Cfu = cfu/ml 
vol. plated (ml) x dilution factor  
 
 
Equation 5.3: Mating efficiency 
No. of cfu/ml of diploids  
No. of cfu/ml of limiting partner 
(either prey library or bait) 
x100 = % diploid 
 
 
The mating efficiency for the strain containing the EGR1Fl construct was 10% and 
6.78% for the EGR1!Act construct. The interactions were confirmed by selecting the 
colonies on SD/-His/-Ade-/-Leu/-Trp plates. Positive colonies were scored for 
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5.3.5 Confirmation of interactions 
 
The presence of the lacZ reporter allows for a further test for activation of reporter 
genes. An X-gal assay was conducted to detect the activation of the lacZ reporter, 
using a colony lift filter assay. Colonies were streaked onto SD/-Leu/-Trp plates (4 
per clone) and allowed to grow for 3 days a 30oC. Positive and negative controls 
were added (provided by GI unit; Invitrogen).  
 
 
LEU2 Plasmid TRP1 Plasmid Control 
pEXP™32/Krev1 pEXP™22/RalGDS-wt Strong positive interaction 
control  
pEXP™32/Krev1 pEXP™22/RalGDS-m1 Weak positive interaction 
control  
pEXP™32/Krev1 pEXP™22/RalGDS-m2 Negative interaction control  
pDEST™32 pDEST™22 Negative activation control 
pGADT7 pDEST™22 Negative activation control 




A nitrocellulose membrane was placed over the yeast colonies, removed and frozen 
at -80oC for 1 hour. Whatman filter paper was then placed in Z buffer with X-gal 
solution, and the nitrocellulose was placed yeast side up on the Whatman paper to 
allow the solution to soak through. After an overnight incubation at 37oC, the 
colonies were scored for blue colour. Any colonies remaining white were eliminated 
as false positives (Figure 5.6). The remaining blue colonies were sequenced to 
determine the interacting proteins. Table 5.5 lists the interacting proteins that were 
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Figure 5.6: Colony lift filter assay 
Yeast colonies were pressed onto nitrocellulose membrane frozen for 1 hour at -
80oC, and soaked in a Z buffer/X-gal solution followed by an overnight incubation at 
37oC to determine activation of the lacZ reporter. Yeast colonies that turn blue 
indicate activation of lacZ. A range of positive and negative controls were added to 
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RPL27 EGR1Fl 2 +++ Group I 
RPL21 EGR1Fl 2 ++ Group I 
RPL5 EGR1Fl 1 ++ Group I 
RPL13a EGR1Fl 2 ++ Group I 
RPS2 EGR1Fl 1 +++ Group I 
TAF8 EGR1Fl 1 ++ Group II 
ZIMZ2 EGR1Fl 1 ++++ Group II 
NFAT5 EGR1Fl 1 +++ Group II 
eEFIA1 EGR1Fl 1 +++ NA 
YIF1A EGR1Fl 2 ++ NA 
CLECD2 EGR1Fl 1 ++ NA  
PTMS EGR1Fl 1 ++ NA 
NACA EGR1Fl 1 +++ NA 
PSPH EGR1Fl 1 +++ NA 
BASP1 EGR1Fl 1 +++ NA 
NPM1 EGR1Fl 3 ++ NA 
eIF4A1 EGR1Fl 2 ++ NA 
FKBP EGR1Fl 2 +++ NA 
GNAS EGR1Fl 1 +++ NA 
SLC7A8 EGR1Fl 2 ++ NA 
PHC1 EGR1Fl 
EGR1!Act 
7 +++ NA 
C11orf17 EGR1Fl 
EGR1!Act 
14 +++ NA 
Table 5.5: Potential EGR1 interaction proteins as determined by Y2H screen. 
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5.3.6 Potential EGR1 interacting proteins 
 
The yeast-two hybrid screen identified 22 novel proteins that potentially interact with 
EGR1. All of the proteins identified were found to interact with the full length EGR1 
protein. Two proteins, PHC1 and C11orf17, interacted with both the full length and 
!Act construct. Ten of the proteins were isolated in two or more clones. The list of 
candidate genes was submitted to The Database for Annotation, Visualization and 
Integrated Discovery (DAVID), an online resource that performs a “Gene Functional 
Classification”, separating genes into functionally related groups (Huang da, 
Sherman et al. 2009; Huang da, Sherman et al. 2009). Upon submission of the list of 
genes for the yeast-hybrid screen, two functionally similar groups were identified 
Five genes were identified in Group I, and three genes were identified in Group II. 
None of the remaining proteins were found to be functionally similar. 
 
5.3.6.1 Ribosomal proteins 
 
Group 1 identified all of the ribosomal proteins as a functionally similar group. It 
contained RPS2, RPL5, RPL13a, RPL21 and RPL27. It was the largest functionally 
similar groups of genes. RPS2 is a component of the 40S ribosomal subunit, and 
RPL5, RPL13a, RL21 and RPL27 are components of the 60S ribosomal subunit. It 
has been suggested however that several of the ribosomal proteins may have 
functions other than their role in protein synthesis. It has been shown for example 
that RPL13a can interact with the gamma activated inhibitor of translation (GAIT) 
element which is involved in the Cp translation silencing (Mazumder, Sampath et al. 
2003; Chaudhuri, Vyas et al. 2007). RPS2 has been shown to interact with PRMT3, 
which has a role in inhibiting ubiquitination of RPS2. It has been suggested that this 
interaction may regulate the enzymatic activity of PRMT3 (Choi, Jung et al. 2008). 
RPL5, along with several other ribosomal proteins, have been shown to interact with 
Mdm2, inhibiting its E3 ligase activity  and resulting in activation of p53 (Macias, 
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5.3.6.2 Transcription factors 
The second group identified by DAVID identified a group of transcription factors, 
and also placed the bait EGR1 in this functional group. This group contained ZMIZ2, 
TAF8 and NFAT5. 
 
5.3.6.2.1 Nuclear factor of activated T-cells 5, tonicity-responsive (NFAT5) 
NFAT5 is a transcription factor of the nuclear factors of activated T cells family and 
is known to regulate gene expression after activation in response to osmotic stress. 
NFAT5 contains a conserved DNA-binding domain, the Rel-homology domain 
(RHD), which is also found in NF-!B (Macian, Lopez-Rodriguez et al. 2001; Muller 
and Rao 2010). NFAT5 is localised in the nucleus and requires dimerisation to bind 
to DNA. Upon activation, NFAT5 regulates the induction of inflammatory cytokines 
(Lopez-Rodriguez, Aramburu et al. 2001; Aramburu, Drews-Elger et al. 2006). 
NFAT5 is expressed in invasive breast cancer and it has been suggested that NFAT5 
is involved in promoting tumour invasion in both human breast and colon cancer 
cells (Jauliac, Lopez-Rodriguez et al. 2002). S100A4, a member of the S100 calcium 
binding proteins, has been associated with the progression of several cancers 
including colon cancer and it has been demonstrated that hyperosmotic stress induces 
S100A4 expression, mediated via NFAT activation by Src, in colon cancer cells 
(Chen, Sastry et al. 2011). 
 
 
5.3.6.2.2 TAF8 RNA polymerase II, TATA box binding protein (TBP)-
associated factor (TAF8) 
TAF8 is a TATA-binding protein (TBP)-associated factor (TAF). It is one of several 
TAFs that comprise a transcription factor complex TFIID which nucleates the 
transcription preinitiation complex (PIC) assembly with RNA polymerase II on 
protein-coding genes. TAF8 contains a histone-fold domain and has been shown to 
interact with several of the TFIID subunits (Guermah, Ge et al. 2003; Soutoglou, 
Demeny et al. 2005; Demeny, Soutoglou et al. 2007; Alvarez and Woolf 2011). 
TAF8 has been identified as having a role in the regulation of gene expression in 
prostate cancer (Huang, Beliakoff et al. 2005; Alvarez and Woolf 2011). 
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5.3.6.2.3 Zinc finger, MIZ-type containing 2 (ZMIZ2) 
ZMIZ2 is a member of the PIAS (protein inhibitor of activated signal transducer and 
activator of transcription) family. ZMIZ2 is a transcriptional coregulator of the 
androgen receptor AR. It has been shown to interact with AR, which enhances AR-
mediated transcription, which is further augmented by an interaction between ZMIZ2 
and PIAS3 (Huang, Beliakoff et al. 2005; Beliakoff and Sun 2006; Peng, Lee et al. 
2010). There is a well established link between AR and prostate cancer (Balk and 
Knudsen 2008). It has been shown that expression of AR is decrease in colorectal 
cancer tumours compared with normal mucosa in male patients only (Leon, Casado 
et al. 2011). This is a very interesting candidate as there is a higher incidence rate of 
CRC in men than women. 
 
 
5.3.6.3 Translation factors 
There are two proteins that were identified in the screen that are involved in the 
translation of proteins, eEF1A1 and eIF4A1 
 
 
5.3.6.3.1 Eukaryotic translation initiation factor 4A1 (eIF4A1) 
eIF4A1 is an ATP-dependent RNA helicase that is involved in the initiation phase of 
the protein translation process. Its function is to unwind RNA at the 5’-untranslated 
region (UTR) of mRNA (Kapp and Lorsch 2004). It forms part of a multi-protein 
complex that also contains eIF4G, eIF4E, eIF4B and eIF4H (Rozovsky, Butterworth 
et al. 2008; Marintchev, Edmonds et al. 2009). 
  
5.3.6.3.2 Eukaryotic translation elongation factor 1 alpha1 (eEF1A1) 
eEF1A1 is involved in the elongation phase of translation and is known to be 
involved in the transport of aminoacyl tRNAs to the ribosomal A-site. It forms a 
ternary complex with GTP and the aminoacyl tRNA (Kapp and Lorsch 2004; 
Lamberti, Caraglia et al. 2004). eEF1A1 is differentially expressed in CRC tumours 
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5.3.6.4 Remaining proteins 
 
5.3.6.4.1 Brain abundant, membrane attached signal protein 1 (BASP1) 
BASP1 was identified as a membrane and cytoskeleton- associated protein. It has 
been shown to associate with WT1 and negatively regulate the transcriptional 
activity of WT1 (Carpenter, Hill et al. 2004; Green, Wagner et al. 2009) (Carpenter 
et al, 2004; Green et al 2008). WT1 is a zinc-finger protein that is related to EGR1 
and is mutated in Wilms’ tumour (Scharnhorst, Menke et al. 2000). It is also 
suggested to have a role in the regulation of actin dynamics (Zakharov and 
Mosevitsky 2010). BASP1 has been shown to be a target of copy number increases 
in cervical cancer through gain of chromosome 5q (Scotto, Narayan et al. 2008). 
Conversely BASP1 been shown to have decreased expression in hepatocellular 
carcinoma (HCC) and is aberrantly methylated in HCC tissue compared with non-
tumour liver tissue (Moribe, Iizuka et al. 2008). A study by Hartl et al, 2009 
identified BASP1 as a potential tumour suppressor, as expression of BASP1 blocks 
myc-induced cell transformation and prevents activation and repression of myc-
regulated genes (Hartl, Nist et al. 2009). 
 
 
5.3.6.4.2 Chromosome 11 open reading frame 17 (C11orf17/BCA3/AKIP1) 
C11orf17 was characterised as a breast cancer associated gene (BCA3), with high 
mRNA expression in breast and prostate tumour cell lines (Kitching, Li et al. 2003). 
It is localised to the nucleus and has been shown to interact with protein kinase A 
(Sastri, Barraclough et al. 2005). It also interacts with p65 and is suggested to 
enhance NF-!B mediated transcription (Gao, Asamitsu et al. 2008). 
 
 
5.3.6.4.3 C-type lectin domain family 2, member D (CLEC2D) 
CLEC2D was identified to code for a lectin-like receptor (LLT1) expressed on 
natural killer (NK) cells (Boles, Barten et al. 1999). It has been suggested to play a 
role in immune regulation and was shown to induce IFN-" in NK cells but does not 
result in cytotoxicity (Mathew, Chuang et al. 2004). CLEC2D has alternatively 
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5.3.6.4.4 FK506 binding protein 9 (FKBP9) 
FKBP9 was identified as a new member of a group of proteins (FKBP) which are 
known to bind to immunosuppressant drugs e.g. FK506, rapamycin and ciclosporin. 
It is highly expressed in the heart, muscle lung and kidney (Jo, Lyu et al. 2001). The 
FKBP proteins have several cellular functions including protein trafficking, 
transcription, protein folding and receptor signalling (Kang, Hong et al. 2008), but 
the exact function of FKBP9 is not yet known. 
 
 
5.3.6.4.5 GNAS complex locus 
GNAS is a complex imprinted locus and codes several gene products including the 
stimulatory G protein !-subunit (Gs!) which mediates c-AMP production by 
activation of adenylate cyclase. It can encode XL!s which is only expressed from the 
paternal allele (Xie, Plagge et al. 2006; Krechowec and Plagge 2008). GNAS has 
been shown to be differentially expressed in epithelial ovarian cancer patients 
(Tominaga, Tsuda et al. 2010). 
 
 
5.3.6.4.6 Nascent polypeptide-associated complex alpha subunit (NACA) 
NACA is a ribosome-associated protein that binds to nascent polypeptide chains as 
they leave the ribosome which prevents them from binding to cytosolic proteins 
(Wiedmann, Sakai et al. 1994). NACA has been proposed to have several other 
functions in the cell other than a role in protein translation. It has been suggested to 
have a role in the regulation of FADD function (Stilo, Liguoro et al. 2003), hypoxia-
mediated apoptosis (Hotokezaka, van Leyen et al. 2009) and in the regulation of 
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5.3.6.4.7 Nucleophosmin (NPM1) 
NPM1 is a phosphoprotein that is localised in the nucleolus, though it is known to 
rapidly translocate between the nucleus and the cytoplasm. It is thought to have 
many functions in the cell such as ribosome biogenesis, cell proliferation, stress-
induced apoptosis and is a positive regulator of ARF (Gjerset 2006; Grisendi, 
Mecucci et al. 2006). NPM1 is differentially expressed in CRC tumours (Bertucci, 
Salas et al. 2004). 
 
 
5.3.6.4.8 Polyhomeotic homolog 1 (PHC1) 
PHC1 is a component of the Polycomb Repressive Complex 1, which is involved in 
gene silencing possibly through reorganisation of chromatin into a compact structure 
(Simon and Kingston 2009). PHC1 has been shown to be overexpressed in testicular 
germ-cell tumours as well as in pituitary adenomas. However expression of PHC1 
was not detected in normal colon tissue or in colorectal adenocarcinomas 
(Rodriguez, Jafer et al. 2003; Sanchez-Beato, Sanchez et al. 2006). 
 
 
5.3.6.4.9 Phosphoserine phosphatase (PSPH) 
PSPH is a phosphotransferase that is involved in the hydrolysis of L-phosphoserine 
in a magnesium dependent manner that results in formation of L-serine (Collet, 
Stroobant et al. 1999; Wang, Cho et al. 2002). It has been shown that calcium 
inhibits the enzymatic activity of PSPH (Peeraer, Rabijns et al. 2002). It has also 
been suggested that PSPH may play a role in regulating the proliferation of neural 
stem cells (Nakano, Dougherty et al. 2007). 
 
 
5.3.6.4.10 Parathymosin (PTMS) 
PTMS is a small (11.5kDa) zinc binding protein. It is predominantly localised in the 
cytoplasm but does contain a functionally active nuclear localisation signal (Clinton, 
Graeve et al. 1991; Trompeter, Blankenburg et al. 1996) and has been shown to have 
a role in the inactivation of phosphofructokinase. PTMS has been shown to interact 
with histone H1 and is suggested to have a role in the modulation of H1 interaction 
with chromatin (Kondili, Tsolas et al. 1996; Martic, Karetsou et al. 2005). 
 




5.3.6.4.11 Solute carrier family 7 (amino acid transporter, L-type), member 
8 (SLC7A8) 
SLC7A8 was identified as a heterometric amino acid transporter with SLC3A2, a 
glycoprotein heavy chain 4F2 and is highly expressed in the skeletal muscle, 
intestine, kidney and placenta, as well as the liver, heart and lung. It has broad 
substrate specificity for zwitterionic amino acids (Bassi, Sperandeo et al. 1999; 
Pineda, Fernandez et al. 1999; Rossier, Meier et al. 1999). 
 
 
5.3.6.4.12 Yip1 interacting factor homolog A (YIF1A) 
Not much is known about the function of this protein but it is thought to be localised 
in the Golgi apparatus (Jin, Zhang et al. 2005). It has been shown that YIF1A is 
significantly differentially expressed in normal and squamous cell carcinoma tumour 
samples by microarray analysis, with expression significantly higher in the tumour 
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5.3.7 Determination of false positives 
 
Once the potential EGR1 protein-interactions had been identified, they were then 
screened for false positives. The ‘prey’ protein in the pGADT7 was isolated from the 
yeast colony and co-transformed with both an empty pGBKT7 vector and with a 
pGBKT7 vector containing EGR1. If the interaction is true it will grow only in the 
presence of the EGR1 protein and no colonies will be evident on the plate with 
transformed empty pGBKT7 and the prey. However if it is a false positive, the ‘prey’ 
protein will activate the transcription of the ADE2 and HIS3 reporter genes in the 
absence of the interacting protein indicating that the prey protein does not require an 
interaction to activate the reporters and colonies will be evident on the plate with 
transformed empty pGBKT7 and the prey plasmid.  
 
Four proteins demonstrated slight auto-activation of the ADE2 and HIS3 reporters, 
TAF8, CLE2D, ZMIZ2 and RPL27. These results are not completely unexpected as 
ribosomal proteins are one of the main groups of proteins known to pulled out as 
false positives in yeast two hybrid screen, as are transcription factors, whose, as 
stated previously, activation domain can activate the gene transcription of the 
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5.3.8 Investigation into the potential interaction of EGR1 and NPM1 
 
The first potential interaction of EGR1 to be investigated was with the NPM1 
protein, as it is has been implicated in tumorigenesis, and has been shown to be over-
expressed CRC (Nozawa et al, 1996).  
 
5.3.8.1 Expression of NPM1 in CRC cells 
In order to confirm a potential interaction between EGR1 and NPM1, we first 
determined the expression and localisation of NPM1 in CRC cells. NPM1 was found 
to be expressed in all four of the CRC cell lines tested, with the lowest expression 
evident in Vaco425 (Figure 5.7 A) Although NPM1 is a nucleolar protein it is known 
to shuttle between the cytoplasm and the nucleus. Using a subcellular localisation kit, 
it is clear that in SW480 cells, NPM1 is localised in both the cytosol and the nucleus 













Figure 5.7: Expression and localisation of NPM1 in CRC cells 
A. Protein extracts (30µg) were prepared from HRT18, HCT116, SW480 and 
VACO425 cells, resolved on a 10% acrylamide gel and probed with anti-NPM1 and 
anti-EGR1 antibodies. An anti-actin antibody was used as a loading control. B. 
SW480 cells were extracted into four cellular compartments, 30µg of protein was 
resolved on a 10% acrylamide gel and probed with anti-NPM1, anti-EGR1 and anti-
HP1 antibodies. Both membranes have been stripped and re-probed with the 
antibodies shown here.  
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5.3.8.2 Immunoprecipitation with EGR1 and NPM1 
 
The interaction between NPM1 and EGR1 proteins was investigated by 
immunoprecipitation. The experiments were conducted using the experimental 
conditions for immunoprecipitation as determined in the previous chapter (Chapter 
4.3.3.3) The immunopreciptation was conducted using agarose G beads, and lysis 
buffer 4 that contains 300mM NaCL and 1% Triton x100.  The interaction between 
EGR1 and NPM1 was investigated in both SW480 and HRT18 cells.  Figure 5.8 
demonstrates that there is a weak interaction between EGR1 and NPM1 in both 
HRT18 and SW480 cells, with and without LPS treatment. As in previous 
experiments there is an increase in non-specific background in the IgG mouse control 
after LPS treatment.  
 






Figure 5.8: Immunoprecipitation with NPM1 and EGR1 
Cells were treated with 1µg LPS for 24 hours, extracted using lysis buffer 4 and 
immunoprecipitated using agarose G beads and anti-NPM1. IgG goat was used as a 
negative control. Immunoprecipitated complexes were run on a 10% resolving gel 
and probed with anti-EGR1.  
 
  224 
 
5.3.9 Investigation into the potential interaction of EGR1 and eEIF1A1 
 
The second protein interaction to be investigated from the Y2H screen is eEIF1A1, 
which is, as previously stated, involved in the elongation stage of protein translation. 
It has been implicated in tumorigenesis and is over-expressed in colon cancer 
(Zhang, Zhou et al. 1997; Bertucci, Salas et al. 2004; Lamberti, Caraglia et al. 2004). 
 
 
5.3.9.1 Expression of eEIF1A1 in CRC cells 
As before, we first confirmed that eEIF1A1 is expressed in CRC cells. eEIF1A1 is 
strongly expressed in HRT18, HCT116 and SW480 cell lines (Figure 5.9.A). 
Expression of eEF1A is evident in both the cytosol and nuclear fraction of SW480 
cells (Figure 5.9.B).  
 
 








Figure 5.9: Expression and localisation of eEF1A1 in CRC cells 
A. Protein extracts (30µg) were prepared from HRT18, HCT116, SW480 and 
Vaco425 cells, resolved on a 10% acrylamide gel and probed with anti-eEF1A1 and 
anti-EGR1 antibodies. An anti-actin antibody was used as a loading control. B. 
SW480 cells were extracted into four cellular compartments, 30µg of protein was 
resolved on a 10% acrylamide gel and probed with anti-eEF1A1, anti-EGR1 and 
anti-HP1 antibodies. Both membranes have been stripped and re-probed with 
antibodies shown here. 
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5.3.9.2 Immunoprecipitation with EGR1 and eEF1A1 
 
The interaction between eEF1A1 and EGR1 was investigated by 
immunoprecipitation. The experiments were conducted using the previously 
developed experimental conditions for immunoprecipitation as before. The 
interaction between EGR1 and eEF1A1 was investigated in both SW480 and HRT18 
cells. However there is only a faint interaction detected between EGR1 and eEFIA1 
in HRT18 cells (Figure 5.10). Although EGR1 has lower level of expression in 
HRT18 and that the original yeast two hybrid was conducted using an SW480 cell 
line library, an interaction was not detected in SW480 cells using this method. 
Interestingly the interaction between EGR1 and eEF1A1 appears to be decreased in 
the cells after treatment with LPS.  
 
There is  > 92% homology between eEF1A1 and eEF1A2 (Soares, Barlow et al. 
2009) and as most antibodies do not differentiate between the two isoforms, it cannot 
be said that the interaction detected is with the eEF1A1 isoform. Antibodies specific 
to the two isoforms became available to use (from Cathy Abbott, MMC), however no 
interaction was detected with either the A1 or A2 isoform in either HRT18 or SW480 
cells. As these antibodies consist of a small specific peptide to each isoform, the 
experiment was conducted by pulling down with an EGR1 anti-mouse antibody (not 
previously used in IP experiments) and probing with the A1 and A2 anti-sheep 
antibodies. It therefore may be necessary to further alter the experimental conditions 
in order to detect a stronger interaction or to confirm the interaction with the A1 
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Figure 5.10: Immunoprecipitation with EGR1 and eEF1A1 
Cells were treated with 1µg LPS for 24 hours, extracted using lysis buffer 4 and 
immunoprecipitated using agarose G beads and anti-NPM1. IgG goat was used as a 
negative control. Immunoprecipitated complexes were run on a 10% resolving gel 
and probed with anti-EGR1. 
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5.4 Discussion 
 
A yeast-two hybrid screen conducted using EGR1 as bait identified 22 novel 
interacting proteins of EGR1 in a SW480 epithelial cell library. As transcription 
factors can activate transcription of the reporters in the yeast without an interacting 
protein, an EGR1 construct without its transactivation domain as well as a full length 
EGR1 construct was cloned into the pGBKT7 vector. However there was no 
evidence of auto-activation by the EGR1 construct with either the full length or the 
truncated EGR1. The yeast-two hybrid screen was conducted using an SW480 CRC 
cell line library, to further increase our knowledge of EGR1 interacting proteins in 
epithelial CRC cells. Interestingly all of the proteins indentified were detected using 
full length EGR1, with only two proteins being identified as also interacting with 
EGR1!Act but gives valuable information with regards to the possible EGR1 
interacting domain for these proteins.  
 
In total ~ 800 colonies were selected and tested for confirmation of interaction using 
the colon lift filter assay. Of these, approximately half of all colonies selected were 
false positives and disgarded. Of the remaining, these were sequenced and analysed 
to see if the colony contained a protein sequence of the human gene. Only sequences 
that coded for a protein were selected. In total 22 protein sequences were isolated, 
however 4 of these were found to be false positives, that is proteins whose structure 
allows them to activated gene transcription in the Y2H system in the absence of an 
interacting protein. It should be noted however that due to time constraints only a 
small scale Y2H screen was conducted and there was not the opportunity to screen 
many more interacting colonies. It is therefore possible that many more proteins 
could be determined as interacting with both EGR1Fl and EGR1!Act if a larger 
scale screen was conducted. However this small screen provided numerous possible 
targets for further investigation 
 
There are several limitations of the yeast-two method that should also be taken into 
account. As the yeast-two hybrid screen requires translocation of the proteins into the 
nucleus to activate the reporter gene expression this method can therefore not detect 
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interactions with membrane proteins or membrane-bound proteins. The proteins of 
interest must be able to fold correctly and be stably expressed in yeast, and it is 
possible that fusion of the DNA-binding domain or activation domain can change the 
confirmation of either the prey or the bait, which may have an impact on binding 
sites and interactions. It is also necessary to confirm any interaction by another 
method in your cell type of choice, such as by immunoprecipitation, therefore it 
should be kept in mind that of the 18 positive interactions determined by the screen, 
not all of these proteins may interact with EGR1 outside of the yeast system. 
 
Bearing in mind these limitations, the yeast two-hybrid screen is still a powerful tool 
to detect novel protein interaction and in this screen many potential interactions and 
proteins of interest were detected. It was decided to first investigate the potential 
interaction between EGR1 and NPM1. NPM1 is currently of interest in the CCGG 
group in relation to aspirin mediated apoptosis of CRC cells. As stated, NPM1 is a 
phosphoprotein that is mainly localised in the nucleolus but can rapidly shuttle 
between the nucleus and the cytoplasm. A mutant form of NPM1 commonly found in 
acute myeloid leukemia (AML) is aberrantly localised in the cytoplasm (Falini, 
Mecucci et al. 2005). NPM1 is also known to translocate from the nucleolus in 
response to genotoxic stress and UV irradiation (Rubbi and Milner 2003). As such it 
is evident that NPM1 can localise in the nucleus or the cytoplasm and therefore it is 
unknown where EGR1 and NPM1 are likely to interact in the cell, as EGR1 can also 
localise in the cytoplasm or the nucleus. Indeed previous work in the CCGG has 
indicated that EGR1 may localise to the nucleolus and as such cannot be ruled out as 
a cellular compartment for the interaction. 
 
NPM1 has been shown to have a variety of cellular functions. It was initially 
identified as having a role in ribosome biogenesis and contributing to cell growth. It 
is known to bind to p53, ARF and p21 and, like EGR1, appears to act as both a 
tumour suppressor and tumour promoter, depending on the circumstances (Gjerset 
2006; Grisendi, Mecucci et al. 2006; Xiao, Zhang et al. 2009). NPM1 has been 
shown to activate p53 transcriptional activity (Gjerset 2006). NPM1 is over-
expressed in various tumours, including CRC (Nozawa, Van Belzen et al. 1996). 
Over-expression of NPM1 has been shown to lead to increased cell growth, as well 
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as inhibiting pro-apoptotic pathways (Grisendi, Mecucci et al 2006). Interestingly 
NPM1 has recently been shown to interact with the kinesin-like protein Eg5 and has 
a role in modulating its ability to destabilise microtubules (Wang, Gao et al. 2010). A 
microarray study demonstrated that there is an increase in NPM1 expression in CRC 
tumours (Bertucci, Salas et al. 2004). 
 
It is unclear what effect an interaction between NPM1 and EGR1 may have on the 
function of either protein. However the cellular functions of both EGR1 and NPM1 
are varied and depend on cellular conditions such as stress and therefore it may be 
difficult to fully elucidate the functional effects of an interaction. Initially it would be 
interesting to determine if an interaction between EGR1 and NPM1 has any effect on 
the transcriptional activity of EGR1, using the luciferase gene reporter assays that are 
available for both EGR1 and NPM1 as a resource in the lab, followed by experiments 
to determine if loss of NPM1 in CRC cells had an effect on the downstream targets 
of EGR1. It would be necessary however to conduct these experiments using NPM1 
siRNA as NPM1 knockout mice are embryonic lethal (Grisendi, Bernardi et al. 
2005).  A further area of research would be to determine if loss of NPM1 has any 
effect on the localisation of EGR1 in the cell, as NPM1 has been reported to act as a 
molecular chaperone (Kerr, Birse-Archbold et al. 2007), and as it also has links with 
cytoskeleton organisation, it would be interesting to determine if its loss has any 
effect on EGR1s interaction with the cytoskeleton. Also as NPM1 responds to stress 
by translocation to the cytoplasm investigating the interaction between EGR1 and 
NPM1 under cellular stress conditions such as UV or LPS would aid in 
understanding their possible role in carcinogenesis. 
 
The second protein investigated was the translation elongation protein eEF1A1. 
Although the function of eEF1A1 in the initation of the elongation stage of protein 
translation is well characterised, it is also thought to have a role in several other 
cellular processes. eEFIA1 can form a complex with both tubulin and actin and it has 
been shown to have an effect on cytoskeletal organisation (Condeelis 1995), which is 
intriguing given that we have shown an interaction with EGR1 and tubulin in CRC 
cells. Interestingly an oncogene, PT-1 (tumour inducing gene) was identified in 
prostate carcinoma which appears to consist of a mutated eEF1A1 protein fused with 
 
  231 
a region of 5’ UTR that has a high homology (~85%) to a 23S ribosomal gene from 
Mycoplasma hyponeumoniae (Gopalkrishnan, Su et al. 1999). PT-I is also expressed 
in breast, colon, and lung cancer cells, which have differential expression of EGR1. 
eEF1A has been reported to be involved in stress-induced apoptosis (Lamberti, 
Caraglia et al. 2004) and been shown to be differentially expressed in CRC by 
microarray, with higher levels of eEF1A1 evident in CRC tumours (Bertucci, Salas 
et al. 2004). 
 
There are two isoforms of eEF1A, eEF1A1 and eEF1A2, which are encoded by 
different genes but are nearly identical at the protein level (Soares, Barlow et al. 
2009). The A1 isoform is ubiquitously expressed whereas the A2 protein expression 
is limited to the brain, heart and skeletal muscle (Lee, Francoeur et al. 1992). We 
have shown that eEF1A is expressed in CRC cells, and there is a faint interaction 
evident in HRT18 cells. Further optimisation may be required to detect a stronger 
interaction in HRT18 and in SW480 cells. Interestingly the interaction that was 
detected in HRT18 cells was reduced when using LPS treated cells. Further 
experiments could involve determining if this reduction is only evident after 
treatment with LPS, or if other inflammatory or stress stimuli cause a similar 
reduction or alteration.  
 
As previously stated the antibody used for the immunoprecipitation is known to be 
non-specific in that it detects both isoforms eEF1A1 and eEF1A2. Therefore further 
work is necessary to confirm which isoform it is that is interacting with EGR1, 
indeed it may be that both isoforms do. As with NPM1, it is unclear as to the effects 
of an interaction between EGR1 and eEF1A. eEF1A1 has been shown to interact 
with other proteins outside of its role as a translation factor, some of which are 
regulated by phosphorylation (Ejiri 2002) and as phosphorylation has also been 
shown to play a role in some EGR1 protein interaction (Adamson, Yu et al. 2005), it 
is possible that the interaction between EGR1 and eEF1A1 is similarly regulated or 









EGR1 has long been of interest due to its role as a transcription factor involved in the 
regulation of several different pathways in both cancer and inflammation. When it 
was first identified in 1988, it was shown to have a role in the regulation of cell 
growth and differentiation. Since then EGR1 has been shown to be induced by many 
different growth and stress stimuli, resulting in downstream activation of targets 
involved in cell growth and differentiation and the inflammatory response pathways. 
EGR1 became an interesting candidate for a role in carcinogenesis, not only because 
of its ability to effect cell growth, but due to the fact that it is differentially expressed 
in many different cancers, including breast and prostate. The role of EGR1 has been 
investigated predominantly in prostate cancer, but it has also been shown to be 
differentially expressed in colorectal cancer. When studies conducted by the CCGG 
and GI unit found that EGR1 is downregulated in the tumour mucosa of patients with 
CRC compared with normal colonic mucosa (in silico work), as well as 
demonstrating an association between common variants of EGR1 with disease 
phenotype in both CRC and IBD it became an interesting candidate gene for both 
CRC and IBD. 
 
Whilst previous studies have looked at the expression of EGR1 in CRC patients 
using microarray and qRT-PCR, this is the first study to look at the expression of 
EGR1 in matched normal and tumour samples. This study used 30 matched normal 
mucosa and tumour samples to determine if there is any differential expression of 
EGR1 in CRC patients. This study is also the first to determine if there is any 
correlation with genotype of three EGR1 SNPs with its expression in CRC as well as 
determining if the differential expression of EGR1 observed is associated with 
aberrant methylation of the EGR1 promoter in epithelial cells.  
 
We have shown that EGR1 is differentially expressed in CRC patients. There appears 
to be three groups of patients as regards EGR1 expression. One group of patients 
have significantly higher levels of EGR1 expression in the tumour compared with the 
normal mucosa, another group of patients has significantly lower EGR1 expression 
in the tumour compared with the normal mucosa whilst several patients show no 
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difference in expression between the normal mucosa and tumour. A large region of 
the EGR1 promoter was investigated for methylation of the CpG islands, however no 
methylation was detected in the large region examined. No association with EGR1 
expression and the genotype of the EGR1 SNPs was proven, however a much greater 
sample size would be necessary to thoroughly examine this and any possible 
haplotype effect.  
 
A study by Habermann et al. has demonstrated that EGR1 is differentially expressed 
at different stages in CRC development, with differential expression seen between 
normal mucosa and adenoma, and between adenoma and carcinoma (Habermann, 
Paulsen et al. 2007). They observed a significant decrease in expression between the 
normal mucosa and adenoma, with a significant increase in EGR1 between adenoma 
and carcinoma tissue. This data agrees with an analysis we conducted using 
Oncomine which showed a study by Skrzypczak et al. demonstrated a decrease in 
EGR1 in colorectal adenocarcinoma with a study conducted by Hong et al. observing 
that EGR1 was differentially expressed in colon and colorectal carcinoma, with 
higher EGR1 expression seen in the colorectal carcinoma (Hong, Downey et al. 
2010; Skrzypczak, Goryca et al. 2010). Therefore it is necessary to determine if the 
differential expression between matched normal and tumour seen in this study can is 
associated with tumour stage of the patients, as this would allow a greater 
understanding to the pattern of differential expression of EGR1 in CRC and its role 
in carcinogenesis.  
 
It is possible that the differential levels of EGR1 seen in this study in the normal and 
tumour may have very different effect on activation of its downstream targets and 
further analysis would allow us to determine if EGR1 has a greater impact on tumour 
suppressor genes or oncogenes, ie whether is EGR1 is growth-promoting or 
inhibiting in this cancer. CRC is a heterogeneous disease so it is possible that EGR1 
may have a different role in different tumours, or at the different stages of the tumour 
progression. The studies mentioned above have indicated that EGR1 expression is 
lower in the adenoma stage of CRC with an increase in the carcinoma stage. If EGR1 
expression is higher at this later stage of the cancer it may have a role in activation of 
growth-promoting genes and metastasis genes. This is the stage of tumour 
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progression in which p53 mutation usually occurs, and it has been shown that EGR1 
can regulate the expression of p53 (Yu, Baron et al. 2007). It has also been observed 
that the mutant status of p53 has an effect on the function of EGR1 (Weisz, 
Zalcenstein et al. 2004). 
 
 
To investigate mechanisms by which EGR1 was differently expressed in CRC 
patients the KRAS and BRAF mutation status were examined in these patients, an 
important pathway to investigate given its role in CRC and that EGR1 expression is 
induced via the MAPK signalling pathway. This pathway also has an important role 
to play as a biomarker for the response to EGFR-targeted drugs for CRC, as 
mutations in KRAS are a good indicator for the effectiveness of the response of 
cetuximab and panitumumab (Soulieres, Greer et al. 2010). At the adenoma stage of 
tumour progression EGR1 has been shown to be decreased, with correlates with 
occurrence of mutation of KRAS and BRAF, which are both involved in the MAPK 
pathway which regulates the expression of EGR1, with an increase of EGR1 in the 
carcinoma stage. In this study we observe that patients with KRAS or BRAF 
mutations had significantly higher levels of EGR1 in the tumour compared with the 
normal. It may be that mutations in KRAS/BRAF are associated with higher EGR1 
expression. Given the role of APC in CRC and its proximity to EGR1 on 
chromosome 5, it is necessary to determine if there is any correlation with APC 
mutation status and EGR1 as well as looking to see if the differential expression is 
correlated with any other phenotypes, or disease characteristics such as stage of 
disease or site of tumour.  
 
Given that mutations in CRC occur at different stages of the cancer progression, 
further analysis the mutation status of some of these genes would give an indication 
of what stage of cancer these patients were at, in the absence of patient data. We 
know the KRAS/BRAF mutation status of the patients, but analysing the samples for 
other mutations, p53 status for example, may indicate if any of the patients were in 
the final stages of tumour development, as presence of p53 mutation would indicate a 
late stage. It would be preferable to look at these data, along with APC, 
KRAS/BRAF and PTEN mutation status, with respect to clinical and pathological 
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data, which was not available in this study and to show that the increase in EGR1 in 
the tumour is around the carcinoma stage, with decrease in EGR1 in the tumour 
correlating with adenocarcinoma as the Oncomine analysis predicts. Given that 
EGR1 is known to regulate the expression of the tumour suppressor genes such as 
p53 and PTEN, an expression analysis of these downstream targets of EGR1, along 
with their mutation status, could provide an indication into the effect that the 
differential expression of EGR1 is having on key tumour suppressor genes.  Again, 
despite the lack of patient data, a study to test for MSI instability would show if the 
patient samples are MSI or MSS, and given than MSI and CIN are usually mutually 
exclusive this would allow us to determine the type of genetic instability present in 
the patients which may provide further information about the type of CRC and EGR1 
expression. 
 
This study also investigates the differential expression of EGR1 mRNA in non-
inflamed tissue of both UC and CD patients, comparing the expression with a group 
of healthy controls. We have also looked at the expression of EGR1 in these three 
patients groups after treatment with inflammatory mediators, LPS, MDP, PGN and 
TNF. Again we examined a large region of the EGR1 promoter to determine if 
aberrant methylation is associated with the differential expression, as well as looking 
at the genotype of the three EGR1 SNPs. The expression of the NAB2 inhibitor of 
EGR1 was also examined to determine if there is any differential expression of it in 
the healthy controls, UC or CD patients. 
 
This study shows that expression of EGR1 is decreased in the uninflammed mucosa 
of ulcerative patients and is significantly lower in Crohn’s disease patients when 
compared with healthy controls. We determined that this decrease in expression is 
not associated with aberrant methylation of a large region of the EGR1 promoter, 
with the genotype of three EGR1 SNPs or with differential expression of the EGR1 
inhibitor NAB2. Upon investigation of EGR1 expression in the three patient groups 
after treatment with the inflammatory mediators we showed that as expected EGR1 
expression was significantly induced in the healthy controls after treatment with LPS 
and TNF. However we have demonstrated that the induction of EGR1 in both UC 
and CD samples does not appear to act in the same manner as in the healthy controls. 
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In UC patients, LPS fails to significantly induce EGR1 expression and treatment with 
PGN appears to reduce expression. In CD patients there is a reduction of EGR1 after 
TNF treatment, and a significant reduction after LPS, demonstrating that in general 
IBD patients appear to have an aberrant induction of EGR1 in response to 
inflammatory mediators. 
 
One important area of further study would be to determine if there is differential 
expression of the EGR1 protein in both the CRC and the IBD patients, and indeed if 
there is any correlation at the protein level with the three EGR1 SNPs in these 
patients. There does appear to be differential expression of the EGR1 mRNA and 
protein in some of the CRC cells lines. In HRT18 and SW480 the mRNA levels (low 
and high respectively) do correlate with the protein levels but this is not the case in 
HCT116 (low mRNA levels, higher protein) and Vaco425 (high mRNA and low 
protein). It appears in the cell lines that presence of the EGR1 variants does result in 
higher EGR1 mRNA expression, with SW480 and Vaco425, both homozygous 
variant, having the highest levels of EGR1 expression in the CRC cell lines but this 
does not correlate entirely with the protein expression but other factors might be 
involved in protein turnover. It would be necessary to undertake a much larger study 
to determine if there is any association with EGR1 expression and the EGR1 
variants, but equally it appears that there may be differential expression or 
localisation the EGR1 protein also which should be investigated, as well as the 
response of the EGR1 protein to inflammatory mediators in IBD.  
 
We have shown that the expression of EGR1 is decrease in patients with IBD in un-
inflamed tissue. It appears that IBD patients with decreased EGR1 expression in the 
mucosa do not respond as expected to inflammatory mediators. This result was 
unexpected, as it was presumed that EGR1 would have high expression in these 
patients, thereby activating gene expression of the inflammatory genes that is 
regulates such as TF and PGE2.  However it may be that the lower levels of EGR1 in 
these patients has an effect on the gene expression in the cells. As EGR1 can activate 
the expression of both pro-and anti-inflammatory genes perhaps the loss of EGR1 
has shifted the balance in favour of the pro-inflammatory genes. We have shown that 
EGR1 in these patients does not respond to inflammatory mediators as expected. In 
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normal cells there is a high expression of EGR1 in the mucosa. After exposure to 
LPS and TNF, the expression of EGR1 is induced. We do not know what genes 
EGR1 goes on to activate in the healthy patients in response to this activation by LPS 
and TNF, which would be an important next step in this analysis. EGR1 expression 
is lower IBD patient mucosa and it does not respond to LPS and TNF in the same 
manner as the healthy controls. If we could determine if the downstream activation 
of EGR1 genes in the healthy controls is different in the healthy controls, before and 
after LPS/TNF treatment, it may be that EGR1 does not activate the same gene 
expression in the IBD patients in response to LPS/TNF treatment. We do not yet 
know if this loss of EGR1 and its lack or response in IBD is a consequence of the 
disruption of the inflammation pathway in these patients or EGR1 has a role to play 
in the disruption of the pathway. Determination of the downstream gene activation of 
EGR1 in these patients may help to answer that question. Given that EGR1 has been 
shown to interact with NOD2 in CD patients, it may well have a role to play in CD. 
Elucidating the function of this interaction may help to determine if the interaction is 
itself playing a role in the development or progression of the disease.  
One important area of further study would be to determine if there is differential 
expression of the EGR1 protein in both the CRC and the IBD patients, and indeed if 
there is any correlation at the protein level with the three EGR1 SNPs in these 
patients. There does appear to be differential expression of the EGR1 mRNA and 
protein in some of the CRC cells lines. In HRT18 and SW480 the mRNA levels (low 
and high respectively) do correlate with the protein levels but this is not the case in 
HCT116 (low mRNA levels, higher protein) and Vaco425 (high mRNA and low 
protein). It appears in the cell lines that presence of the EGR1 variants does result in 
higher EGR1 mRNA expression, with SW480 and Vaco425, both homozygous 
variant, having the highest levels of EGR1 expression in the CRC cell lines but this 
does not correlate entirely with the protein expression but other factors might be 
involved in protein turnover. It would be necessary to undertake a much larger study 
to determine if there is any association with EGR1 expression and the EGR1 
variants, but equally it appears that there may be differential expression or 
localisation the EGR1 protein also which should be investigated, as well as the 
response of the EGR1 protein to inflammatory mediators in IBD.  
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The expression level of EGR1 in a cell may be important in deciding its role in the 
cell. We still do not know if the differential expression of EGR1 mRNA in both CRC 
and IBD has an impact on its protein expression. This would be an important step in 
determining the role, if any, of the EGR1/NOD2 interaction in IBD. A greater 
knowledge of the other EGR1-protein interactions may also be useful in 
understanding its role in both CRC and IBD. The aberrant response of EGR1 in IBD 
shown in this study and a future investigation into the EGR1 protein expression and 
its response to inflammatory mediators would be especially informative given that 
we have demonstrated an interaction between EGR1 and the CD susceptibility gene 
product NOD2. This study has investigated the expression and localisation of EGR1 
and NOD2 in CRC cells and shown that NOD2 is predominantly localised in the 
cytoplasm and EGR1 is localised in both the nucleus and the cytoplasm, with the two 
proteins co-localising in the cytoplasm. We have demonstrated a positive interaction 
between EGR1 and NOD2 in SW480 cells, in untreated and LPS-treated cells. The 
confirmation that EGR1 and NOD2 do interact in CRC cells offers the potential to 
further examine this interaction in order to determine if it mediates any gene 
activation of target genes of both EGR1 or NOD2, or if the interaction facilitates a 
role outside that of a transcription factor. This finding further opens up the possibility 
that EGR1 has a significant role to play in IBD.  
 
 
A limitation of this study has been the difficulty in acquiring reliable antibodies for 
EGR1 and NOD2. There are several commercially available antibodies for EGR1 
which were tested and optimised in this thesis, however the availability of NOD2 
antibodies is poor, and therefore it was not possible to do any IP experiments using 
EGR1 as a pull down and probing with NOD2. Further experiments characterising 
the interaction between NOD2 and EGR1 may be dependent on acquiring a suitable 
NOD2 antibody. However there are several key experiments that need to be 
conducted to further characterise the EGR1/NOD2 interaction. The first would be to 
determine the functional consequences, if any, of this interaction in the cell. 
Luciferase reporter assays using gene constructs with EGR1 promoter regions such 
as TF in conjunction with siRNA could be utilised to determine if NOD2 is required 
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for EGR1-mediated transcription, especially of genes involved in inflammation. 
Similarly reporter constructs with gene promoters of genes activated by NOD2 such 
as NF-!B could be utilised to determine if EGR1 has any role to play in NOD2-
mediated gene transcription, with and without stimulation by MDP. Given that 
NOD2 localisation to the membrane has been determined to play a role in its MDP-
induced activation of NF-!B, with the cytoskeleton thought to play a role in NOD2-
mediated transcription, a second area to research would be to investigate the role of 
the cytoskeleton in the EGR1/NOD2 interaction, especially given that we have 
demonstrated an interaction with EGR1 and the tubulin cytoskeleton. In order to 
confirm that the cytoskeleton has a role to play in the interaction it would be 
necessary to determine what effect disruption or stabilising the cytoskeleton would 
have on the interaction between NOD2 and EGR1. 
 
A third area of study would be to investigate whether EGR1 interacts only with wild-
type NOD2, or whether it also interacts with any of the three NOD2 mutants. There 
are three common NOD2 mutations that have been found in CD which do not appear 
to respond to stimulation by MDP with the Leu1107fsinsC mutant unable to localise 
to the cell membrane. The three NOD2 mutants are available as a resource in the lab, 
gifted by Colin Stevens, as HA-tagged constructs. Experiments to determine the 
localisation of the NOD2 mutants in CRC cells, and whether they co-localised with 
EGR1 would lend to a further understanding of a role of the EGR1/NOD2 
interaction, as would confirming if EGR1 physically interacts with any of the 
mutants in CRC cells.   
 
By disrupting regions of EGR1 or NODD2 by site-directed mutatgenesis we could 
determine the regions of the protein that are involved in the EGR1/NOD2 interaction. 
There are three domains in EGR1, the zinc-finger DNA binding domain, a 
transactivation domain and a regulatory domain which is known to bind the two 
transcriptional co-factors NAB1/2, which have a predominantly inhibitory effect on 
the transcription of EGR1. Knowledge of the region of EGR1 that binds to the NOD2 
may lead to a better understanding of role of the interaction, whether NOD2 may act 
as a co-activator of EGR1 transcription or have an inhibitory effect of EGR1. 
Similarly it would be useful to determine what region of NOD2 is involved in the 
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interaction with EGR1. The NOD2 mutations found in CD are localised in the LRR 
domain of NOD2 and might prove useful in determining the interacting domain on 
NOD2. 
 
EGR1 is known to localise with components of the cytoskeleton in prostate cancer 
and it has been suggested that this localisation is necessary for the translocation of 
EGR1 from the cytoplasm to the nucleus in these cells. We have shown that EGR1 
also co-localises and interacts with components of the cytoskeleton in CRC cells, and 
it may be that this interaction is required for its translocation in this type of cancer 
cell also. We have demonstrated that EGR1 is localised in both the nucleus and the 
cytoplasm in CRC cells, and indeed there appears to be EGR1 present in the 
membrane bound and organelle fraction which may have other implications for its 
interaction with NOD2. Experiments investigating if the interaction between EGR1 
and tubulin is involved in the translocation of EGR1 between the cytoplasm and 
nucleus would determine if the role of this interaction is similar in CRC as in prostate 
cells, and involved in the regulation of EGR1 translocation and localisation within 
the cell especially given that SW480 and HRT18 cells appear to have differences in 
the cellular localisation of EGR1, with more cytoplasmic EGR1 evident in HRT18 
cells and greater nuclear localisation of EGR1 in SW480. Investigating the EGR1 
and cytoskeletal interactions during cell cycle arrest, or at different stages of the cell 
cycle could determine if the localisation of EGR1 in the nucleus or the cytoplasm 
oscilliates during the cell cycle and whether it correlates with its interaction with 
tubulin.   
 
Although we have demonstrated an interaction with EGR1 and NOD2, and EGR1 
and tubulin in SW480 cells in the presence and absence of LPS treatment, further 
experiments into the interaction in the presence of stress stimuli and inflammatory 
mediators needs to be conducted, especially given the abnormal response of EGR1 
mRNA after treatment with the inflammatory mediators in CD patients as 
demonstrated by the qRT-PCR experiments. Also given how stimulation of EGR1 by 
different stress stimuli not only effects the post-translational modifications of EGR1 
but also its interactions with other transcription factors such as p300 and CBP with 
different effects on the targets of EGR1, further investigation into the interaction 
 
  241 
between EGR1 and NOD2 is warranted under different stress conditions to see if 
there is any difference in the interaction, post-translational modifications of the 
proteins and their functions in the cell. A key experimemt would be to determine if 
EGR1 and NOD 2 interaction occurs using a phospho-EGR1 antibody, and whether 
under different stress conditions if this interaction is gained or lost. 
 
  
Little is known about proteins that may interact with EGR1. One of the first proteins 
found to interact with EGR1 acts as an inhibitor of EGR1. Other proteins that interact 
with EGR1 are also thought to be involved in either its regulation or its role as a 
transcription factor. Although there are several reports of yeast-two hybrid screen 
conducted using EGR1 as a bait protein, this is the first time it has been reported in 
epithelial cell lines. The yeast-two hybrid screen was conducted using two EGR1 
constructs, a full length EGR1 and an EGR1 construct minus its transactivation 
domain. The screen was conducted against an SW480 cell line library. 
 
This study identified 22 novel potential interacting proteins of EGR1, which are 
involved in several different cellular functions. It is of great interest to further 
investigate these protein interactions, where they occur, and if they have an 
important cellular role. Two interesting candidate proteins were selected for further 
investigation, NPM1 and eEF1A1. NPM1 is a good candidate gene for CRC, as it has 
been shown to be highly expressed in CRC tumour compared with normal tissue, as 
has our other tested candidate, eEF1A1.  
 
These novel interactions were confirmed in CRC cells, as well as preliminary studies 
to determine their localisation within the cells to determine if they would be in 
proximity to EGR1 to allow an interaction to occur. We have confirmed that both 
NPM1 and eEF1A1 are expressed in CRC cells, and have a positive interaction with 
EGR1. In the case of NPM1 this interaction has been demonstrated in SW480 and 
HRT18 cells, with and without treatment of LPS, however an interaction with 
eEF1A1 has so far only been detected in HRT18 in untreated cells. Like the 
interaction with NOD2, it does appear that the interaction with NPM1 is likely to 
occur in the cytoplasm of the CRC cell lines, but it may turn out that the interaction 
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is localised in the nucleus and be involved in the transcritptional activity of either 
NPM1 or EGR1. Previous work in the CCGG has demonstrated that EGR1 can also 
localise to the nucleolus in CRC cells by immunocytochemistry and this is a potential 
site of interaction with EGR1 for both NPM1 and eEF1A1. 
 
The confirmation that EGR1 does interact with both NPM1 and eEF1A1 opens up 
many different areas of research to be considered. As with the interaction with 
NOD2 it is necessary to elucidate the function of an interaction between EGR1 and 
NPM1 or eEF1A1. As regards the interaction with NPM1 there are several resources 
available in the CCGG that would allow for further investigation into the interaction 
with EGR1 including several different commercial antibodies, luciferase reporter 
assays for genes that are regulated by NPM1 and NPM1 siRNA primers. However 
given the variety of cellular roles that have been attributed to NPM1, fully 
determining its role with EGR1 may prove difficult.  
 
As discussed there are two isoforms of eEF1A found, eEF1A1 and A2, which are 
very closely related. It would be necessary to confirm that it is the A1 isoform that 
interacts with EGR1 and to either determine or rule out an interaction with the A2 
isoform. The commercially available antibodies are not specific enough to determine 
which isoform is involved in the interaction we have detected with EGR1 but 
specific antibodies have been made available (gift from Cathy Abbott). Due to the 
nature of these antibodies it would first be necessary to optimise the experiments to 
allow pull down with EGR1 and use the eEF1A antibodies to probe to determine an 
interaction before investigating the role that this interaction may have in relation to 
the function of EGR1 or eEF1A in the cell. However this interaction and the finding 
that EGR1 potentially interacts with many of the candidate proteins determined in 
the yeast-two hybrid screen opens that possibility of novel roles/pathways for EGR1 
that may be important in furthering our understanding of the role of EGR1 in cancer 
and inflammation.   
 
One final area of future research in relation to the various novel interacting proteins 
of EGR1 found in thesis would be to determine if EGR1 interacts with these proteins 
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in colon tissue of patients which could be achieved by conducting the interaction 
experiments using protein extracts from the normal mucosa and tumour of CRC 
patients, and particularly in the case of the EGR1/NOD2, in IBD patients to 
determine if the EGR1 interactions occur in cancer and/or in IBD. This would help 
us to begin to determine if the EGR1/NOD2 interaction has a functional role in IBD, 
and indeed if any of the novel proteins found in the yeast-two hybrid screen have a 
role in CRC/IBD with EGR1. Experiments are also being conducted in the CCGG to 
establish an ex-vivo model of both normal mucosa and tumour, which would present 
a further resource in looking at how EGR1 is expressed and localised and responds to 
stress stimuli in the colon over a time course as well as investigating the various 
EGR1-protein interactions.  
 
To conclude, this study has shown that EGR1 is differentially expressed in matched 
normal mucosa and tumours of CRC patients, as well as in patients with IBD. We 
have found no correlation between this differential expression and the genotype of 
three EGR1 SNPs or the methylation of a large region of the EGR1 promoter. In the 
case of the IBD patients there does not appear to be a correlation with differential 
expression of the EGR1 inhibitor NAB2. There also appears to be an aberrant 
stimulation response of EGR1 expression to various inflammatory mediators in the 
IBD patients, in particular the CD patients. This study has demonstrated the 
localisation of EGR1 in both the cytoplasm and the nucleus in CRC cell lines and 
shown that EGR1 interacts with the CD susceptibility gene product NOD2 in SW480 
and HRT18 cells, in the presence and absence of LPS. EGR1 has also been shown to 
interact with components of the cytoskeleton, !- and "-tubulin, in SW480 cells. In 
this thesis we have found 22 potential novel interacting proteins of EGR1 using a 
yeast-two hybrid screen using a SW480 cell line library, and verified the interaction 
for two of these proteins, NPM1 and eEF1A1, in CRC cells. This yeast-two hybrid 
screen has identified several interesting novel proteins for further study in relation to 
EGR1 and CRC with many more interesting candidates to investigate which may 
help to identify new genes and novel pathways involved in CRC in order to further 
our understanding of the disease to aid the development of better diagnosis and new 
treatments. It is clear from our study that EGR1 may play a role in both CRC and 
 
  244 
IBD, hence with a better understanding of the role that EGR1 plays and the pathways 
it regulates, it will hopefully lead to a greater understanding of colorectal diseases 
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